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Professor Robert D. Schreiber, Chair 
 
 
 The idea that a functionally intact immune system can protect against cancer 
development forms the basis of the long-postulated and once controversial concept of 
cancer immunosurveillance.  A substantial body of evidence, however, now exists 
defining a role for immunity in extrinsic tumor suppression – work that broadened our 
understanding of the tumor-immune interface and led to the cancer immunoediting 
hypothesis.  The interferons, both type I (IFNα/β) and type II IFN (IFNγ), are critical 
mediators of cancer immunoediting, yet their respective roles in promoting anti-tumor 
immune responses remain unclear.  Herein, we have examined the actions of IFNα/β and 
IFNγ during tumor rejection, providing evidence for distinct functions on the host as well 
as the tumor.   
 We have established that host hematopoietic cells represent important targets of 
IFNα/β’s actions, however these cytokines can have potent stimulatory effects on both 
innate and adaptive immune cells.  Using bone marrow chimeras, we demonstrated that 
IFNα/β sensitivity within innate immune cells, but not T or B lymphocytes, was essential 
  iii 
for the priming of tumor-specific T cells and the generation of protective immunity.  
Whereas NK cells were not required for IFNα/β-dependent tumor rejection, CD8α+ 
dendritic cells were critical, and the direct actions of type I IFN on CD8α+ DCs enhanced 
antigen cross-presentation.   
 When we instead examined the requirements for IFNγ during tumor rejection, we 
observed an important function for both hematopoietic and nonhematopoietic host cell 
sensitivity, as well as a more prolonged duration of action.  Selective reconstitution and 
RNAi knockdown of IFNGR1 also corroborated the importance of tumor cell 
responsiveness to IFNγ, but not IFNα/β.  
 As exogenous type I IFN has shown clinical efficacy in cancer therapy, we 
performed similar studies using a model of IFNβ immunotherapy.  We observed that 
local production of IFNβ could induce either reversible tumor equilibrium (at higher 
doses) or elimination (at lower doses).  The effects of high-dose IFNβ were independent 
of adaptive immunity and required hematopoietic and nonhematopoietic IFNα/β 
responsiveness; in contrast, tumor elimination with low-dose IFNβ required adaptive 
immunity and responsiveness only in hematopoietic cells.  Collectively, these studies add 
to our understanding of the protective functions of the interferons during anti-tumor 
immunity.     
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THE EVOLUTION OF CANCER IMMUNOSURVEILLANCE 
 
 With the elucidation of molecular pathways normally regulating cell growth and 
differentiation, and their obligatory subversion by cancerous cells, the recognition of a 
common set of ‘intrinsic’ tumor suppressor mechanisms has emerged (1, 2).  The idea 
that the immune system could also provide a barrier to cancer development by serving in 
an ‘extrinsic’ tumor suppressor capacity to eliminate or control neoplastic cells, is a 
notion that has long been postulated yet only more recently demonstrated experimentally.  
Originally proposed nearly a century ago by Paul Erlich, this view was more formally 
articulated some fifty years later by Macfarlane Burnet and Lewis Thomas (3).  Prompted 
by the then recent demonstration that specific immune recognition of tumors could in fact 
occur, Burnet and Thomas postulated that the immune system may function to suppress 
the natural development of tumors – a theory that became known as ‘cancer 
immunosurveillance’ (4).  Subsequent efforts to test this hypothesis using animal models, 
however, yielded little support for ‘cancer immunosurveillance,’ and by 1980 this idea 
had been largely abandoned (3).   
 In retrospect, early attempts to study possible immune control of tumor formation 
were limited by the experimental tools available at the time, and only more recently was 
this hypothesis revisited and rigorously investigated using molecularly-defined models of 
immunodeficiency (3).  Indeed, a growing body of work over the past fifteen years has 
prompted a revival of the original idea of cancer immunosurveillance; yet, recent data 
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have also added new layers of complexity to the initial premise, leading to the 
formulation of the ‘cancer immunoediting’ hypothesis (3, 5, 6).   
 
 
THE CANCER IMMUNOEDITING HYPOTHESIS 
 
 The concept of ‘cancer immunoediting’ emphasizes the tumor-sculpting as well as 
the protective activity of the immune system, and describes host-tumor interactions in the 
framework of three phases: elimination, equilibrium, and escape (7, 8) (Figure 1).  The 
elimination phase, which encompasses the original immunosurveillance idea, involves 
the successful recognition and eradication of a developing tumor.  A failure of these 
immune mechanisms may lead to the equilibrium or escape phases.  During the 
equilibrium phase, tumor growth and immune destruction enter into a dynamic balance 
wherein an increasingly heterogeneous tumor is subjected to the sculpting forces of 
immunity.  This process may then result in the emergence of a clinically apparent tumor 
which has escaped the selective pressure of the immune system. 
  Work from numerous laboratories has implicated a number of different cellular 
components and immune effector molecules in host protection against tumor 
development, including IFNγ, perforin, αβ T cells, γδ T cells, NKT cells, NK cells, IL-
12, TRAIL, NKG2D, and IFNα/β (3, 9-11).  Yet, while some of the important effectors 
are known, the processes leading to the initiation and progression (or failure) of a 
naturally occurring anti-tumor immune response remain incompletely understood.  
 4 
Evidence suggesting a dynamic relationship between the immune system and developing 
tumors emerged from studies comparing tumors arising in different immunologic 
environments.  Specifically, tumor transplantation experiments demonstrated that 
methylcholanthrene (MCA)-induced fibrosarcomas arising in immunodeficient RAG2-/- 
mice were, as a group, more immunogenic than MCA-induced tumors from WT mice (5).  
Whereas both sets of tumors grew progressively with similar kinetics in RAG2-/- mice, 
when transplanted into syngeneic immunocompetent hosts, 8/20 RAG2-/--derived tumors 
(termed RAG2-/- regressors) were rejected, in contrast to 0/17 WT-derived tumors.  
Therefore, the immunogenicity of these tumors was shaped by the immune environment 
in which they developed.  In addition, the increased immunogenicity of tumors 
developing in other immunodeficient hosts – including nude, SCID, TCR Jα281
-/-, 
perforin-/-, and IFNAR1-/- mice – has been demonstrated (12-16).  These observations 
thus prompted a refinement of the original cancer immunosurveillance theory into the 
current concept of cancer immunoediting.      
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Figure 1.  Cancer immunoediting: a unifying principle describing the spectrum of tumor-
immune system interactions.  The progression of normal cells into clinically apparent 
cancers is facilitated by oncogenic stimuli and inhibited by both cell-intrinsic and cell-
extrinsic tumor suppressor mechanisms.  The cancer immunoediting process, which 
encompasses the tumor-protective and/or tumor-promoting activities of host immunity, is 
represented by the three proposed phases – elimination, equilibrium, and escape.     
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 7 
THE INTERERONS IN CANCER IMMUNOEDITING 
 
 Strong experimental evidence exists in support of a protective cancer 
immunosurveillance system, and the IFNs have emerged as critical components.  In fact, 
early studies on the role of IFNγ in anti-tumor immunity were largely responsible for 
triggering a resurgence in the previously discarded theory of cancer immunosurveillance.  
Some of the key data implicating the IFNs in the cancer immunoediting process will now 
be reviewed.   
    
Evidence for IFNγ-dependent Cancer Immunoediting 
 The initial findings supporting a role for endogenous IFNγ in anti-tumor 
immunity emerged from studies of the Meth A fibrosarcoma, an MCA-induced tumor 
derived from BALB/c mice.  Although this tumor grows progressively when transplanted 
into syngeneic WT mice, its rejection can be induced upon intraperitoneal injection of a 
sublethal dose of bacterial lipopolysaccharide (LPS).  Using a neutralizing mAb specific 
for IFNγ, it was discovered that blockade of endogenous IFNγ prevented the rejection of 
Meth A cells following LPS injection (17).  Additional experiments revealed the central 
importance of IFNγ’s actions on the tumor during this process, since abrogation of IFNγ 
sensitivity in Meth A cells – via overexpression of a dominant-negative IFNGR1 
construct (IFNGR1.ΔIC) – also blocked LPS-mediated rejection.  Importantly, it was also 
observed that (i) Meth A cells grew more rapidly in mice treated with anti-IFNγ mAb 
than in untreated mice, and (ii) IFNγ-unresponsive Meth A.IFNGR1.ΔIC cells displayed 
 8 
more aggressive growth in unmanipulated WT mice than the IFNγ-responsive parental 
tumor.  These studies therefore indicated that endogenous IFNγ, in the absence of an 
external LPS stimuli, had anti-tumor activity mediated at least in part through its actions 
directly on the tumor.   
 These results using transplantable tumor models prompted an examination of the 
role of IFNγ during the development of primary carcinogen-induced and spontaneous 
tumors.  Such studies demonstrated that IFNγ-insensitive IFNGR1-/- or STAT1-/- mice on 
a 129 background developed MCA-induced tumors at a higher incidence and with a 
shorter latency than WT 129 control mice (18).  In addition, when bred onto a p53-null 
genetic background, IFNγ-insensitive p53-/-xIFNGR1-/- and p53-/-xSTAT1-/- mice 
developed spontaneous tumors more rapidly than IFNγ-sensitive p53-/- control mice.  
Moreover, the spectrum of tumors discovered in the IFNγ-unresponsive doubly deficient 
mice was considerably more diverse, including a variety of non-lymphoid tumors, 
compared to the overwhelming development of lymphoid cancers in control mice.  
Additional work using gene-targeted mice on a C57Bl/6 strain that instead lack the IFNγ 
gene has also demonstrated an increased incidence of both carcinogen-induced and 
spontaneous tumors (15, 19).   
 In a subsequent study, the incidence of MCA-induced tumor formation in 
IFNGR1-/- and STAT1-/- mice was also compared with those in lymphocyte deficient 
RAG2-/- mice and in RAG2-/-xSTAT1-/- mice lacking both lymphocytes and IFN 
responsiveness (5).  Compared to genetically-matched WT control mice, each of these 
immunodeficient strains developed nearly three times the number of tumors following 
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carcinogen treatment.  Based on these results, it was postulated that the mechanisms of 
tumor protection afforded by IFNγ and lymphocytes were largely overlapping.  Taken 
together, the aforementioned studies – on both 129 and B6 genetic backgrounds, and 
using models of transplantable, carcinogen-induced, and spontaneous tumor development 
– have conclusively shown that IFNγ is an integral component of the protective cancer 
immunosurveillance system.   
 
IFNγ’s Actions on the Tumor 
 Initial studies using Meth A and MCA-207 revealed the importance of IFNγ’s 
actions on the tumor cell (17), and the significance of this mechanism has been 
strengthened by a large amount of additional evidence.  Analysis of MCA sarcomas from 
IFNGR1-/- mice showed them to be highly tumorigenic in WT mice (18).  Yet, when their 
ability to respond to IFNγ was restored by introduction of the missing IFNGR1 receptor 
component, these tumors were now rejected by WT mice in a lymphocyte-dependent 
manner.  If instead, components of the antigen processing and presentation pathway such 
as TAP1 and H-2Db (known to be modulated by IFNγ) were constitutively expressed in 
IFNγ-insensitive tumor cells, they were also now rejected (5) (A.T. Bruce and R.D. 
Schreiber, unpublished data).  These findings therefore indicate that the enhancement of 
tumor cell immunogenicity is an important downstream mediator of IFNγ’s actions on the 
tumor.  More recently, additional evidence was obtained from studies utilizing RAG2-/- 
regressor tumors, which are highly immunogenic and are rejected in WT mice.  When 
RAG2-/- regressor cells (normally IFNγ responsive) were rendered insensitive to IFNγ 
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through overexpression of the dominant-negative IFNGR1.ΔIC construct, these cells now 
grew progressively in WT hosts (G.P. Dunn, C.M. Koebel, and R.D. Schreiber, 
unpublished data).   
 A logical extension of the prominent role for IFNγ’s actions on the tumor is that 
some tumor cells may develop IFNγ insensitivity as a mechanism of immune escape.  
Indeed, one analysis of a panel of human lung adenocarcinoma cell lines revealed that 
4/17 contained identifiable defects in the IFNγ signaling pathway which caused these 
cells to be IFNγ unresponsive (18).  Similarly, other downstream components affecting 
tumor immunogenicity, such as MHC class I, TAP1, and β2-microglobulin, have been 
found to be lost in a variety of tumors (20).  Insight into the mechanism of IFN 
insensitivity was provided by a recent study showing that Jak1 expression in the LNCaP 
human prostate cancer cell line was repressed by epigenetic mechanisms (21). 
 
IFNγ’s Actions on the Host 
 Recent studies in our laboratory aimed at defining the host requirements for 
rejection of immunogenic RAG2-/- regressor tumors have also demonstrated a role for 
IFNγ’s actions on host cells (G.P. Dunn, C.M. Koebel, and R.D. Schreiber, unpublished 
data).  When a panel of 129 RAG2-/--derived sarcomas normally rejected in 
immunocompetent hosts were injected into syngeneic IFNGR1-/- mice, many were found 
to grow progressively.  Since analyses of these same tumors using the IFNGR1.ΔIC 
construct or RNAi (see Chapter 4) to inhibit IFNγ sensitivity also showed the tumor cell 
to be an essential target, we could now conclude that both the tumor and the host were 
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relevant sites of IFNγ’s actions during tumor rejection.  These data are also consistent 
with prior studies indicating a role for IFNγ responsiveness at the level of the host, 
though this work relied on adoptive transfer or immunization and rechallenge tumor 
models.     
 In one such report, a CD4+ T cell-mediated adoptive transfer model was 
employed involving transfer of activated tumor-specific CD4+ T cells into SCID mice 
challenged with 6132A-PRO tumor cells (22).  Rejection of this tumor challenge was 
found to require IFNγ since it could be blocked by treatment with anti-IFNγ mAb.  Yet, 
tumor cell sensitivity was not required, prompting the conclusion that indirect effects of 
IFNγ on host cells, rather than on the tumor, was the key determinant of rejection.  
Although this work highlights the potential importance of host IFNγ responsiveness 
during tumor rejection, the observation that IFNγ’s actions on the tumor were not 
required likely reflect the particular model used.  Indeed, in our own work we have noted 
that rejection can also occur independent of tumor cell IFNγ sensitivity if mice are 
previously immunized with or reject the IFNγ-sensitive tumor cell counterpart (A.T. 
Bruce and R.D. Schreiber, unpublished data).  This observation may merely reflect a 
lower MHC class I threshold for reactivation of previously activated or memory T cells 
compared to naïve T cells.   
 Another study using an immunization and rechallenge model primarily mediated 
by CD4+ T cells also pointed to a prominent role for host cell IFNγ responsiveness (23).  
In this model, mice previously immunized with irradiated Mc51.9 tumor cells rejected a 
second challenge with live cells two weeks later, and this rejection was found to require 
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host cell IFNγ sensitivity.  Interestingly, in this model IFNγ’s actions on the host were 
only required during the effector phase, but not during priming of tumor-specific T cells.  
This conclusion was based on adoptive transfer experiments showing that splenocytes 
from immunized WT or IFNGR1-/- mice could provide equal protection when transferred 
into WT recipients but had no effect in IFNGR1-/- recipients.  Subsequent experiments 
using reciprocal bone marrow chimeras with limited IFNGR1 expression then showed 
that sensitivity to IFNγ within nonhematopoietic host cells was necessary and sufficient 
for tumor protection in this model.  Given that T cell responses and tumor infiltration by 
immune cells appeared to be comparable in WT and IFNGR1-/- hosts, the authors propose 
that angiostatic effects of IFNγ acting on host stromal cells are required for tumor 
inhibition.  In support of this idea, immunostaining of tumor tissue appears to show 
reduced infiltration of CD31+ endothelial cells in WT mice compared to IFNGR1-/- mice. 
 In a later study by the same group, these observations were also extended to 
tumor models requiring CD8+ T cells for rejection (24).  Again, however, rejection relied 
wholly on prior immunization with irradiated tumor cells.  Nevertheless, a correlation 
between tumor rejection and decreased angiogenesis was observed.  In addition, 
experiments using IFNγ-deficient or perforin-deficient mice indicated that IFNγ 
production but not perforin-mediated killing was responsible for the inhibition of tumor 
growth.  Although the two previously described studies support the idea that anti-
angiogenesis may be central to the effects of IFNγ on the host, it will be important to test 
this hypothesis in models of naturally-occurring immune responses to rejectable tumors 
in naïve mice.   
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 Additional mechanisms for IFNγ’s actions on the host have also been suggested, 
including its well-established function in promoting Th1 cell development as well as a 
more recently proposed role in inhibiting the activity of CD4+CD25+ T regulatory cells 
(Treg).  Using STAT1-/- mice, it was shown that rejection of an immunogenic P815 tumor 
variant was impaired in the absence of host IFN responsiveness, though effects of IFNγ 
versus IFNα/β could not be distinguished (25).  Nevertheless, this defect was found to 
correlate with a lack of T cell cytotoxic activity.  In another study, it was demonstrated 
that the actions of IFNγ could modulate the generation/activation of Foxp3-expressing 
CD4+CD25+ Tregs following immunization against SEREX-defined self-antigens (26).  
Whereas immunization with these self-antigens has been shown to promote the 
generation and activity of Tregs and lead to enhanced tumor development, the presence 
of IFNγ effectively prevented this effect.  Thus, early production of IFNγ may provide a 
key regulatory mechanism controlling the balance between suppressive CD4+CD25+ 
Tregs and CD4+CD25- Th cells promoting CTL responses.  While the source of IFNγ was 
suggested to be CD8+ T cells, it remains unclear if Tregs were the direct targets or if an 
indirect mechanism was involved.   
 
Evidence for IFNα/β-dependent Cancer Immunoediting 
Early Studies on Exogenously Delivered IFNα/β 
 Although type I IFN was originally identified due to its potent antiviral activity, 
the observation that it also had substantial growth inhibitory effects incited early 
investigations into its use against cancer (27).  Several early studies indeed demonstrated 
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the efficacy of exogenous type I IFN treatment in murine tumor models, and these effects 
were presumed to be due to IFNα/β’s direct actions on tumor cells.  In Balb/c and 
C57Bl/6 mice injected with the RC19 and EL4 tumors, enhanced survival times were 
noted in mice treated with relatively crude interferon preparations (28, 29).  These 
observations were later extended to the murine leukemia L1210 tumor cell line (30).  The 
anti-tumor effects of exogenous IFNα/β, however, were also observed in mice injected 
with an IFNα/β-insensitive subline of L1210 (30, 31), suggesting that the activity of type 
I IFNs on host cells was perhaps more critical in mediating its effects.  Subsequent 
experiments with IFNα/β-insensitive or IFNα/β-sensitive clones of Friend leukemia cells 
supported this finding as the effects of exogenous IFNα/β treatment in prolonging 
survival or inhibiting visceral metastases was equivalent regardless of tumor cell IFN 
responsiveness (32-34).  More recent studies using the AGS-1 melanoma cell line, 
derived from a STAT1-deficient mouse, also showed that tumor cell IFNα/β 
responsiveness was not required for the antitumor effects of exogenously administered 
IFNα; in contrast, the effects of IFNα in this model were abrogated in STAT1-/- mice, 
even upon challenge with STAT1-reconstituted AGS-1 or WT-derived melanoma lines 
(35)  Collectively, the findings from several murine models of tumor immunotherapy 
underscore the importance of host-dependent mechanisms in the efficacy of exogenous 
IFNα/β.  In addition to exogenous treatment, various studies have demonstrated the 
immunotherapeutic effects of ectopically expressing IFNα/β in otherwise poorly 
immunogenic tumors cells (36, 37).             
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 The administration of IFNα/β has also shown some efficacy in the clinical 
treatment of human cancer patients, though effectiveness has been demonstrated only in 
certain tumor types.  The first observation of a therapeutic effect for recombinant IFNα 
was in the treatment of hairy cell leukemia, and it was approved by the FDA for this use 
in 1986 (27, 38).  Since then, subsequent studies have shown beneficial effects for the 
treatment of over 14 types of human cancers including both hematological malignancies 
(e.g. hairy cell leukemia and chronic myeloid leukemia) and solid tumors (e.g. 
melanoma, renal cell carcinoma, and Kaposi’s sarcoma) (39).  Despite the fact that IFNα 
is now the most frequently used cytokine in patients, little is known about the 
mechanisms underlying its clinical efficacy (37).  It is also unclear why some tumors are 
responsive to IFNα/β treatment yet others do not seem to be affected. 
 
Critical Function for Endogenous IFNα/β 
 In addition to the therapeutic effects of exogenous IFNα/β, studies using murine 
tumor models have also demonstrated a role for endogenously produced IFNα/β during 
anti-tumor immune responses.  Initial studies used polyclonal antiserum to murine 
IFNα/β to show that neutralization of the type I IFNs enhanced the growth of xenogeneic 
tumors in athymic nude mice (40).  In subsequent studies, decreased survival times were 
noted in mice treated with anti-IFNα/β polyclonal antiserum and challenged with several 
syngeneic tumors, including the IFNα/β-insensitive Friend leukemia cell line (41).  These 
findings thus suggested a role for endogenous IFNα/β in controlling the growth of 
transplanted tumors, while also indicating that tumor cell IFNα/β responsiveness was not 
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required for its effects.  More recent studies have utilized gene-targeted IFNAR1-/- mice 
to demonstrate the enhanced growth of transplanted tumors in the absence of host IFNα/β 
responsiveness (42) – yet these studies were limited by the use of progressively growing 
tumors and an allogeneic transplantation system.  
 Recent studies from our laboratory have more definitively established a role for 
endogenous IFNα/β in immune-mediated protection against tumor development (16).  
Using a panel of highly immunogenic tumors derived from RAG2-/- mice, we 
demonstrated that global blockade of IFNα/β signaling by treatment with a novel anti-
IFNAR1 mAb abrogated tumor rejection in immunocompetent WT mice.  In addition, 
treatment of IFNα/β-unresponsive IFNAR1-/- mice with MCA yielded a higher incidence 
of primary tumors compared to WT controls at two different doses of carcinogen.  
Similar to RAG2-/--derived sarcomas, analysis of IFNAR1-/--derived tumors by 
retransplanting them into immunocompetent mice revealed an unedited phenotype – that 
is, as a group, these tumors were more immunogenic than comparable tumors originating 
in WT hosts.  Specifically, although IFNAR1-/--derived tumors all grew progressively in 
RAG2-/- hosts, 4/11 were uniformly rejected in WT mice (designated IFNAR1-/- 
regressors), while one additional tumor showed an intermediate phenotype.  WT-derived 
tumors, in contrast, grew progressively in both RAG2-/- and WT recipients.  These data 
therefore indicate that type I IFNs are important components of the cancer 
immunosurveillance network. 
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IFNα/β’s Actions on the Host 
 In subsequent studies, the critical targets of IFNα/β’s actions were explored.  
Several lines of evidence suggested that tumor cell IFNα/β responsiveness was not 
essential in mediating its anti-tumor activity.  First, the fact that IFNAR1-/- regressor 
tumors, which are totally unresponsive to the type I IFNs, can be rejected in WT mice 
affirms that the activity of these cytokines on the tumor are indeed dispensable for 
rejection.  Additionally, experiments with the GAR4 tumor, an MCA-induced tumor 
derived from a IFNAR1-/- x IFNGR1-/- mouse, revealed that selective reconstitution with 
IFNGR1, but not with IFNAR1, converted this tumor from a progressor to a regressor.  
This result was corroborated by two other observations: (i) the reconstitution of IFNAR1 
progressor tumors by enforced expression of IFNAR1 had no effect on their growth in 
WT mice, and (ii) an analysis of one IFNAR1-/- regressor demonstrated that abrogation of 
IFNγ signaling, through overexpression of a dominant-negative IFNGR1 construct, 
prevented its rejection (which normally occurred in the parental tumor independent of 
IFNα/β responsiveness).  Thus, tumor responses to IFNγ, but not IFNα/β, appeared to be 
important for the rejection of this tumor.  Taken together, these findings point to a critical 
role for IFNα/β on cells of the host.  
 In order to examine the significance of host IFNα/β responsiveness for anti-tumor 
immunity, the growth of several RAG2-/- regressor tumors in globally-insensitive 
IFNAR1-/- mice was assessed.  Progressive growth of these tumors demonstrated that host 
type I IFN responses were indeed required for tumor rejection.  Subsequently, bone 
marrow chimeras were used to further define the functionally relevant host cells as 
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derived from the hematopoietic or nonhematopoietic compartment.  Lethally irradiated 
RAG2-/- or IFNAR1-/- mice were reconstituted with wild type bone marrow, generating 
two types of chimeras:  WT→RAG2-/- (IFNα/β-responsive in both hematopoietic and 
nonhematopoietic cells) and WT→IFNAR1-/- (IFNα/β-responsive only in hematopoietic 
cells).  The successful rejection of two RAG2-/- regressor tumors in both sets of chimeras 
– yet progressive growth in IFNAR1-/-→IFNAR1-/- control chimeras – indicated that 
IFNα/β responsiveness in the host hematopoietic compartment was sufficient for 
rejection.  Conversely, the failure of tumor elimination by IFNAR1-/-→RAG2-/- chimeras 
(IFNα/β-responsive only in nonhematopoietic cells) showed that responsiveness in the 
hematopoietic compartment is also required for anti-tumor immunity.  These data 
therefore demonstrate that the key mediators of IFNα/β’s actions reside at the level of the 
host, and specifically host hematopoietic cells.   
 A more recent study using C57Bl/6 strain mice also confirmed the increased 
incidence of MCA-induced sarcomas in the absence of IFNα/β responsiveness (both 
IFNAR1-/- and IFNAR2-/- mice) (43), thus corroborating the importance of this cytokine 
family for tumor protection on a second genetic background.  In this study, IFNα/β-
unresponsive mice were also shown to be more susceptible to the growth of RMA-S 
tumor cells which are normally controlled in WT mice via the actions of NK cells.  In this 
model, the early actions of IFNα/β were critical as anti-IFNAR1 mAb blockade at day 3 
following RMA-S challenge of WT mice had no effect on tumor control.  The temporal 
requirements for IFNα/β thus corresponded to those of NK cells, as NK depletion at day 
3 also had no effect on tumor rejection.  Since NK cell cytotoxic activity can be strongly 
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enhanced by type I IFN, it is likely that NK cells represented the relevant targets of 
IFNα/β, though this was not directly tested.  Nevertheless, these data suggest that 
modulation of NK cell function may be an important component of IFNα/β’s anti-tumor 
function.   
 
Cellular Targets of the IFNs in Cancer Immunoediting 
 The previously described studies have established fundamental roles for IFNγ and 
IFNα/β in the cancer immunoediting process.  Their respective cellular targets, however, 
do not completely overlap.  Whereas type I IFN’s actions on host hematopoietic cells 
were found to be essential for tumor rejection, IFNγ responsiveness within both the tumor 
and the host was required.  Given the range of biologic activity ascribed to the IFNs, it is 
unclear which cellular components within the host are the functionally important 
responders.  Prior to a more thorough discussion of the proposed anti-tumor functions of 
the IFNs, some of their relevant biology will be reviewed.   
 
 
THE BIOLOGY OF THE INTERFERONS 
 
 Initially described over fifty years ago based on their potent antiviral activity (44, 
45), interferons are now recognized as a heterogeneous family of cytokines with 
important immunoregulatory and antiproliferative, as well as antiviral, effects.  The 
interferons are grouped into type I (IFNα/β), type II (IFNγ), and type III (IFNλ) 
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interferon subfamilies according to gene structure and sequence homology, biochemical 
and functional differences, and the usage of distinct cellular receptors.  The type I IFN 
family is composed of a large array of related cytokines which can be produced by most 
cell types in response to infectious stimuli.  In contrast, type II IFN consists of a single 
member, IFNγ, produced by specialized immune cells including activated T cells, NK 
cells, and NKT cells.  Given its strong immunostimulatory activity and prominent role in 
TH1 responses, IFNγ has long been a focal point in the study of immune regulation (46).  
More recently, a number of critical functions for type I IFNs in modulating immune 
responses have emerged; extending the scope of this cytokine family beyond the initial 
containment of viral spread, and establishing IFNα/β as a key link between innate and 
adaptive immunity (47).  The recently described IFNλ family of type III IFNs includes 
IFNλ1, IFNλ2, and IFNλ3 (or IL-28A, IL-28B, and IL-29, respectively) (48, 49).  While 
these cytokines display antiviral activity and share sequence similarities with the type I 
IFNs, they have a different chromosomal location and gene structure and signal through a 
distinct receptor complex consisting of IFNλR1 and CRF2-4.  Given similarities in 
downstream signaling pathways and biologic effects mediated by the IFNλ’s and IFNα/β 
(50, 51), it remains unclear whether the type III IFNs have unique functional properties 
and they will not be discussed further. 
 
Type I Interferon  
 The type I IFN family is comprised of many subclasses, including the IFNα 
subtypes, IFNβ, IFNω, IFNκ, IFNε, IFNδ, IFNτ, and limitin.  Several of these are 
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exclusive to a particular species, as IFNω is functional in humans but not in mice, limitin 
has been described only in the mouse, and IFNδ and IFNτ are confined to pigs and 
ruminants, respectively (52).  In addition, relatively little is known about IFNκ, which is 
expressed in keratinocytes, and IFNε, which is found in the placenta and reproductive 
organs and may function during pregnancy (53).  There is only a single IFNβ, but both 
the human and murine genomes contain numerous IFNα genes, encoding 13 functional 
proteins (54).  Members of the IFNα subclass share 75-80% amino acid homology, 
whereas IFNβ is approximately 30% homologous to the IFNα’s (39).  The mouse type I 
IFN locus also includes an as of yet undefined number of limitin genes (55).  Limitin, 
which is constitutively expressed in T lymphocytes and bronchial epithelial cells, shares 
several functional characteristics with other type I IFNs but lacks myelosuppressive 
activity (56).  All of the type I IFNs function as monomers, act through a common 
IFNα/β receptor, and share certain biological properties such as the inhibition of viral 
replication.    
 The existence of so many different type I IFNs, and the particular abundance of 
IFNα subtypes, is intriguing considering the lack of such apparent redundancy with other 
known cytokines.  This may reflect the tremendous importance of this cytokine family, 
such that the presence of many functionally equivalent molecules would be 
advantageous.  It is also possible that this redundancy allows for the differential 
regulation of subtypes by various cells.  Alternately, each of the type I IFNs, including 
the IFNα subtypes, may have distinct though partially overlapping functions.  While 
these possibilities are not mutually exclusive, their relevance is poorly understood at 
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present.  There is some evidence, however, for the presence of unique activity among the 
various type I IFNs (52, 57).  For example, studies comparing the antiviral, 
antiproliferative, and NK cell stimulatory activities of different human IFNα subtypes 
have revealed unique activity profiles (58).  Furthermore, no clear correlation among the 
activities was evident, indicating that differences were not attributable to the affinities of 
receptor binding (52).  The preferential induction of certain genes by IFNβ has also been 
demonstrated (59, 60), which is consistent with differences in its engagement of the 
IFNα/β receptor (61).  Thus, the natural existence of various subtypes may reflect in vivo 
functional differences not yet recognized.   
 The generation of mice lacking components of the IFNα/β receptor or alternately 
the use of receptor blocking antibodies, has permitted the in vivo study of biologic 
responses in the absence of signaling by all type I IFN subtypes.  Consistent with their 
initial description as antiviral molecules, mice lacking IFNα/β sensitivity display more 
severe phenotypes upon infection with a number of different viruses (62-64).  Evidence 
in humans also supports a role for IFNα/β in antiviral immunity, specifically, the 
identification of human patients with genetic deficiencies in the STAT1 or Tyk2 
molecules, or the UNC-93B protein (involved in viral-induced IFNα/β production) (65).  
The observed deficits in antiviral immunity in the absence of IFNα/β can be attributed to 
multiple mechanisms involving both cell-intrinsic and non-cell autonomous effects (66).  
The direct antiviral actions of type I IFN, mediated by autocrine and paracrine signaling 
by cells responding to infection, includes the inhibition of viral replication, through 
induction of antiviral genes such as PKR, 2′,5′-OAS, RNase L, and Mx, as well as the 
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pro-apoptotic effects of IFNα/β on infected cells.  More indirect immunoregulatory 
effects promote the generation of cellular immune responses through enhancement of 
NK, DC, and T cell function, via mechanisms discussed in more detail later.  As 
previously outlined, these immunomodulatory activities are also critical outside the realm 
of viral infection, such as during naturally-occurring responses to tumors.  Yet, the 
stimuli which might lead to IFNα/β production in this context remain unclear.  
Interestingly, the function of type I IFN during infection with non-viral pathogens (e.g. 
bacteria, protozoa, and helminths) appears more complex (67).  In some cases, type I IFN 
may have host protective effects, yet in other cases such as during Listeria infection, mice 
lacking IFNα/β responsiveness are actually more resistant to infection (68-71).   
 
Type II Interferon 
 In contrast to IFNα/β, type II IFN consists of a single member, IFNγ, which binds 
to a distinct cellular receptor and is encoded by a separate chromosomal locus.  The 
critical importance of IFNγ in promoting immune responses to viral and intracellular 
bacterial infections, as well as to tumors, is corroborated by the phenotypes of mice and 
human patients with defects in IFNγ production or deficiencies in the necessary signaling 
components.  Generally induced by immune and inflammatory stimuli, IFNγ has a 
prominent role in promoting the generation of innate and adaptive immune responses 
through its ability to upregulate antigen processing and presentation, induce macrophage 
activation, promote the production of proinflammatory cytokines, enhance the 
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development of CD4+ T cells into Th1 cells, and increase lymphocyte recruitment 
through the induction of chemokines (72, 73). 
 
Interferon Signaling 
 The type I IFNs mediate their effects by binding to a specific cell surface receptor 
which is generally expressed on all cell types.  The IFNα/β receptor is comprised of two 
subunits, IFNAR1 and IFNAR2, which are constitutively associated with members of the 
Janus kinase (JAK) family, Tyk2 and Jak1, respectively.  Ligand-induced dimerization of 
the receptor subunits leads to the activation of associated Janus kinases by auto- and 
trans-phosphorylation.  Upon activation, these kinases phosphorylate a critical tyrosine 
residue within the IFNAR1 intracellular domain, allowing the recruitment of STAT2 
(which is pre-associated with STAT1 on IFNAR2) via its SH2 domain (53, 61).  
Phosphorylation of STAT2 is followed by recruitment and phosphorylation of STAT1 
and the release of STAT1/STAT2 heterodimers.  The phosphorylated heterodimer enters 
the nucleus by an unknown mechanism, where it associates with IRF-9 (p48) to form the 
heterotrimeric interferon stimulated gene factor 3 (ISGF3) complex.  ISGF3 then initiates 
gene transcription by binding to regulatory regions containing IFN-stimulated response 
elements (ISREs) (74, 75).  In addition to ISGF3, STAT1 homodimers and other STAT 
complexes can also form, although activation of certain STATs appears limited to 
particular cell types (76).  Initiation of a number of ancillary pathways by receptor-
associated JAKs has also been described, including the p38 MAPK and PI3K cascades 
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(76).  Type I IFN stimulation leads to the modulation of many genes, yet the biochemical 
function of most of these remain unknown.    
 Signaling by IFNγ is also transduced via a JAK-STAT pathway upon engagement 
of a ubiquitous cell surface receptor composed of two subunits, IFNGR1 and IFNGR2.  
These receptor chains are constitutively associated with inactive forms of Jak1 and Jak2, 
which become activated following IFNγ binding and receptor oligomerization.  The 
activated JAK kinases phosphorylate a key tyrosine residue within the cytoplasmic 
domain of IFNGR1, leading to binding and phosphorylation of STAT1.  Upon 
dissociation from the receptor, reciprocal homodimers of phosphorylated STAT1 
translocate to the nucleus, where they initiate transcription by binding to DNA regulatory 
elements known as gamma-interferon activation sites, or GAS elements (77, 78).  In 
addition to tyrosine phosphorylation, serine phosphorylation of STAT1 is required for 
full transcriptional activity.  Similar to IFNα/β signaling, ancillary pathways involving 
additional downstream molecules have been described for IFNγ signaling (76).  Evidence 
has also emerged for IFNγ signaling independent of STAT1 (79, 80), though the majority 
of IFNγ-induced responses require STAT1, as well as Jak1 and Jak2 (6).   
 
IFNα/β  Production 
 As most cell types are capable of producing type I IFNs in response to viral and 
bacterial stimuli, there are many possible cellular sources of IFNα/β in vivo.  In addition, 
at least two pathways contribute to IFNα/β production, one involving membrane 
receptors of the Toll-like receptor (TLR) family which are expressed on specialized cell 
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types, and the other employing more ubiquitously-expressed cytoplasmic receptors.  Both 
classes of pattern recognition receptors (PRRs) recognize conserved microbial 
components and are therefore critical for the initial detection of invading pathogens.  
Signaling through these receptors leads to the production of proinflammatory 
cytokines/chemokines and the induction of costimulatory molecules, thus promoting the 
generation of both innate and adaptive immune responses.  Multiple TLRs including 
TLR3, TLR4, TLR7, TLR8, and TLR9, as well as the cytoplasmic proteins retinoic acid 
inducible gene-1 (RIG-1) and melanoma differentiation associated gene-5 (MDA-5) can 
mediate type I IFN production in response to infectious stimuli (66, 81).  Yet, the 
possible induction of IFNα/β in response to other stimuli, such as the growth of 
immunogenic tumors, is poorly understood.   
 TLR-dependent IFNα/β production can occur in response to pathogen-derived 
components including extracellular dsRNA, LPS, viral ssRNA, and unmethylated CpG 
DNA, which activate TLR3, TLR4, TLR7 (or TLR8 in humans), and TLR9, respectively 
(82).  The TLRs, which are expressed primarily on dendritic cells (DCs) and 
macrophages, display distinct patterns of subcellular localization and utilize different 
adaptor molecules to transduce their signals.  Stimulation of TLR7 and TLR9 proceeds 
through the adaptor protein MyD88, whereas IFNα/β production mediated by TLR3 and 
TLR4 is MyD88-independent – instead utilizing the adaptor molecule TRIF, though 
TLR4 shows an additional requirement for the adaptor TRAM (81).  TRIF, which can 
directly associate with the kinases TBK1 and IKKε (83), leads to activation of the 
interferon regulatory factor (IRF) family member IRF3 and IFNα/β transcription.   
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 The cytosolic receptors RIG-I and MDA-5 provide a more universal and TLR-
independent pathway to type I IFN induction.  Although the two receptors detect different 
viral RNA structures, they both utilize the adaptor protein MAVS to induce activation of 
IRF3 and lead to IFNβ production.  The phenotypes of RIG-I and MDA-5 deficient mice 
demonstrate that these two systems are functionally non-redundant, each being required 
for detection of particular viruses.  The recent discovery of a cytoplasmic DNA receptor 
provides an additional pathway for activation of IRF3 and type I IFN production (84).    
 The production of type I IFNs is transcriptionally regulated, and some of the 
relevant transcription factors mediating its induction have been identified.  As alluded to 
earlier, members of the IRF family, including IRF3 and IRF7, have important roles in 
IFNα/β induction.  While IRF3 is constitutively expressed, most cells do not express or 
only weakly express IRF7, which is upregulated by IFNα/β-mediated ISGF3 activation 
(85).  A classical positive feedback mechanism for full induction of the type I IFNs has 
thus been described – whereby initial activation of IRF3 leads to production of IFNβ and 
IFNα4, which signal through the IFNα/β receptor in an autocrine/paracrine manner to 
upregulate IRF7 (86, 87).  Subsequent activation of IRF7 then mediates the expression of 
the majority of IFNα subtypes.  Both IRF3 and IRF7 are activated by phosphorylation of 
carboxy-terminal serine residues by virus-activated kinases, including the IκB kinase-
related kinases IKKε and TANK-binding kinase 1 (TBK1) (83, 88).  Upon activation, 
IRF3 translocates into the nucleus where it associates with the coactivator CBP/p300 to 
drive IFNβ transcription (85).  Induction of the IFNβ gene, whose promoter is well 
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characterized, depends on the cooperative binding of several transcription factors in 
addition to IRF3 – specifically, NF-κB and ATF-2/c-Jun (81).     
 Although all cells bearing the appropriate PRRs can respond to infectious stimuli 
and produce IFNα/β, a recently described subset of dendritic cells – the plasmacytoid 
dendritic cells (pDCs) – are particularly potent producers of IFNα/β during viral 
infections (89, 90).  These cells are found in the T cell areas of secondary lymphoid 
organs and their recruitment from the blood is enhanced under inflammatory conditions 
(91).  pDCs secrete high levels of IFNα/β upon stimulation of TLR7 and TLR9 present in 
endosomal compartments.  This signaling pathway is mediated through the formation of a 
MyD88-TRAF6-IRF7 complex, leading to IRF7 activation and gene transcription (92).  
The transcription factor IRF7 is constitutively expressed at high levels in pDCs compared 
to other cell types and shows a preferential ability to activate IFNα promoters (91).  This 
may explain the particularly robust production of IFNα in pDCs (though IFNβ is also 
produced).  Yet, recent studies have also implicated the regulation of endosomal 
trafficking, as preferential retention of an IFN-inducing TLR9 ligand was apparent in 
pDCs but not conventional DCs (93).  The MyD88-IRF7 pathway appears to be the major 
conduit to type I IFN production in pDCs since these cells do not express TLR3 or TLR4 
and IFNα/β production by pDCs is abrogated in MyD88-/- as well as IRF7-/- animals (94, 
95). 
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IFNγ  Production 
 In contrast to the rather ubiquitous expression potential of type I IFN, IFNγ 
production is mediated by a relatively small subset of cell types – including NK, NKT, 
αβ T cells, and γδ T cells – generally in response to activation rather than viral infection.  
Additional studies also demonstrate IFNγ production by APCs such as macrophages and 
DCs (96-98), yet the functional significance of these cells as sources of IFNγ in vivo is 
unclear at present.  NK cell IFNγ production in response to engagement of NK activating 
receptors is an important early source, whereas production by CD4+ Th1 cells and CD8+ 
T cells upon TCR stimulation are major sources of IFNγ during the adaptive phase of the 
immune response.  An alternative pathway involving IL-12 and IL-18 can also lead to 
IFNγ production (6).  In the context of anti-tumor immunity, prior studies in the literature 
support a role for γδ T cells as important early producers of IFNγ during responses to 
transplantable tumor challenge and during primary MCA-induced carcinogenesis (99).  
Other recent studies, however, have contested this conclusion, suggesting that innate 
immune cells rather than T cells are the relevant producers of IFNγ during anti-tumor 
responses (100).  The recently described subset of interferon-producing killer dendritic 
cells (IKDC) has also been suggested to be an important source of IFNγ during immune 
surveillance of tumors (101).  
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POTENTIAL FUNCTIONS DURING CANCER IMMUNOSURVEILLANCE 
Type I IFN  
 Despite fervent study using animal models and many years of clinical experience 
with its use, the critical functions mediating IFNα/β’s anti-tumor effects remain poorly 
understood.  The type I IFNs may exert their activity through both direct effects on the 
tumor and indirect immunostimulatory activity on various immune components.  Indeed, 
IFNα/β has been shown to promote the differentiation and function of DCs, enhance the 
cytotoxicity of NK cells, boost the activation and survival of T cells, and enhance B cell 
function (37) (Figure 2).  The diversity of IFNα/β’s functions also raises the possibility 
that different mechanisms are operative depending on the tumor phenotype or the 
experimental model involved.  Thus, whereas several studies have demonstrated that 
tumor cell responsiveness is dispensable for IFNα/β’s effects (16, 32, 33), its 
antiproliferative and pro-apoptotic properties may also be important under certain 
circumstances.   
 
Effects on Tumor and Stromal Cells 
 The antiproliferative and pro-apoptotic activity of the type I IFNs, properties 
shared with IFNγ, are potentially important mechanisms for the suppression of tumor 
growth and the containment of infection.  While IFNα/β can inhibit the growth of both 
normal and transformed cells in vitro, different cell lines often show varying degrees of 
sensitivity.  This activity has been linked to a prolongation of the G1 phase of the cell 
cycle and a reduction in the rate of entry into S phase (102).  Specific cell-cycle 
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components affected include c-myc, pRB, cyclin D3, and cdc25A (61).  The type I IFNs 
are also capable of inducing apoptosis under certain conditions, through the classic 
mechanisms involving caspase activation, increases in mitochondrial membrane 
permeability, and the release of cytochrome c (103).  Caspase-8 activation appears to be 
an early event after the treatment of sensitive cells with IFNα, but the initiating events 
are unclear (104).  Importantly for antiviral defense, IFNα/β can sensitize cells to 
inducers of apoptosis such as dsRNA and influenza virus that act through the 
FADD/caspase-8 pathway (105).  Recent work identifying p53 as an IFNα/β-induced 
gene also suggests that these cytokines can sensitize cells to p53-mediated apoptosis in 
response to DNA damage (106).   
 Revealing a previously unrecognized link between IFNα/β and p53, Takaoka et 
al. demonstrated that type I IFN treatment of MEFs led to the upregulation but not 
activation of p53 protein (106).  In addition to enhancing p53-dependent apoptosis upon 
exposure to DNA-damaging agents, IFNα/β treatment also mediated the suppression of 
oncogene-induced cellular transformation.  This was demonstrated in transformation 
assays using MEFs expressing Ha-Ras and the HPV E6 protein, which is known to target 
p53 by ubiquitin-mediated degradation.  While the significance of this mechanism in vivo 
is unknown, this data raises the possibility that IFNα/β modulates intrinsic tumor 
suppressor mechanisms to inhibit cellular transformation – through both an enhancement 
of the p53 pathway and antiproliferative effects which may be p53-independent.  As 
mutational inactivation and loss of heterozygosity are frequently observed in human 
cancers (107), the effects of p53 induction within established tumors might be minimal.  
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Thus, at later stages the anti-tumor activity of IFNα/β may depend more on its 
immunostimulatory functions.  Nevertheless, the role of type I IFNs in suppressing 
primary tumor formation via intrinsic versus extrinsic tumor suppressor mechanisms 
requires further study.     
 In addition to its antiproliferative and pro-apoptotic activity, other direct effects 
on the tumor and surrounding stroma are possible.  For example, the upregulation of 
MHC class I molecules on tumor cells by both type I and type II IFNs could significantly 
enhance recognition by tumor-specific CTL.  The IFNs can also inhibit angiogenesis 
within the tumor by reducing the production of pro-angiogenic factors like bFGF, while 
also stimulating the production of angiostatic chemokines of the non-ELR CXC family 
(i.e. IP-10, Mig, and I-TAC) (108, 109).  The induction of chemokines such as IP-10 may 
also be important in promoting the recruitment of lymphocytes and monocytes to sites of 
inflammation (81).           
 
Immunomodulatory Functions 
 The enhancement of NK cell cytotoxicity was one of the earliest recognized 
effects of the type I IFNs on innate immune cells.  During the course of LCMV infection, 
the induction of early cytotoxic cells was found to correlate with the kinetics of type I 
IFN production in the spleen (110).  Indeed, NK killing of sensitive targets in vitro is 
increased by treatment with IFNα/β, and antibody neutralization studies have 
demonstrated that IFNα/β is responsible for the augmentation of NK cell cytotoxicity in 
vivo following MCMV infection (111, 112).  This increased cytotoxicity against virally-
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infected cells may be partially mediated through the upregulation of TRAIL, which 
contains an ISRE within its promoter (113).  Type I IFNs are also involved in viral-
induced NK cell proliferation through the induction of IL-15 (114).  Similarly, the 
homeostasis of peripheral NK cells (as well as CD8 memory T cells and NKT cells) is 
modulated by IFNα/β through the production of IL-15, which promotes survival possibly 
through maintenance of the anti-apoptotic protein Bcl-2 (115).  Thus, type I IFNs may 
have a prominent role in supporting the function of NK cells, which are involved in host 
protective mechanisms against both infection and tumor formation (116).             
 The effects of IFNα/β in promoting DC maturation have been more recently 
elucidated.  With a central role in the initiation and control of immune responses, DCs 
perform a number of critical functions.  These cells are capable of acquiring and 
processing antigen, homing to the secondary lymphoid organs, and leading to the 
activation (or tolerization) of T and B lymphocytes.  The outcome of this interaction is 
largely determined by levels of co-stimulatory molecules and cytokine production, which 
are induced by infection-associated stimuli including IFNα/β (47, 117).  Thus, type I 
IFNs can have profound effects on T and B cell activation through their modulation of 
DC function.       
 Several studies have demonstrated that IFNα/β treatment of immature DCs in 
vitro can induce their phenotypic maturation, with upregulation of MHC class I and II, 
CD80, CD86, and CD40 (118, 119).  The maturation of splenic DCs after in vivo 
exposure to IFNα/β was also shown, and this phenotype correlated with an increased 
ability to stimulate T cell proliferation in vitro (120).  In vivo models have also been used 
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to demonstrate IFNα/β’s actions in enhancing adaptive immune priming.  Antigen-
specific CD4 T cell and antibody responses to a poorly immunogenic soluble protein 
were augmented by exogenous treatment with IFNα/β or poly(I:C), an effect abrogated in 
IFNAR1-/- mice (121).  Furthermore, adoptive transfer studies were used to show that the 
effect of type I IFNs on DCs alone was sufficient to mediate this enhanced antibody 
production and isotype switching.  These experiments involved the injection of antigen-
pulsed IFNAR1-/- or wild type DCs along with IFNα/β into IFNAR1-/- mice (such that 
only the DCs were IFNα/β responsive).  Additional studies have also confirmed the 
strong adjuvant properties of IFNα when co-injected with a soluble antigen (119).  
Similarly, a role for virally-induced type I IFNs in promoting the cross-priming of CD8 T 
cells has recently been demonstrated (122).  Thus, IFNα/β can act as a potent maturation 
factor for DCs, thereby enhancing the stimulation of T and B cell responses and 
effectively linking the innate and adaptive immune systems (123).   
 The actions of IFNα/β on adaptive immune cells are mediated by both direct and 
indirect effects.  As previously discussed, the type I IFNs can enhance T cell activation 
through the upregulation of MHC and costimulatory molecules on APCs.  Additionally, a 
role for IFNα/β in the induction or maintenance of CD8 memory T cells has been 
demonstrated (124).  Although type I IFNs inhibit T cell proliferation in vitro, IFNα/β or 
IFNα/β-inducing agents lead to the selective proliferation in vivo of memory-phenotype 
(CD44hi) CD8 T cells – through TCR-independent mechanisms involving IFNα/β-
induced secretion of IL-15 by APCs (125, 126).  In addition to these indirect effects, the 
enhancement of activated CD4 and CD8 T cell survival due to IFNα/β’s direct actions on 
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T cells has also been shown (127).  These studies demonstrated that IFNα/β treatment, 
like IL-2, augmented the survival of previously activated CD4 and CD8 T cells in vitro, 
though treatment with other cytokines including IFNγ had no effect.  Further experiments 
involving the co-culture of activated T cells derived from normal or IFNAR1-deficient 
mice indicated that such effects were dependent on T cell IFNα/β responsiveness, 
suggesting that indirect effects by IL-15 were not involved (127).  In contrast to IL-15, it 
was also found that IFNα/β did not upregulate the anti-apoptotic proteins Bcl-2 or Bcl-
XL in T cells, although other studies using activated human CD4 T cells noted increases 
in Bcl-2 and decreases in Bax upon IFNα treatment (128).  It has therefore been 
postulated that IFNα/β induced by inflammatory stimuli may enhance immune responses 
through its role in preventing the apoptosis of activated T cells.           
 Recent work has also demonstrated the ability of IFNα/β to augment the 
activation of naïve CD8 T cells, aside from its enhancement of APC stimulatory activity.  
Using a model system involving the stimulation of naïve TCR-transgenic CD8 T cells 
with artificial APCs (microspheres bearing MHC class I/peptide Ag and the B7-1 ligand), 
it was shown that naïve T cell activation requires an additional or “third signal” provided 
by inflammatory cytokines for full clonal expansion and the development of effector 
function (129, 130).  For naïve CD8 T cell activation, IL-12 was capable of providing this 
signal, and more recently the ability of IFNα/β to perform this function through its direct 
actions on the T cell was established (131).  A role for IFNα/β in the activation of naïve 
CD8 T cells was also noted in prior studies, wherein IFNα/β-dependent CXCR3-
mediated signals were found to be important (132).  In addition to T cell activation, a 
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function for the type I IFNs in enhancing IFNγ production by CD8 T cells during LCMV 
infection was observed (133).  The involvement of IFNα/β in promoting Th1 
development has also been proposed (134), yet this remains controversial and may entail 
species-specific differences between mouse and human T cells (135, 136).  Interestingly, 
while IFNα/β appears to augment T cell activation in most cases, recent studies have 
indicated that in the context of Listeria monocytogenes infection, IFNα/β signaling can 
actually be detrimental by enhancing lymphocyte apoptosis caused by bacterial pore-
forming toxins such as listeriolysin O (68-70). 
 The modulation of B cell function by IFNα/β has also been described, yet the role 
of B cells during antitumor immune responses is unclear.  Through its effects on DCs, 
IFNα/β can lead to the enhancement of humoral responses and isotype switching (121).  
In addition, IFNα/β produced by pDCs in response to viral infection was shown to 
promote the differentiation of CD40-activated B cells in vitro, which further 
differentiated into antibody-secreting plasma cells in the presence of IL-6 (137).  Finally, 
although IFNα/β can exert inhibitory effects on B cell development, the type I IFNs have 
antiapoptotic effects on mature B cells, perhaps through their upregulation of the B cell 
survival factors BlyS and APRIL (53).              
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Figure 2.  Potential functions of type I IFN in cancer immunoediting.  The type I IFNs 
are potent immunomodulators which shape host immunity through direct actions on both 
innate and adaptive immune cells.  In this schematic diagram, some of the 
immunostimulatory functions ascribed to IFNα/β are outlined.  Given the ubiquitous 
expression of IFNα/β receptors and their pleiotropic effects, defining the critical cellular 
targets of type I IFN will be important for understanding their role in promoting anti-
tumor immunity.   
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Type II IFN 
 The potential anti-tumor functions of IFNγ, many of which are shared with type I 
IFN, also include both direct effects on tumor and stromal cells as well as a plethora of 
immunostimulatory activities.  In contrast to IFNα/β, the importance of IFNγ’s actions on 
the tumor cell has been extensively documented and some of the relevant mechanisms are 
apparent.  
 
Effects on Tumor and Stromal Cells 
 As described earlier, IFNγ and IFNα/β share a number of common biologic 
activities including their capacity to exert anti-proliferative, pro-apoptotic, and 
angiostatic effects.  IFNγ can exert growth inhibitory effects on a wide variety of tumor 
cells, through its induction of the cyclin dependent kinase inhibitors p21WAF1/CIP1 and 
p27Kip1.  In addition, sensitization of cells to apoptosis can be enhanced by IFNγ-induced 
caspase-1, PKR, cathepsin D, and surface Fas and Fas ligand (73).  Upregulation of MHC 
class I molecules and other components of the antigen processing and presentation 
pathway (such as TAP1 and immunoproteasome subunits LMP2, MECL-1, and LMP7) 
are important effects for the enhancing immune recognition and promoting the immune 
response.  IFNγ also has a prominent function in facilitating leukocyte-endothelial cell 
interactions through upregulation of cell adhesion molecules such as ICAM-1 and 
VCAM-1, as well as by inducing endothelial cell production of chemokines including 
MCP-1, fractalkine, IP-10, Mig, and I-TAC (138).  As previously discussed, induction of 
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angiostatic chemokines as well as the inhibition of VEGF and basic FGF production 
within the tumor environment are key anti-angiogenic mechanisms.     
 
Immunomodulatory Functions 
 The macrophage activating properties of IFNγ have been extensively 
characterized and are vital for both antimicrobial immunity as well as the induction of 
non-specific killing of tumor cell targets.  Activation of macrophages by IFNγ leads to 
production of reactive oxygen intermediates, nitric oxide, enhancement of MHC class II 
and costimulatory molecule expression, as well as the secretion of proinflammatory 
cytokines such as TNFα and IL-12 (78).  Adaptive immune responses are also promoted 
through direct effects on T and B cells, leading to enhanced CD4+ Th1 development (and 
reciprocal inhibition of Th2 development) as well as B cell isotype switching (73).  As 
previously discussed, inhibition of Treg development or function is another potentially 
important mechanism for promoting protective adaptive immune responses.   
 
 
GOALS OF THIS STUDY 
 
 In the experiments presented in this thesis, we have addressed issues relevant both 
to our understanding of the roles of endogenous IFNα/β and IFNγ in the cancer 
immunoediting process and to the use of exogenous type I IFN for cancer 
immunotherapy.  In the first study, we extended prior work demonstrating the importance 
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of the IFNs in anti-tumor immunity, while examining various parameters of IFN-
dependent tumor rejection including the temporal requirements for their actions, 
contributions to tumor-specific adaptive immune priming, and role of host-derived IFNβ.  
The second study focused on defining the essential host cell targets of type I IFN during 
the rejection of immunogenic sarcomas.  In the third study, we subsequently used similar 
approaches to localize the relevant host targets of IFNγ during tumor rejection, as well as 
confirm the importance of its direct actions on the tumor cell.  Finally, we turned our 
attention to the anti-tumor activity of exogenous IFNα/β using a model of type I IFN 
immunotherapy.  Through a more complete understanding of the protective effects of the 
IFNs during tumor development, as well as identification of critical immune pathways to 
augment therapeutically, such investigation will hopefully translate into more 
sophisticated approaches to cytokine-based cancer immunotherapy.   
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CHAPTER 2 
 
 
 
 
Interferon-Dependent Tumor Rejection: 
 
Exploring the Parameters of the Anti-Tumor 
 
Immune Response 
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INTRODUCTION 
 
 Recent studies have begun to establish the key molecular and cellular components 
of host immunity involved in protective cancer immunosurveillance and immunoediting 
(8, 10).  Both type I (IFNα/β) and type II (IFNγ) interferon were found to play critical 
roles in this process, and some of the relevant functions of these cytokines have begun to 
emerge.  Mice deficient in either IFNα/β or IFNγ responsiveness display an increased 
susceptibility to both primary and transplantable tumor formation.  Yet, further studies 
dissecting the important sites of IFN action have noted prominent differences.  Whereas 
IFNγ’s effects on the tumor cell were absolutely essential, a role for tumor cell IFNα/β 
sensitivity was not observed (5, 16-18).  On the other hand, the actions of both IFNγ and 
IFNα/β on the host were found to be imperative for immune-mediated tumor rejection 
(16, 22, 23) (G.P. Dunn and R.D. Schreiber, unpublished data).  Thus, while the cellular 
targets of the IFNs do not completely overlap, they both exert critical effects on the host 
in promoting anti-tumor immunity.  Elucidation of the relevant mechanisms involved is 
central to our understanding of the cancer immunoediting process. 
 In addition to the functions mediated by type I IFN during this process, little is 
known about the specific contributions of individual members of this cytokine family.  
The type I IFNs include multiple IFNα subtypes, a single IFNβ, and several other poorly 
characterized species, all of which activate a common IFNα/β receptor ubiquitously 
expressed on all cells.  Despite acting through a common receptor, there is some evidence 
for differential signaling among the IFNα/β subtypes, and individual species reportedly 
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possess different activity profiles in vitro (with regard to their antiviral, anti-proliferative, 
and NK cell stimulatory properties).  Whether IFNα/β subtypes perform distinct biologic 
functions in vivo, however, remains unknown.  Alternatively, the numerous type I IFN 
subtypes may be functionally redundant in vivo, yet certain subtypes could be more 
important due to their preferential induction during anti-tumor responses or non-
redundant roles in the regulation/augmentation of IFNα/β production. 
 In this study, we have investigated several aspects of the IFN-dependent response 
to immunogenic tumors.  Using antibody-mediated blockade at different time points, we 
established the temporal requirements for the actions of IFNα/β and IFNγ during tumor 
rejection.  Analysis of tumor-specific T cell priming revealed a prominent defect in the 
absence of host sensitivity to the IFNs, while tumor mixing experiments provide evidence 
for specificity in the mechanisms of tumor elimination.  We also assessed the specific 
contribution of IFNβ during tumor rejection using tumor transplantation studies in IFNβ-
deficient mice.  
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MATERIALS AND METHODS 
 
Mice.  Inbred 129/SvEv and C57Bl/6 mice were purchased from Taconic Farms, and 
129/SvPas mice were from Charles River Laboratories.  129 IFNAR1-/-, IFNGR1-/-, and 
RAG2-/- mice, as well as B6 RAG2-/- mice, were bred in our specific pathogen-free 
animal facility.  B6 IFNAR1-/- mice (previously backcrossed by speed congenics to >99% 
B6 by Tony French and Wayne Yokoyama) were obtained and bred in our animal 
facility.  STAT1Y701F mutant mice were generated in our laboratory and maintained on a 
129/SvEv background (K.S. Lai, J.M. White, and R.D. Schreiber, unpublished data).  
Homozygous mutant mice derived from the A10-C4 and A10-C8 ES cell clones were 
used with similar results.  IFNβ-/- mice (139), originally on a mixed B6x129 genetic 
background, were backcrossed in our laboratory by speed congenics to >99% pure 
129/SvEv or C57Bl/6 backgrounds.     
 
Tumor cells.  RAG2-/- regressor fibrosarcoma cell lines were previously generated by 
subcutaneous 3′-methylcholanthrene (MCA) injection of 129 or B6 strain RAG2-/- mice 
as described (5, 140), and are designated regressors since they are rejected when 
transplanted into syngeneic immunocompetent hosts.  IFNAR1-/--derived progressor 
(d97m915) and regressor (d93m1244) fibrosarcomas have been described (16).  
Progressor tumors, which grow progressively when transplanted into syngeneic 
immunocompetent mice, were generated by MCA injection of WT 129 SvEv (F244) or 
WT B6 (9609, 9614) mice.  GAR4.GR1 is a subclone of the GAR4 MCA-induced 
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fibrosarcoma (derived from a 129 IFNGR1-/-xIFNAR1-/- mouse) in which IFNγ-
responsiveness has been restored by retroviral transduction of IFNGR1 (16).     
 
Tumor transplantation experiments.  Tumor cells were thawed from frozen stocks and 
cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 
2 mM L-glutamate, 1 mM sodium pyruvate, 50 U/ml penicillin, 50 µg/ml streptomycin, 
and 50 µM β-mercaptoethanol (R-10 medium).  After expansion for several passages, 
cells were harvested by incubation in 0.05% trypsin, washed once with R-10 medium, 
and washed three times with sterile, endotoxin-free PBS.  Prior to the last wash, cells 
were counted using a hemacytometer and cell viability was assessed by trypan blue 
exclusion (injected cells were >90% viable).  Cells were injected subcutaneously in a 
volume of 0.15 ml PBS into the shaved flanks of mice.  Tumor size was measured on the 
indicated days and is presented as the average of two perpendicular diameters.  When 
calculating percent tumor growth, mice with tumors larger than 6x6 mm in diameter at 
the end of the observation period were counted as positive.  
 
Antibody Treatment.  For IFNα/β blockade, mice were injected i.p. with a single 2.5 
mg dose of the anti-IFNAR1 mAb MAR1-5A3 (64) or isotype control mAb GIR-208 
(141) at day -1 or as indicated.  For IFNγ neutralization, 750 µg of the anti-IFNγ mAb 
H22 (142) or isotype control anti-GST mAb PIP (143) was injected i.p. followed by a 
250 µg dose every 7 days.  Broad immunodepletion was achieved by i.p. administration 
of a mixture of the anti-CD4 mAb GK1.5 (144), anti-CD8 mAb YTS-169.4 (145), and 
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anti-IFNγ mAb H22.  For this regimen, an initial dose of 750 µg of each mAb or of the 
control mAb PIP was followed by 250 µg of each every 7 days as described previously 
(140).     
 
Ex vivo tumor-specific CTL killing assay.  Spleens were harvested from H31m1 or 
d38m2 tumor-bearing WT, IFNAR1-/-, or IFNGR1-/- mice 20 days after tumor 
implantation and cell suspensions were obtained by homogenization using frosted glass 
slides.  4x107 splenocytes were cultured with 2x106 IFNγ-treated, irradiated (10,000 rads) 
H31m1 or d38m2 tumor cells.  5 days later, the cells were harvested and used as CTL 
effector cells in a cytotoxicity assay.  To generate target cells, H31m1, d38m2, or 1773 
tumor cells were treated with 100 U/ml IFNγ for 48 hours before use.  106 tumor cells 
were radioactively labeled with 25 µCi of Na251CrO4 (PerkinElmer) for 90 minutes at 
37ºC.  The labeled target cells were washed three times and seeded at 10,000 cells/well in 
96-well round-bottom plates.  The effector and target cells were cocultured at indicated 
effector/target cell ratios for 4 hours at 37ºC in 5% CO2.  For blocking assays, 10 µg/ml 
of α-CD8 (YTS-169.4), α-CD4 (GK1.5), or control immunoglobulin (PIP mAb specific 
for glutathione S-transferase) were added to the cell culture of effector and target cells.  
Radioactivity was determined in the supernatants.  Percent specific killing was defined as 
(experimental condition cpm - spontaneous cpm)/(maximal (detergent) cpm - 
spontaneous cpm) x 100.  Data points were obtained in duplicate.  All experiments were 
done at least twice.   
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IFNγ  production assay.  2x107 splenocytes obtained from H31m1 tumor-bearing WT or 
IFNAR1-/- mice 20 days after implantation were cultured with 2x106 IFNγ-treated, 
irradiated (10,000 rads) H31m1 tumor cells.  5 days later, the cells were harvested and 
used as CTL effector cells in an IFNγ production assay.  For target cells, H31m1 or 1773 
tumor cells treated with 100 U/ml IFNγ for 48 hours were seeded at 10,000 cells/well in 
96-well round-bottom plates.  The effector and target cells were cocultured at indicated 
effector/target cell ratios overnight at 37ºC in 5% CO2.  Production of IFNγ in the 
supernatants was measured by using a mouse IFNγ ELISA kit (eBioscience).  
 
Ex vivo analysis of tumors and immune infiltrate.  Tumors were excised from 
euthanized mice, physically disaggregated by mincing with razor blades, then 
enzymatically disaggregated by digestion with 1 mg/ml collagenase IA (Sigma-Aldrich) 
in 10 ml HBSS medium for 1.5-2 hrs at room temperature with occasional mixing.  Cell 
suspensions were washed once with R-10 medium, RBCs were lysed with Hybrimax 
RBC lysing buffer (Sigma-Aldrich), and cells were filtered through a 40 µm strainer to 
remove aggregates and debris.  Cells were incubated with purified anti-CD16/CD32 mAb 
(2.4G2) (BD Biosciences) to prevent non-specific antibody binding to Fc receptors, then 
stained with FITC-conjugated anti-CD45.2 (BioLegend), and biotinylated anti-IFNAR1 
mAb (MAR1-5A3) (64) followed by SA-APC (BioLegend).  Immediately prior to flow 
cytometry, propidium iodide (PI) was added. 
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RESULTS 
 
Immunogenic RAG2-/- Regressor Tumors of Different Genetic Backgrounds Display 
Interferon-Dependent Rejection 
 
 To extend our prior observations that endogenously produced IFNα/β and IFNγ 
play critical roles in the rejection of immunogenic 129 strain RAG2-/- regressor tumors, 
we examined the IFN requirements of a cohort of RAG2-/- regressor tumors derived from 
C57Bl/6 mice recently generated in the laboratory (C.M. Koebel, J.D. Bui, and R.D. 
Schreiber, unpublished data).  These highly immunogenic tumors are termed “RAG2-/- 
regressors” since they are rejected when transplanted into syngeneic WT mice, but grow 
progressively in immunodeficient RAG2-/- hosts.  Of the original group of eight 129 
RAG2-/- regressors screened, four tumors (H31m1, d38m2, d42m1, and F510) were found 
to require host type I IFN responsiveness, as they failed to be rejected when transplanted 
into IFNAR1-/- mice (16) (also see Figure 1).  Additionally, after screening several 
regressor tumors from a new bank of MCA-induced sarcomas derived from completely 
pure 129 SvEv RAG2-/- mice (C.M. Koebel and R.D. Schreiber, unpublished data), we 
observed that the 1773 tumor also required host cell sensitivity to IFNα/β for its 
rejection.  In agreement with these results, when three representative B6 strain RAG2-/- 
regressors were transplanted into IFNAR1-/- mice, all three exhibited IFNα/β-dependent 
rejection, though 1969 and 7835 more strongly than the 6494 tumor (Figure 1). 
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 When the same three B6 regressor tumors were transplanted into WT mice treated 
with the IFNγ-specific neutralizing monoclonal antibody (mAb) H22 (142), two out of 
the three (1969 and 6494, but not 7835) were found to require IFNγ signaling for their 
rejection (Figure 2).  This finding is also consistent with data from the original 129 
RAG2-/- regressors, of which 5/8 (H31m1, d42m1, d38m2, F510, and F515) required 
IFNγ for their rejection (C.M. Koebel, G.P. Dunn and R.D. Schreiber, unpublished data; 
also see Figure 2).  Subsequent studies on this group of IFNγ-dependent 129 regressors 
identified both tumor cells and host cells as obligate sites of IFNγ’s actions.  For 
example, rejection of 4/5 tumors (H31m1, d42m1, d38m2, and F510) was impaired in 
IFNGR1-/- hosts, while overexpression of a dominant-negative IFNGR1 construct 
abrogated rejection of the same four tumors in WT hosts (G.P. Dunn, C.M. Koebel, and 
R.D. Schreiber, unpublished data).  Oddly, the F515 tumor grows progressively with anti-
IFNγ mAb treatment, yet neither grows in IFNGR1-/- mice nor grows when rendered 
IFNγ-insensitive via IFNGR1.ΔIC overexpression.  Thus, for rejection of F515, IFNγ 
sensitivity in either the tumor or the host may be sufficient.  A similar set of experiments 
to dissect the relevant sites of IFNγ’s actions for rejection of the B6 regressor tumors is 
currently ongoing, and it has already been observed that tumor cell IFNγ responsiveness 
is required for 1969 rejection (S.H. Lee and R.D. Schreiber, unpublished data).   
 In establishing the IFN-dependence of B6 strain RAG2-/- regressor tumors, these 
data corroborate – on a second genetic background – the importance of endogenous 
IFNα/β and IFNγ for the rejection of immunogenic transplantable tumors.  The current 
analysis, however, has also uncovered an intriguing point of divergence from previously 
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examined regressor sarcomas; specifically, the observation that rejection of 7835 tumor 
cells requires IFNα/β’s actions on the host, but not the actions of IFNγ on the tumor or 
the host.  This suggests that type I IFN performs a unique function on host cells during 
the lymphocyte-dependent rejection of 7835 tumor cells.  In contrast, of the four original 
129 regressors that required host cell sensitivity to IFNα/β for rejection, the same four 
also required host cell responsiveness to IFNγ.  One additional tumor (F515) was IFNγ-
dependent, but IFNα/β-independent, yet the functionally relevant targets of IFNγ during 
its rejection remain unclear.  Nevertheless, the identification of tumors that specifically 
require type I but not type II IFN, or vice versa, provides preliminary evidence that the 
interferons may perform distinct functions, not only at the level of the tumor cell – which 
has already been established – but also at the level of the host, a possibility that we have 
investigated throughout this study.   
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Figure 1.  Rejection of immunogenic 129 and B6 strain RAG2-/- regressor tumors 
requires host sensitivity to type I IFN.  Groups of WT, IFNAR1-/-, and RAG2-/- mice were 
injected s.c. with 1x106 RAG2-/- regressor tumor cells as indicated and growth was 
monitored.  Data represent mean tumor diameter ± s.e.m.  
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Figure 2.  Antibody-mediated blockade of endogenous IFNγ signaling abrogates 
rejection of 129 and B6 strain RAG2-/- regressor tumors.  Groups of RAG2-/- mice or WT 
mice treated with either anti-IFNγ mAb H22 or isotype control mAb PIP were 
transplanted with 1x106 tumor cells as indicated and growth was monitored.  Mean tumor 
diameter ± s.e.m. over time is plotted.       
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Enhanced Tumor Growth in the Absence of Host STAT1 Signaling 
 
 We postulated that if endogenous IFNα/β and IFNγ did indeed perform distinct 
functions on host cells, then RAG2-/- regressor tumor cells may exhibit more aggressive 
growth in mice unresponsive to both cytokines.  For these studies we utilized gene-
targeted mice engineered to express mutant STAT1 (Y→F mutation at position 701) 
recently generated in the laboratory (K.S. Lai, J.M. White, and R.D. Schreiber, 
unpublished data).  STAT1 phosphorylation at tyrosine 701 is required for signal 
transduction as the Y701F mutant STAT1 displays no nuclear translocation, DNA 
binding activity, or IFN-mediated gene induction when introduced into STAT1-deficient 
U3A cells (146).  As expected, cells isolated from homozygous STAT1Y701F mutant mice 
were unresponsive to IFN treatment when examined in a variety of in vitro biologic 
assays (K.S. Lai, K.C.F. Sheehan, C. Arthur, and R.D. Schreiber, unpublished data).   
 To examine the growth of a transplantable tumor, H31m1 cells (which require for 
their rejection both IFNα/β and IFNγ at the level of the host) were injected into groups of 
WT, RAG2-/-, and STAT1Y701F mice (Figure 3A).  Whereas this tumor challenge was 
rejected in WT hosts, the progressive growth of H31m1 tumor cells was almost identical 
in RAG2-/- and STAT1Y701F mice.  The H31m1 tumor would indeed be expected to grow 
in STAT1Y701F mutant mice, yet the phenotype observed was more severe than that seen 
in either IFNAR1-/- or IFNGR1-/- mice, as summarized in Figure 3B from multiple 
independent experiments with each genotype.  While H31m1 tumor cells grew with rapid 
kinetics in 100% of STAT1Y701 mice inoculated, growth in IFNAR1-/- or IFNGR1-/- mice 
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generally exhibits slower kinetics and is observed in a fraction of mice (ranging from 60-
90% of mice between experiments) (see Figure 1 and Chapter 4, Figure 8).   
 The additive effect of host deficiencies in both IFNα/β and IFNγ responsiveness 
on the growth of transplanted H31m1 cells provides additional indirect support for the 
notion that the IFNs exert non-redundant functions on the host.  Experiments using 
IFNAR1-/-xIFNGR1-/- doubly deficient mice, however, would be required to rule out any 
IFN-independent effects of the STAT1Y701F mutation, though prior studies with STAT1-/- 
mice generated in the laboratory failed to show deficits in response to signaling via other 
cytokine ligands known to activate STAT1 – including EGF, GH and IL-10 (147).  The 
differences we observed on the growth of transplanted tumor cells were not detected in 
previous work comparing the incidence of tumor development following MCA treatment 
of IFNGR1-/- mice compared to STAT1-/- mice (5, 18).  This disparity may reflect 
differences in the respective models employed (i.e. tumor transplantation versus the 
multistep process of primary MCA carcinogenesis). 
 Interestingly, mice heterozygous for the STAT1Y701F mutation showed an 
intermediate phenotype upon H31m1 challenge, with progressive tumor growth 
exhibiting slower kinetics and occurring in only 5/7 mice (data not shown).  Additional 
studies in the laboratory have also documented intermediate responses in STAT1Y701F 
heterozygous cells upon in vitro IFN treatment (K.S. Lai, K.C.F. Sheehan, C. Arthur, and 
R.D. Schreiber, unpublished data).  These data are consistent with the reported ability of 
the STAT1Y701F mutant protein to act in a dominant negative fashion when overexpressed 
in cells containing wild type STAT1 or cotransfected with a wild type STAT1 construct 
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(148, 149); yet, they also demonstrate that such an effect is not merely an artifact of an 
overexpression system as it is also observed both in vitro and in vivo in cells expressing 
normal and mutant STAT1 from its endogenous promoter.  The possibility that mutant 
STAT1Y701F protein could occupy phosphorylated receptor docking sites (thereby 
impeding the binding of wild type STAT1) or the recent demonstration that 
unphosphorylated STAT1 exists predominantly as a dimer in the cytoplasm (150) may 
provide an explanation for these findings.   
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Figure 3.  Enhanced growth of H31m1 tumor cells in the absence of host responsiveness 
to both IFNα/β and IFNγ.  (A) WT, RAG2-/-, and STAT1Y701F homozygous mutant mice 
were injected s.c. with 1x106 H31m1 tumor cells.  (B) Percent of WT, RAG2-/-, 
STAT1Y701F, IFNAR1-/-, and IFNGR1-/- mice with progressively growing tumors 
following H31m1 injection.  Mice with tumors >6x6 mm in diameter at the end of the 
observation period were considered tumor-positive.  Cumulative results from 2-3 
independent experiments are shown.      
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More Prolonged Requirement for the Actions of IFNγ  Compared to IFNα/β  During 
the Anti-Tumor Immune Response 
 
 Given the importance of both type I and type II IFN in the rejection of 
immunogenic transplantable tumors, we wanted to dissect the precise temporal 
requirements for their actions during the generation and execution of the immune 
response.  In this set of experiments, type I IFN blockade was achieved by treatment of 
WT mice with anti-IFNAR1 mAb MAR1-5A3 (64), and IFNγ blockade via treatment 
with anti-IFNγ mAb H22.  By initiating antibody treatment at different times following 
the inoculation of mice with H31m1 tumor cells, we were able to determine when the 
actions of the IFNs were no longer required for successful tumor rejection.  As a control, 
we also treated mice with a cocktail of mAbs to deplete CD4+ and CD8+ cells and 
neutralize IFNγ (anti-CD4/CD8/IFNγ), in order to achieve a broad immunodepletion at 
different times and thus to better define the duration of immune function necessary for 
complete tumor rejection. 
 As summarized in Figures 4-5, anti-IFNAR1 mAb treatment of WT mice prior to 
H31m1 injection led to tumor outgrowth in 80% (12/15) of mice; whereas blockade at 
day 4 or day 6 (relative to tumor challenge at day 0) blocked rejection in a substantial, 
though slightly reduced fraction of mice – 53% (8/15) or 57% (8/14), respectively.  In 
contrast, IFNα/β blockade beginning at day 8 or day 10 resulted in outgrowth in only 
15% (3/20) or 13% (2/15) of mice, which was similar to that observed in mice treated 
with the same regimen of isotype control mAb (Figure 5 and data not shown).  In 
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comparison, the actions of IFNγ were required for a more prolonged time period, as anti-
IFNγ mAb treatment beginning as late as day 8 or day 10 was still able to abrogate 
rejection in a substantial number of animals, 55% (11/20) or 40% (6/15), respectively.  
This effect eventually diminished by day 12 or day 14.  With anti-CD4/CD8/IFNγ mAb 
treatment, however, tumor recovery and outgrowth still occurred in a significant fraction 
of mice (50%, 4/8) even when the immune response was impeded as late as day 14. 
 These data indicate that the requirement for type I IFN is lost between day 6 and 
day 8, thus underscoring the importance of IFNα/β’s actions during the early stages of an 
anti-tumor response.  The finding that tumor outgrowth can still occur upon relatively late 
abrogation of immune function by anti-CD4/CD8/IFNγ mAb treatment, also suggests that 
type I IFN is not essential throughout the duration of immune effector function.  This is 
in contrast to the more prolonged temporal requirement for IFNγ signaling during H31m1 
rejection, perhaps signifying a more prominent role during the effector phase of the 
response due to its actions directly on the tumor cell in enhancing tumor immunogenicity 
and facilitating immune killing.  An important role for tumor cell IFNγ sensitivity in 
H31m1 rejection has, in fact, been demonstrated both through overexpression of a 
dominant-negative IFNGR1 construct (G.P. Dunn, C.M. Koebel, and R.D. Schreiber, 
unpublished data) and by RNAi-mediated knockdown of IFNGR1 expression (see 
Chapter 4).  This point may underlie another interesting observation emerging from these 
studies; specifically, the apparent discrepancy between the rapid and uniform growth of 
H31m1 in WT mice treated with anti-IFNγ mAb as compared to its less robust growth in 
IFNGR1-/- hosts.  Antibody treatment would be expected to block IFNγ signaling in both 
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tumor and host cells, while the defect in IFNGR1-/- lies only in the cells of the host.  
Interestingly, given the hypothesis that IFNα/β’s actions on the tumor cell is of little 
significance during the rejection of RAG2-/- regressors, the growth of H31m1 in WT mice 
treated with anti-IFNAR1 is more comparable to that observed in IFNAR1-/- mice.  
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Figure 4.  More prolonged temporal requirement for IFNγ’s actions than those of IFNα/β 
during tumor rejection.  WT mice challenged with 1x106 H31m1 tumor cells were treated 
beginning on the indicated day with anti-IFNAR1 mAb, anti-IFNγ mAb, or a mixture of 
anti-CD4/CD8/IFNγ mAb’s and tumor growth was monitiored.  Mice with tumors >6x6 
mm at the conclusion of the observation period were considered tumor-positive.  Control 
mice injected with H31m1 and treated similarly with isotype control mAb were included 
in each experiment, and data shown represent percent tumor growth above the control 
group.  Data from 2-4 independent experiments were pooled.           
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Figure 5.  Kinetics of H31m1 tumor growth following antibody-mediated IFN blockade 
at different times.  Growth curves of H31m1 tumor cells in WT mice treated with anti-
IFNAR1, anti-IFNγ, or anti-CD4/CD8/IFNγ mAb’s beginning on different days after 
tumor injection are shown (as summarized in Figure 4).  Similar treatments with the 
respective isotype control mAb were performed for all time points, though only one 
representative graph for each isotype control is shown.  Lines represent individual mice 
and the fraction of tumor-positive mice is indicated.  The higher background levels 
observed with GIR-208 mAb treatment compared to the other isotype controls is 
unexplained, though perhaps due to the higher mAb dose administered (2.5 mg single 
injection).   
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Impaired Generation of Tumor-Specific T Cells in IFNAR1-/- and IFNGR1-/- Mice 
 
 To examine the mechanism underlying the defect in anti-tumor immunity in the 
absence of host responsiveness to the IFNs, we looked specifically at the priming of 
tumor-specific T cells in IFNAR1-/- and IFNGR1-/- mice following tumor challenge.  In 
collaboration with Hirokazu Matsushita in the laboratory, we utilized an ex vivo 
restimulation protocol to assay for the presence of tumor-specific T cells in the spleen.  
At a given time point following tumor inoculation, splenocytes were isolated and 
cocultured in vitro with irradiated IFNγ-treated tumor cells.  Five days later, splenocytes 
were used as CTL effectors in a cytotoxicity assay with 51Cr-labeled, IFNγ-treated tumor 
cells as targets at the indicated E:T ratios.  In each case, killing of radiolabeled irrelevant 
tumor cells (to which the mouse should be naïve) was also assayed to ensure specificity 
of tumor cell killing.  This protocol was used previously to demonstrate a lack of T cell 
priming in CD8α+ DC-deficient p21SNFT-/- mice following H31m1 tumor challenge 
(151).  In addition, we have demonstrated that (i) tumor cell killing is CD8-dependent, 
since blocking mAb’s to CD8 but not CD4 were able to inhibit killing (data not shown, 
see Chapter 3, Figure 12), and (ii) in vitro restimulation of naïve splenocytes yields no 
cytotoxic activity (see Chapter 3, Figure 11).   
 Using this experimental protocol, we assayed splenocytes from WT, IFNAR1-/-, 
and IFNGR1-/- mice at day 20 following injection of H31m1 or d38m2 tumor cells.  
Although robust killing of the respective tumor targets was detected with splenocytes 
from WT mice, very little cytotoxic activity was observed with splenocytes from 
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IFNAR1-/- or IFNGR1-/- mice (Figure 6A).  In addition to cytotoxicity, splenocytes from 
H31m1 tumor-challenged IFNAR1-/- mice showed impaired IFNγ production compared 
to WT mice when cocultured with tumor targets (Figure 6B).  While poor tumor-specific 
T cell priming is not unexpected given the inability of IFNAR1-/- and IFNGR1-/- mice to 
reject these immunogenic tumors, these data suggest a defect relatively early in the anti-
tumor response, as opposed to more downstream deficits in effector cell trafficking to the 
tumor or tumor cell killing.   
 As described previously, a minority of IFNAR1-/- and IFNGR1-/- mice challenged 
with RAG2-/- regressor tumor cells exhibit complete (though sometimes delayed) 
rejection of the tumor inoculum.  To ask whether tumor-specific T cell generation 
correlates with the success of the anti-tumor response in IFNAR1-/- mice, we performed 
similar experiments on WT mice, IFNAR1-/- bearing progressively growing tumors, and 
IFNAR1-/- mice which had rejected the tumor by day 20 (Figure 6C).  Whereas H31m1 
tumor-bearing IFNAR1-/- mice again showed poor cytotoxic activity, IFNAR1-/- hosts 
that had rejected the tumor challenge displayed considerably better tumor cell killing – 
though levels were still intermediate compared to WT mice.  While T cell priming in 
IFNAR1-/- hosts may be less efficient in all cases, these findings indicate that rarely the 
generation of tumor-specific T cells can surpass the threshold needed for successful 
tumor rejection.  Though we have not specifically looked at IFNGR1-/- mice that have 
rejected a tumor challenge, it is likely that a similar finding would be observed given the 
importance of effector T cells for rejection.  The IFN-independent compensatory 
pathways which can drive the generation of tumor-specific T cells (though perhaps less 
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efficiently) are unclear at present and will require further study.  Interestingly, it has been 
suggested that either IL-12 or IFNα/β can function as “signal 3” (in addition to antigen 
and costimulation), necessary for full clonal expansion and acquisition of effector 
function by CD8+ T cells (131, 152).  In addition, during viral infection with LCMV, IL-
12 was found to provide an alternative pathway to the generation of IFNγ-producing 
CD8+ T cells in IFNAR1-/- mice, even though the T cell response was normally 
independent of IL-12 in WT hosts (133).   
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Figure 6.  Lack of tumor-specific T cell priming in IFNAR1-/- and IFNGR1-/- mice.   
(A) Splenocytes from WT, IFNAR1-/-, or IFNGR1-/- mice were isolated 20 days 
following tumor challenge, restimulated in vitro, and used as effector CTL in a 
cytotoxicity assay with radiolabeled tumor targets.  Percent specific lysis at the indicated 
E:T ratio is plotted for n=2-4 animals/group assayed in duplicate and data is 
representative of multiple independent experiments.  (B) IFNγ production by ELISA after 
overnight coculture of splenocytes and tumor cells.  Data from one of two independent 
experiments with similar results are shown.  (C) Cytotoxicity assay using splenocytes 
from WT mice, IFNAR1-/- with growing tumors, or IFNAR1-/- mice that had rejected 
H31m1 tumor cells.  Data are from two independent experiments with n=2-4 mice/group 
assayed in duplicate.          
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Immunogenicity of RAG2-/- Regressor Tumors is Cell Intrinsic, Suggesting 
Specificity in Immune-Mediated Tumor Elimination 
 
 Given the strong IFN-dependence of RAG2-/- regressor tumor rejection, one might 
hypothesize that the differences in immunogenicity between a regressor and a progressor 
sarcoma are related to a differential ability to induce interferon production in the host, 
either through mechanisms of innate immune recognition or by the elaboration of 
endogenous danger signals.  If this were indeed the case, then coinjection of regressor 
tumor cells along with progressor cells may promote the initiation of an immune response 
and lead to rejection of a normally tumorigenic dose of progressor cells.  To test this 
hypothesis we used mixtures of progressor and regressor tumor cells differing in their 
surface expression of IFNAR1, providing a neutral marker (since tumor cell IFNα/β 
sensitivity does not seem to affect tumor immunogenicity) with which to track the two 
different cell types.   
 When a 50:50 mixture of RAG2-/- regressor cells (H31m1 or d38m2) and 
IFNAR1-/--derived progressor cells (d97m915) were injected into mice, progressive 
tumor growth was still observed in both RAG2-/- and WT hosts (Figure 7).  The converse 
mixture – that is, an IFNAR1-/--derived regressor (d93m1244) and a WT progressor 
(F244) – also yielded similar results.  The addition of immunogenic regressor tumor cells 
was therefore unable to induce rejection of a tumorigenic inoculum of progressor cells, 
arguing against a divergence only in their ability to stimulate IFN production or induce 
early innate immune activation.  An alternate possibility, however, is that mechanisms of 
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immune suppression mediated by progressor cells are dominant, and may thus prevent 
the elimination of immunogenic regressor cells within the mixture.  To examine this 
possibility, we harvested late stage tumors (at day 24) from RAG2-/- and WT mice and 
analyzed the tumor cell composition by IFNAR1 staining.  Interestingly, whereas the 
tumors from RAG2-/- mice contained a mixture of regressor and progressor cells (even 
somewhat skewed toward the regressor), those from WT mice consisted of tumors cells 
almost uniformly derived from the progressor cell component (Figure 8 and data not 
shown).  A similar result was obtained with both d38m2/d97m915 and H31m1/d97m915 
tumor cell mixtures, though we did not test different ratios of mixing.   
 These observations indicate that the immunogenicity of RAG2-/- regressor tumors 
is cell intrinsic, while also providing an example of lymphocyte-dependent 
immunoediting in a tumor transplantation setting.  The inherent immunogenicity of 
regressor cells compared to progressor cells may be related to differences in the 
efficiency of immune priming (perhaps due to the spectrum of antigens they possess) or 
to a selective resistance against immune killing or other effector mechanisms (perhaps 
through expression of inhibitory ligands or antigen-specific suppression mediated by 
Treg cells).  The capacity of the immune system to specifically eliminate the regressor 
cells within the mixture also argues against a mechanism of RAG2-/- regressor tumor 
rejection involving immune targeting of the tumor stroma or tumor-associated 
endothelium as postulated by others (153-155), since this would presumably affect the 
growth of progressor cells as well.  In addition, it implies a mechanism of specific killing, 
consistent also with the requirement for T and B lymphocytes.  While tumor cell killing 
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by T cells is perhaps the most likely explanation, NK cells and macrophages may be 
afforded the necessary specificity by tumor-specific antibody bound to the tumor targets 
(eliciting ADCC) or perhaps other mechanisms.         
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Figure 7.  Coinjection of a progressor tumor with immunogenic IFNα/β- and IFNγ-
dependent regressor tumor cells does not elicit rejection.  Groups of WT and RAG2-/- 
mice were injected with 50:50 mixtures of the regressor and progressor tumor cells as 
indicated injected at a dose of 2x106 cells/mouse (1x106 cells of each tumor).  Tumor size 
was measured over time and is plotted as mean tumor diameter ±s.e.m.  Data is 
representative of two independent experiments with n=3-4 (RAG2-/-) or n=5-7 (WT) 
mice/group.       
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Figure 8.  Immunogenicity of RAG2-/- regressor tumors is cell intrinsic.  A 50:50 mixture 
of regressor (d38m2) and progressor (d97m915) tumor cells, distinguishable by 
differential expression of IFNAR1, were injected into RAG2-/- or WT mice.  At day 24 
post-injection, tumors were harvested, disaggregated, and stained for CD45 and IFNAR1 
expression.  FACS plots show IFNAR1 staining of cells within the tumor (CD45-PI-) or 
leukocyte (CD45+PI-) gates from two representative RAG2-/- and WT mice.  Similar 
results were also observed when mixtures of H31m1 and d97m915 were analyzed ex vivo 
at day 24 (data not shown).   
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IFNβ  is Not Essential for the Rejection of Immunogenic RAG2-/- Regressor Tumors  
 
 A critical role for type I IFN’s actions on the host during tumor rejection have 
been well documented, yet little is known about the specific contributions of individual 
members of this cytokine family.  In order to test whether IFNβ performs a unique 
function and is therefore required for the rejection of immunogenic transplantable tumors, 
we employed gene-targeted mice with a genetic deficiency in IFNβ due to insertion of the 
lacZ gene (139).  Since these mice had been maintained on a mixed B6x129 genetic 
background, we backcrossed them onto the 129 SvEv strain using a speed congenics 
approach, thus allowing for tumor transplantation studies with our previously 
characterized regressor sarcomas.  As shown in Figure 9, when three representative 
regressor tumors (H31m1, d38m2, and GAR4.GR1) were injected into IFNβ-/- mice, we 
observed no significant defect in the anti-tumor response – a very minimal difference 
perhaps following challenge with H31m1 (growth in 1/14 IFNβ-/- mice vs. 0/13 WT 
mice) or GAR4.GR1 (2/11 IFNβ-/- vs. 0/10 WT).  In contrast, all three of these tumors 
grew progressively in IFNAR1-/- hosts as well as RAG2-/- control mice.  Uniform 
rejection in IFNβ-/- mice was also observed when mice were challenged with two 
additional IFNα/β-dependent regressor tumors, F510 and 1773 (data not shown).  Taken 
together, these data demonstrate that type I IFN-dependent rejection can occur normally 
in the absence of IFNβ, indicating either no role for IFNβ or potential redundancy in the 
functions of IFNβ and the relatively large number of other IFNα/β subtypes.   
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 To ensure that tumor rejection in IFNβ-/- mice was still dependent on IFNα/β 
signaling, we treated IFNβ-/- mice with either anti-IFNAR1 or isotype control mAb prior 
to transplantation of H31m1 tumor cells.  Whereas control mAb treatment had no effect 
on tumor rejection, IFNα/β receptor blockade abrogated rejection in the majority (9/12) 
of IFNβ-/- mice (Figure 10), comparable to the effect of anti-IFNAR1 treatment of WT 
mice.  Although we also attempted to neutralize IFNα using several pan-IFNα-specific 
mAbs, treatment of WT or IFNβ-/- mice had no effect on tumor rejection (data not 
shown).  Efforts to develop IFNα-specific mAb’s of higher affinity and broader coverage 
against the different IFNα subtypes are currently ongoing in the laboratory. 
 The above experiments were performed using IFNβ-/- mice of approximately 95% 
genetic purity to the 129 SvEv strain (by microsatellite analysis), yet these results were 
subsequently confirmed with completely backcrossed 129 SvEv IFNβ-/- mice.  
Nevertheless, one could still argue in either case that very minor genetic differences 
remain which might contribute to an allogeneic immune response to the transplanted 
tumor cells.  For this reason, we wanted to address the possible contribution of an 
allogeneic response to tumor rejection in IFNβ-/- mice, as well as the potential role of 
type I IFN in allogeneic tumor rejection.  We thus tested the growth of a WT 129 SvEv 
strain progressor tumor (F244) in IFNβ-/- mice and observed no difference in its growth 
kinetics as compared to growth in WT 129 SvEv mice, despite the fact that F244 tumor 
cells were rejected in B6 strain WT mice and B6 IFNAR1-/- mice (Figure 11).  This 
suggests the small contribution of B6 alleles to the background of IFNβ-/- mice is 
insufficient to cause an alloresponse, while also indicating that host sensitivity to IFNα/β 
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is not required for the rejection of allogeneic tumor cells.  Therefore, we find it unlikely 
that an allogeneic immune response directed at minor antigens is contributing to tumor 
rejection in IFNβ-/- mice given that (i) a 129 SvEv WT progressor tumor grows in IFNβ-/- 
mice but not B6 strain WT or IFNAR1-/- mice, and (ii) type I IFN blockade abrogates 
rejection in IFNβ-/- mice, whereas allogeneic tumor rejection does not require IFNα/β 
responsiveness in the host (see also Figure 12).   
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Figure 9.  Host-derived IFNβ is not required for the rejection of immunogenic tumors.  
(A) H31m1, d38m2, and GAR4.GR1 regressor tumor cells were injected at a dose of 
1x106 cells/mouse into groups of WT, RAG2-/-, IFNAR1-/-, and IFNβ-/- mice.  Mean 
tumor diameter ± s.e.m. over time is plotted and the percent tumor growth for each group 
is summarized in (B).   
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Figure 10.  Tumor rejection in IFNβ-/- mice is still dependent on IFNα/β signaling.   
(A) Groups of IFNb-/- mice were treated with anti-IFNAR1 mAb MAR1-5A3 or isotype 
control GIR-208 mAb and transplanted with 1x106 H31m1 tumor cells.  Tumor growth 
over time for mAb treated and RAG2-/- control mice is shown as mean tumor diameter ± 
s.e.m.  Percent tumor growth per experimental group is summarized in (B) from multiple 
independent experiments.        
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Figure 11.  Absence of allogeneic tumor rejection in IFNβ-/- mice.  129 strain WT and 
IFNβ-/- mice as well as B6 WT and B6 IFNAR1-/- mice were challenged with 1x106 F244 
(129/SvEv-derived) progressor tumor cells and tumor growth was monitored over time.  
Data represent the mean tumor diameter ± s.e.m. of n=3-5 mice/group.   
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Host Cell Sensitivity to IFNγ  But Not IFNα/β  is Required for Rejection of an 
Allogeneic Tumor Challenge 
 
 Given the observation that the 129 SvEv strain WT progressor tumor F244 was 
rejected when transplanted into both WT and IFNAR1-/- mice on a C57Bl/6 background, 
we decided to investigate more fully the role of the IFNs in the rejection of an allogeneic 
tumor challenge.  For these experiments, we employed two different B6 strain WT 
progressors, 9609 and 9614, which exhibit extremely aggressive growth when 
transplanted into syngeneic B6 WT hosts (Figure 12).  In contrast, when transplanted into 
WT 129 SvEv (or 129 SvPas) strain mice, these tumors grew quite large initially 
(reaching approximately 10mm in average diameter by day 8), before being rapidly 
rejected in the majority of mice.  Surprisingly, transplantation into 129 strain IFNAR1-/- 
and IFNGR1-/- mice revealed that the allogeneic rejection of these two tumors was largely 
independent of host IFNα/β responsiveness, yet almost completely abrogated in the 
absence of host IFNγ sensitivity.  The reasons for the differential requirement of IFNα/β 
and IFNγ during allogeneic tumor rejection will require further study.  Nevertheless, 
these findings highlight potentially interesting differences in the mechanism of allogeneic 
tumor rejection versus rejection of syngeneic, though still highly immunogenic, RAG2-/- 
regressor sarcomas.   
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Figure 12.  Allogeneic tumor rejection requires host responsiveness to IFNγ but not 
IFNα/β.  B6 strain progressor tumor cells 9609 and 9614 were injected at a dose of 1x106 
cells/mouse into groups of B6 WT, 129 WT, 129 IFNAR1-/-, and 129 IFNGR1-/- mice.  
Each line represents an individual mouse and the fraction of mice with progressively 
growing tumors is indicated.  Allogeneic rejection of 9609 and 9614 was observed in 
both 129/SvEv and 129/SvPas WT mice.   
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DISCUSSION 
 
 In order to further understand the immunostimulatory mechanisms promoted by 
the IFNs during anti-tumor responses, we examined various aspects of the host response 
to immunogenic tumors and the role of the IFNs in these processes.  Using a new cohort 
of RAG2-/--derived regressor tumors from C57Bl/6 strain mice, we generalized original 
observations made with 129 tumors by showing that rejection of B6 regressors also 
required IFNγ signaling as well as host responsiveness to IFNα/β.  To determine when 
during the immune response the respective IFNs were acting, we performed antibody 
blockade experiments and demonstrated that whereas the early actions of IFNα/β were 
sufficient for tumor rejection, the temporal requirement for IFNγ’s actions was more 
prolonged.  We further showed that in the absence of host sensitivity to either IFNα/β or 
IFNγ, generation of tumor-specific T cells with effector activity is severely impaired, 
suggesting a central role in promoting the initiation of adaptive responses to tumors.  
Using mixtures of immunogenic and non-immunogenic tumor cells, we then confirmed 
that specific adaptive immune killing was responsible for rejection, since regressor tumor 
cells were selectively eliminated within tumor cell mixtures.  Finally, because the type I 
IFN family consists of a large number of individual subtypes which might possess non-
redundant functions in vivo, we examined whether IFNβ was essential during the 
rejection of transplantable tumors.  IFNβ-deficient mice, however, showed no defect in 
their ability to reject immunogenic 129 regressor tumors, suggesting potential 
redundancy or a more prominent role for the IFNα subtypes. 
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 Several pieces of data gleaned from these initial studies provide preliminary 
evidence that the IFNs might be performing distinct functions on the host during tumor 
rejection.  In addition to their differing temporal requirements, analysis of STAT1Y701F 
mutant mice showed that growth of transplantable tumor cells was more aggressive in 
mice lacking responsiveness to both IFNα/β and IFNγ than in mice lacking sensitivity to 
one or the other.  In addition, the identification of individual tumors that require only the 
actions of IFNα/β but not IFNγ (or vice versa) for their rejection, also implies their 
unique function.  Although mechanisms contributing to allogeneic tumor rejection may 
be quite different from those involved in the rejection of immunogenic syngeneic tumors, 
we also observed that allogeneic rejection of aggressive progressor tumors required host 
sensitivity to IFNγ but not IFNα/β.   
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CHAPTER 3 
 
 
 
 
IFNα /β’s Actions on Innate Immune Cells 
  
are Critical for Tumor Rejection  
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INTRODUCTION 
 
 Although the anti-tumor properties of exogenously administered type I interferon 
(IFNα/β) have long been recognized, only more recently has a critical function for 
endogenous IFNα/β in tumor protection emerged.  The type I IFNs were initially 
identified based on their antiviral properties, and consist of a large number of related 
cytokines all acting through a common cell surface receptor.  It soon became apparent, 
however, that in addition to antiviral activity, these molecules had potent antiproliferative 
and proapoptotic effects on cells, and could inhibit the growth of a variety of cancer cells 
in vitro (27).  Indeed, early studies demonstrated increased survival times of tumor 
bearing mice when treated with relatively crude, viral-induced interferon preparations 
(28-30).  While initially assumed that the observed effects were due to direct actions of 
IFNα/β on the tumor, subsequent experiments established the in vivo efficacy of 
exogenous IFNα/β treatment even against IFN-insensitive cancer cells (30, 32, 33).  A 
more recent study using the AGS-1 melanoma cell line (derived from a STAT1-/- mouse) 
showed that improved survival with IFNα treatment required IFN responsiveness within 
host cells, but not the tumor (35).  Thus, collective results from a number of different 
model systems emphasize the importance of host-dependent mechanisms for the 
protective effects of exogenous IFNα/β.   
 The first study indicating a role for endogenous IFNα/β in inhibiting tumor 
growth used polyclonal antiserum against murine IFNα/β, demonstrating enhanced 
growth of xenogeneic tumor cell lines in nude mice (40).  Additional work showed 
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decreased survival times in mice treated with anti-IFNα/β polyclonal antiserum when 
injected with several syngeneic tumors (41).  Once again, this phenotype was observed 
when either IFN-sensitive or IFN-insensitive Friend leukemia cells were used.  In a more 
recent report, the progressive growth of tumors was found to be enhanced in IFNα/β-
insensitive IFNAR1-/- mice (42) – yet these studies were limited by an allogeneic 
transplantation system and the use of tumor cell lines that also grew progressively in WT 
mice.   
 Recent work from our laboratory has definitively established endogenous type I 
IFN as an important component of the host protective cancer immunosurveillance 
network using models of both primary and transplantable tumor formation (16).  Utilizing 
a panel of highly immunogenic regressor tumors, we found that treatment of 
immunocompetent WT mice with a novel blocking mAb against IFNAR1 abrogated 
tumor rejection.  In addition, mice deficient in IFNα/β responsiveness (IFNAR1-/- mice) 
were more susceptible than WT controls to the development of primary carcinogen-
induced sarcomas.  As previously demonstrated for tumors derived from other 
immunodeficient mice, IFNAR1-/--derived tumors were as a group more immunogenic 
(thus displaying an unedited phenotype) than tumors arising in WT mice.   
 To investigate the relevant targets of type I IFN, immunogenic IFNα/β-responsive 
tumors were transplanted into IFNAR1-/- hosts, revealing a requirement for IFNα/β’s 
actions on the host during tumor rejection.  In addition, selective reconstitution of IFN 
responsiveness in the GAR4 tumor (derived from an IFNGR1-/-xIFNAR1-/- mouse) 
determined that tumor cell sensitivity to IFNγ, but not IFNα/β could mediate tumor 
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rejection (see also Chapter 4).  These data, along with the observation that IFNAR1-/--
derived tumors could still be rejected in WT hosts, argued against an important role for 
IFNα/β acting on the tumor cell, similar to findings with exogenous IFNα/β treatment.  
Additional studies using bone marrow chimeric mice further localized the essential 
IFNα/β-responsive host cells to the hematopoietic compartment.  This work therefore 
highlights the critical immunomodulatory functions of IFNα/β acting on host 
hematopoietic cells.  The physiologic relevance of this anti-tumor mechanism is also 
supported by recent correlative data in human patients treated with high-dose adjuvant 
IFNα for metastatic melanoma (156).  In this study, manifestations of autoimmunity 
detected in IFNα-treated patients were associated with significantly improved relapse-
free and overall survival.           
 The key role of type I IFN in initiating and enhancing immune responses is being 
increasingly recognized through studies using a variety of experimental systems (47, 53).  
Yet, IFNα/β has been shown to mediate an array of potent immunoregulatory effects on 
cells of both the innate and adaptive immune system.  One of the earliest described 
immunostimulatory effects of type I IFN is its profound enhancement of NK cell 
cytotoxic activity following IFNα/β induction in response to viral infection (110, 111).  
Type I IFN also has prominent effects in promoting the differentiation and maturation of 
DCs, inducing macrophage activation, and eliciting IL-15 production – thereby 
promoting T and B cell responses (67, 121, 122, 126).  In addition to its effects on innate 
immune cells, IFNα/β can augment adaptive immunity through direct actions on T and B 
lymphocytes, including its enhancement of T cell activation and expansion (131, 157-
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159), the survival of activated T cells (127), and B cell antibody production and class 
switching (160, 161).   
 Given the array of immunomodulatory activities ascribed to the type I IFNs, it is 
unclear at present which functions represent the relevant mediators of its anti-tumor 
activity.  In this study, we have therefore investigated the host cell targets of IFNα/β 
required for the rejection of immunogenic tumors.  We demonstrate that the actions of 
endogenous IFNα/β on cells of the innate immune compartment are essential, as selective 
reconstitution of bone marrow chimeric mice with IFNα/β sensitivity only in innate 
immune cells restored tumor rejection.  To investigate the mechanisms involved, we 
subsequently show that depletion of NK cells had no effect on IFNα/β-dependent tumor 
rejection, whereas IFNα/β-responsive innate cells promoted the generation of tumor-
specific CTL which were required for rejection.  Additional studies using p21SNFT-/- 
mice with a selective deficiency in CD8α+ DCs, revealed an obligate function for this DC 
subset in tumor-specific CTL priming and tumor rejection.  Taken together with previous 
data establishing the importance of early IFNα/β action (see Chapter 2), these findings 
underscore the critical role of type I IFN on innate immune cells for the generation of 
protective adaptive responses to immunogenic tumors.  
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MATERIALS AND METHODS 
 
Mice.  Inbred 129/SvEv, C57Bl/6, and 129xB6 F1 mice were purchased from Taconic 
Farms, and 129/SvPas mice were from Charles River Laboratories.  129 IFNAR1-/-, 129 
RAG2-/-, and B6 RAG2-/- were bred in our specific pathogen-free animal facility.  
p21SNFT-/- mice generated and maintained on a pure 129/SvEv background have been 
described (151).  OT-I transgenic mice on a RAG1-/- background were obtained through 
the NIAID Exchange Program, NIH (C57BL6-Tg(OT-I)-RAG1tm1Mom 004175) (162, 
163).  C57Bl/6 strain MHC class I-deficient Kb-/-Db-/-β2m-/- mice (164) were a gift from 
H. Virgin and T. Hansen (Washington University School of Medicine, St. Louis, 
Missouri).   
 
Generation of bone marrow chimeras.  5-FU treated adult bone marrow cells or E14.5 
fetal liver cells were used as donor HSCs for reconstitution of lethally-irradiated 
recipients.  To isolate 5-FU treated bone marrow, donor mice were treated i.p. with 150 
mg/kg 5-FU (American Pharmaceutical Partners) 4-5 days prior to harvest and elution of 
bone marrow cells.  For harvest of E14.5 FLCs, embryos were extracted 14 days 
following implantation, livers were removed, and FLCs were isolated by homogenization 
through a metal mesh strainer with a 6 cc syringe plunger.  Following RBC lysis by 
incubation in Hybrimax RBC lysing buffer (Sigma-Aldrich), cells were filtered through a 
40 µm cell strainer, washed 2 times with sterile endofree PBS, and counted.  Cells were 
resuspended in PBS for injection of 5x106 (FLCs) or 1x106 (bone marrow) cells per 
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mouse in a volume of 0.2 ml using a 0.5 cc 29 gauge insulin syringe.  Recipient mice, 
lethally irradiated with a single dose of 9.5 Gy several hours prior, were anesthetized by 
i.p. avertin and HSCs were infused i.v. via retro-orbital injection.  Animals were 
generally maintained on TMS water for 4 weeks following irradiation and reconstitution, 
and tumor transplantation experiments were performed at least 10-12 weeks post-
reconstitution.      
 
Flow cytometry.  Single cell suspensions were isolated, incubated with purified anti-
CD16/CD32 mAb (2.4G2) (BD Biosciences) to prevent non-specific antibody binding to 
Fc receptors, then stained with the indicated antibodies prior to data collection on a BD 
FACSCalibur (BD Biosciences) and data analysis using FlowJo software (Tree Star).  
The following were purchased from BioLegend:  anti-CD3-FITC (145-2C11), anti-CD4-
PE (RMA4-5), anti-CD8-APC (53-6.7), anti-DX5-PE (DX5), anti-B220-FITC (RA3-
6B2), anti-CD11b-PE (M1/70), anti-CD11b-PerCP-Cy5.5 (M1/70), anti-NK1.1-FITC 
(PK136), anti-CD24-FITC (M1/69), and SA-APC.  Anti-CD11c-PE (HL3) and anti-
CD8α-PerCP-Cy5.5 (53-6.7) were from BD Biosciences, anti-F4/80-FITC (BM8) and 
anti-NKp46-PE (29A1.4) were from eBioscience, and anti-IFNAR1-biotin (MAR1-5A3) 
was described previously (64).  Immediately prior to analysis, propidium iodide (PI) was 
added to assess cell viability.   
 
Tumor cells.  RAG2-/- regressor fibrosarcomas were generated by s.c. MCA injection of 
129 or B6 strain RAG2-/- mice as previously described (5, 140).  The WT progressor 
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tumor 1877 was generated by MCA treatment of WT 129/SvEv mice.  RMA-S is an 
MHC class I-deficient mutant cell line derived from the Rauscher virus-induced 
lymphoma RBL-5 of B6 origin (165).   
 
Tumor transplantation experiments.  Tumor cells were thawed from frozen stocks and 
cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 
2 mM L-glutamate, 1 mM sodium pyruvate, 50 U/ml penicillin, 50 µg/ml streptomycin, 
and 50 µM β-mercaptoethanol (R-10 medium).  After expansion for several passages, 
cells were harvested by incubation in 0.05% trypsin, washed once with R-10 medium, 
and washed three times with sterile, endotoxin-free PBS.  Prior to the last wash, cells 
were counted using a hemacytometer and cell viability was assessed by trypan blue 
exclusion (injected cells were >90% viable).  Cells were injected subcutaneously in a 
volume of 0.15 ml PBS into the shaved flanks of mice.  Tumor size was measured on the 
indicated days and is presented as the average of two perpendicular diameters.  When 
calculating percent tumor growth, mice with tumors larger than 6x6 mm in diameter at 
the end of the observation period were counted as positive.  
 
Antibody treatment.  For depletion of CD4+ and/or CD8+ cells, mice were treated by i.p. 
injection with anti-CD4 mAb (GK1.5), anti-CD8 mAb (YTS-169.4), a mixture of both, or 
control mAb (PIP) at an initial dose of 750 µg followed by 250 µg every 7 days.  NK cell 
depletion was achieved in B6 mice by i.p. injection of 200 µg anti-NK1.1 mAb (PK136) 
(BioLegend) on days -2, 0, and +2, then 100 µg every 5 days thereafter.  Anti-asialoGM1 
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antibody (Wako Chemicals) was resuspended in 4 ml sterile endofree PBS and 100 µl 
(diluted to 0.5 ml in PBS) was administered by i.p. injection on days -2, 0, +2, and +7, 
then every 7 days thereafter.  Control mice received i.p. injections of an equal volume of 
PBS.  In all cases, effective cell depletion was confirmed by flow cytometry or functional 
assay.   
 
Ex vivo tumor-specific CTL killing assay.  Spleens were harvested from H31m1 tumor-
bearing WT, IFNAR1-/-, or bone marrow chimeric mice 20 days after tumor implantation 
and cell suspensions were obtained by homogenization using frosted glass slides.  4x107 
splenocytes were cultured with 2x106 IFNγ-treated, irradiated (10,000 rads) H31m1 
tumor cells.  5 days later, the cells were harvested and used as CTL effector cells in a 
cytotoxicity assay.  To generate target cells, H31m1 or 1773 tumor cells were treated 
with 100 U/ml IFNγ for 48 hours before use.  106 tumor cells were radioactively labeled 
with 25 µCi of Na251CrO4 (PerkinElmer) for 90 minutes at 37ºC.  The labeled target cells 
were washed three times and seeded at 10,000 cells/well in 96-well round-bottom plates.  
The effector and target cells were cocultured at indicated effector/target cell ratios for 4 
hours at 37ºC in 5% CO2.  For blocking assays, 10 µg/ml of α-CD8 (YTS-169.4), α-CD4 
(GK1.5), or control immunoglobulin (α-GST mAb PIP) were added to the cell culture of 
effector and target cells.  Radioactivity was determined in the supernatants.  Percent 
specific killing was defined as (experimental condition cpm - spontaneous 
cpm)/(maximal (detergent) cpm - spontaneous cpm) x 100.  Data points were obtained in 
duplicate.  All experiments were done at least twice.   
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NK cell cytotoxicity assay.  Splenocytes were isolated from mice treated by i.p. injection 
of 300 µg polyI:C 24 hours prior and were used as effector cells with YAC-1 cells as 
tumor targets.  106 YAC-1 cells were radioactively labeled by incubating with 25 µCi of 
Na251CrO4 (PerkinElmer) for 90 minutes at 37ºC.  The labeled target cells were washed 
three times and seeded at 5,000 per well in 96-well round-bottom plates.  Splenocytes 
were added at the indicated E:T ratios.  After 4 hours of culture, radioactivity was 
determined in the supernatants.  Percent specific killing was defined as (experimental 
condition cpm – spontaneous cpm)/(maximal (detergent) cpm – spontaneous cpm) x 100.  
Data points were obtained in duplicate.  All experiments were done at least twice.   
 
DC adoptive transfer.  WT or p21SNFT-/- donor mice were treated i.p. with 10 µg of 
Flt3 ligand (FL) Fc for 3 consecutive days.  10 days after initiation of FL Fc treatment, 
CD11c+ splenocytes were positively selected by MACS (Miltenyi Biotec) (>90% purity).  
A fraction of enriched cells were stained for CD11c, CD8α, and B220 and analyzed by 
flow cytometry.  Whole tumor cell lysates were prepared by harvesting H31m1 cells, 
washing them 3 times with sterile endofree PBS, then performing 5 quick-freeze/thaw 
cycles.  Isolated CD11c+ donor cells were cultured in the presence of tumor lysate 
(DC/tumor cell ratio: 2/1) and 1 µg/ml LPS (Sigma-Alrich) ex vivo for 4 hours.  Cells 
were then washed 3 times with HBSS before transfer.  p21SNFT-/- mice received 9x106 
CD11c+ cells both i.v. and s.c. in the right flank.  Following DC transfer, mice were 
immediately challenged with 1x106 H31m1 tumor cells.   
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Antigen cross-presentation assay.  Dendritic cell cross-presentation of antigen to CD8+ 
OT-I T cells was assessed as previously described (151).  Briefly, spleens from naïve WT 
and IFNAR1-/- mice were digested with collagenase B (Roche) and DNase I (Sigma-
Aldrich), and cellular subpopulations were isolated by MACS purification (Miltenyi 
Biotec).  Total CD11c+ DCs were obtained by negative selection using B220, Thy1.2, 
and DX5 microbeads followed by positive selection with CD11c microbeads.  CD8α+ 
DCs were recovered by B220, Thy1.2, DX5, and CD4 negative selection, followed by 
CD8α positive selection.  CD4+ DCs were isolated by B220, Thy1.2, DX5, and CD8α 
negative selection, followed by CD4 positive selection.  In all cases, purity of the 
population of interest was >97%.  Splenocytes from Kb-/-Db-/-β2m-/- mice were prepared in 
serum-free medium, loaded with 10 mg/ml ovalbumin (Calbiochem) by osmotic shock, 
and irradiated (13.5 Gy) as described (151).  OT-I T cells were purified from OT-
I/RAG1-/- mice by CD11c and DX5 negative selection followed by positive selection 
with CD8α microbeads (purity >99%).  T cells were fluorescently labeled by incubation 
with 1 µM CFSE (Sigma-Aldrich) for 9 minutes at 25°C at a density of 2x107 cells/ml.  
For the assay, 5x104 purified DCs were incubated with 5x104 CFSE-labeled OT-I T cells 
in the presence of varying numbers of irradiated, ovalbumin-loaded Kb-/-Db-/-β2m-/- 
splenocytes.  After 3 days, cells were stained with anti-CD8α-APC and CFSE dilution 
was measured by flow cytometry.  For exogenous IFNα treatment, recombinant murine 
IFNα5 (a gift from D. Fremont, Washington University School of Medicine, St. Louis, 
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Missouri) was added at 1,000 U/ml, whereas IFNα/β blockade was achieved by 
incubation with 5 µg/ml IFNAR1-specific mAb MAR1-5A3.   
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RESULTS 
 
Host Cell Sensitivity to Type I IFN in the Hematopoietic Compartment is Both 
Necessary and Sufficient for Tumor Rejection 
 
 To confirm and extend our previous findings, we investigated the requirements 
for IFNα/β sensitivity within hematopoietic versus nonhematopoietic host cells during 
the rejection of several additional RAG2-/- regressor tumors.  Bone marrow chimeric mice 
were generated by reconstituting lethally-irradiated recipient mice with donor 
hematopoietic stem cells (HSCs) from either 5-fluorouracil (5-FU)-treated adult bone 
marrow or fetal liver cells (FLCs) isolated from embryonic day 14.5 (E14.5) fetuses.  
Although our initial studies utilized 5-FU-treated bone marrow as a source of HSCs, the 
majority employed FLCs due to their ease of isolation as well as their enhanced 
hematopoietic reconstitution potential compared to adult bone marrow cells (166, 167).  
In order to verify the successful reconstitution of recipient mice using this protocol, we 
transplanted different doses of unfractionated FLCs from WT embryos into irradiated 
RAG2-/- mice and monitored both survival and repopulation of hematopoietic-derived 
cell lineages.  While injection of 107 or 106 FLCs yielded recovery of immune cell 
subsets to WT levels, mice given lower doses of cells either failed to survive lethal 
irradiation or demonstrated reduced spleen cellularity and cell percentages (Figure 1).  
Thus, in subsequent experiments a dose of 5x106 FLCs/mouse was typically used.   
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 Mice with type I IFN responsiveness specifically in the hematopoietic 
compartment were produced by reconstituting IFNAR1-/- recipients with WT FLCs 
(WT→IFNAR1-/- chimeras), whereas mice with IFNα/β sensitivity only in 
nonhematopoietic cells were generated by reconstitution of RAG2-/- recipients with 
IFNAR1-/- FLCs (IFNAR1-/-→RAG2-/- chimeras).  The expected phenotypes of these 
mice, along with WT→WT and IFNAR1-/-→IFNAR1-/- control chimeras, were confirmed 
by analysis of IFNAR1 expression on splenocyte subsets by FACS staining (Figure 2).  
We consistently observed that all immune cell lineages were entirely donor HSC-derived, 
with the exception of a small minority of the T cell population which remained recipient-
derived.  Thus, approximately 10-20% of T cells in WT→IFNAR1-/- chimeras were 
IFNAR1-deficient and probably represent long-lived radioresistant memory T cells.  The 
use of RAG2-/- mice as recipients for IFNAR1-/-→RAG2-/- chimeras eliminated this 
potential caveat, and the entire T cell compartment lacked IFNAR1 expression.  In 
addition to the expected IFNα/β receptor status, all of the bone marrow chimeras 
displayed normal cellularity and immune cell percentages in the spleen, as well as 
exhibiting normal splenic architecture (data not shown) – thus providing evidence for the 
normal hematopoietic reconstitution of these mice.         
 To assess the requirements for type I IFN sensitivity during tumor rejection, we 
transplanted the RAG2-/- regressor tumors H31m1 and d38m2 into groups of control and 
bone marrow chimeric mice (Figure 3).  As previously described, these immunogenic 
tumors are rejected when transplanted into naïve syngeneic WT mice, but grow 
progressively in immunodeficient RAG2-/- or IFNAR1-/- hosts.  Similar phenotypes were 
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also observed in control bone marrow chimeras, as H31m1 and d38m2 tumor cells were 
rejected in WT→WT chimeras but grew progressively in IFNAR1-/-→IFNAR1-/- 
chimeras.  Importantly, IFNAR1-/-→RAG2-/- chimeras (IFNα/β-responsive only in 
nonhematopoietic cells) were unable to reject this tumor challenge;  yet, WT→IFNAR1-/- 
chimeras (IFNα/β-responsive only in hematopoietic cells) displayed no defect in tumor 
rejection.  Taken together, these results demonstrate that IFNα/β sensitivity within host 
hematopoietic cells is both necessary and sufficient for rejection of the H31m1 and 
d38m2 RAG2-/- regressor sarcomas.   
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Figure 1.  Titration of unfractionated FLCs for hematopoietic reconstitution of lethally-
irradiated recipients.  WT FLCs at the indicated dose were transplanted i.v. into irradiated 
RAG2-/- recipients and mice were monitored for survival (A) and hematopoietic 
reconstitution at 12 weeks post-transplantation (B and C).  Spleens from control and bone 
marrow chimeric mice were analyzed for cellularity and immune subset composition by 
FACS.     
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Figure 2.  Generation of bone marrow chimeras with selective IFNα/β sensitivity in the 
hematopoietic or nonhematopoietic compartment.  (A) Experimental scheme for 
generating chimeras with selective IFNα/β responsiveness.  (B) Immune compartment 
from a representative cohort of bone marrow chimeras was analyzed for expression of 
IFNAR1 by FACS.  Data represent the percentage of IFNAR1+ splenocytes within each 
cellular subset.       
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Figure 3.  Host hematopoietic IFNα/β responsiveness is both necessary and sufficient for 
rejection of immunogenic tumors.  Groups of control and bone marrow chimeric mice 
were injected with 1x106 H31m1 or d38m2 tumor cells and tumor growth was monitored 
over time (A) for group sizes as indicated in (B).  Results from 2-3 independent 
experiments with each tumor is shown.   
 
 
 
 
Controls
Chimeras
Days post transplant
M
ea
n 
tu
m
or
 d
iam
et
er
 (m
m
)
RAG2-/-
IFNAR1-/-
WT
IFNAR1-/-→RAG2-/-
WT→IFNAR1-/-
WT→WT
H31m1
IFNAR1-/-→IFNAR1-/-
d38m2
Controls
Chimeras
RAG2-/-
IFNAR1-/-
WT
IFNAR1-/-→RAG2-/-
WT→IFNAR1-/-
WT→WT
IFNAR1-/-→IFNAR1-/-
Tu
m
or
 g
ro
wt
h 
(%
)
A
B
12/12
0/20
14/18
0/20
15/18
1/15
10/12
11/11
3/16
14/24
0/14
15/15
3/13
10/12
114 
 115 
Generation of IFNAR1-/- Mixed Bone Marrow Chimeras with Partial IFNα/β  
Sensitivity Within the Hematopoietic Compartment 
 
 Having established the key function of IFNα/β on host hematopoietic cells during 
tumor rejection, we wanted to investigate more specifically the relevant cellular targets 
mediating its protective effects.  After all, the hematopoietic compartment includes the 
entire immune system – a collection of diverse cell types, all of which can respond to and 
are potentially modulated by type I IFN.  To determine the relative contribution of 
IFNα/β’s actions on innate versus adaptive immune cells, we generated a series of mixed 
bone marrow chimeras as outlined in Figure 4, which take advantage of the selective 
deficiency in T and B lymphocyte development in mice lacking the RAG2 gene.  For 
example, hematopoietic reconstitution of recipient mice using a mixture of RAG2-/- and 
IFNAR1-/- HSCs would yield an adaptive immune compartment (T and B cells) 
comprised entirely of IFNAR1-/- cells, whereas innate immune cells (including NK cells, 
macrophages, DCs, and granulocytes) would consist of a mixture of IFNAR1-sufficient 
(RAG2-/- HSC-derived) and IFNAR1-deficient (IFNAR1-/- HSC-derived) cells.  In order 
to skew the composition of the innate immune compartment toward IFNα/β-responsive 
cells, we would simply use a greater ratio of RAG2-/-:IFNAR1-/- HSCs.  The resulting 
chimera would thus have IFNα/β sensitivity in innate but not adaptive immune cells.  
The converse condition – normal IFNα/β responsiveness in the adaptive but not innate 
immune compartment – could be similarly achieved by reconstitution using an unequal 
mixture of RAG2-/-IFNAR1-/- and WT HSCs.     
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 The prediction would be that in the absence of a competitive developmental 
advantage by one of two genetically distinct HSCs infused into an irradiated recipient, the 
mature cellular output of bone marrow-derived lineages would reflect the input ratio of 
the HSC mixture.  Several studies using congenic bone marrow cells have, in fact, shown 
this to be the case (168, 169), suggesting that unequal mixing of HSCs could indeed be 
exploited to generate the desired chimeras.  In order to test this approach and to arrive at 
an optimal ratio for donor stem cell mixing, we reconstituted lethally-irradiated RAG2-/- 
mice with five different ratios of RAG2-/-:IFNAR1-/- HSCs (90:10, 80:20, 70:30, 50:50, 
and 10:90).  At 10-12 weeks post-transplantation, the composition of various immune cell 
lineages in the resulting chimeras was assessed by IFNAR1 staining of splenocytes and 
peripheral blood cells (Figure 5 and data not shown).  At all of the different ratios, T and 
B cells were found to be uniformly IFNAR1-negative as expected.  In contrast, the 
composition of innate immune cells (e.g. NK cells, DCs, and myeloid cells) closely 
mirrored the input ratio, ranging from largely IFNAR1-positive at the 90:10 ratio to 
largely IFNAR1-negative at the 10:90 ratio.  Although a careful analysis of absolute cell 
numbers was not performed, the cellular percentages of T and B cells at the 90:10 
(RAG2-/-:IFNAR1-/-) ratio appeared notably diminished, whereas normal percentages 
were observed at the remaining ratios (data not shown).  Subsequent studies have 
therefore used the 80:20 ratio of mixing to ensure full adaptive immune reconstitution by 
the minority component of the mixture. 
 Using this protocol we have specifically reconstituted IFNAR1-/- mice with either 
innate IFNα/β sensitivity (RAG2-/-+IFNAR1-/-→IFNAR1-/- mixed chimeras, hereafter 
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referred to as “innate” chimeras) or adaptive IFNα/β sensitivity (RAG2-/-IFNAR1-/-
+WT→IFNAR1-/-, “adaptive” chimeras).  As controls, reconstitution of both innate and 
adaptive compartments (RAG2-/-+WT→IFNAR1-/-, “innate+adaptive”) or neither 
compartment (IFNAR1-/-→IFNAR1-/-, “neither”) was achieved.  IFNAR1 staining on 
different immune cell subsets from the spleens of a representative cohort of IFNAR1-/- 
mixed chimeras is shown in Figure 6.  Normal type I IFN responsiveness of reconstituted 
cells was also confirmed by pSTAT1 staining following IFNα treatment (data not 
shown).  In addition, a recent study examining the role of type I IFN during Listeria 
monocytogenes infection has similarly reported the generation of the “innate”-type 
IFNAR1-/- mixed chimeras by using a 5:1 ratio of RAG2-/- and IFNAR1-/- 5-FU-treated 
bone marrow cells to reconstitute lethally-irradiated IFNAR1-/- mice (71).  
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Figure 4.  Strategy for the generation of IFNAR1-/- mixed bone marrow chimeras with 
IFNα/β responsiveness in either innate or adaptive immune cells.  Shown is the 
experimental scheme and protocol for the generation of mixed chimeras by hematopoietic 
reconstitution using mixtures of E14.5 FLCs.     
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Figure 5.  Mixing ratio of RAG2-/- to IFNAR1-/- HSCs determines the composition of 
type I IFN responsive and unresponsive cells within the innate immune compartment.  
Lethally-irradiated RAG2-/- mice were injected i.v. with mixtures of RAG2-/- and 
IFNAR1-/- HSCs at the indicated ratios (1x106 total cells).  At 10-12 weeks post-
transplantation, splenocytes were analyzed for expression of IFNAR1 within various 
immune cell compartments.  Similar results were obtained using either 5-FU treated adult 
bone marrow or FLCs as donor HSCs and the data was pooled, representing n=2-8 mice 
at each ratio.   
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Figure 6.  Validation of selective IFNAR1 expression within innate or adaptive immune 
cells in IFNAR1-/- mixed bone marrow chimeras.  Splenocytes were isolated from a 
representative cohort of mixed chimeras at 12 weeks post-transplantation and IFNAR1 
staining was analyzed by FACS.  Shown are the percentages of IFNAR1+ cells within the 
indicated immune cell subsets.   
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IFNα/β  Sensitivity in Innate Immune Cells is Critical for Tumor Rejection 
 
 To assess the role of IFNα/β’s actions on innate versus adaptive immune cells, we 
injected H31m1 RAG2-/- regressor tumor cells into groups of control and IFNAR1-/- 
mixed chimeric mice (Figure 7).  While this tumor challenge is rejected in WT hosts, it 
grows progressively in RAG2-/- mice and in the majority of IFNAR1-/- mice.  Consistent 
with our prior results, “innate+adaptive” IFNAR1-/- chimeras (IFNα/β-responsive within 
the entire hematopoietic compartment) were also able to reject H31m1 tumor cells, while 
“neither” IFNAR1-/- chimeras (globally IFNα/β-unresponsive) showed a considerable 
defect in anti-tumor immunity.  Importantly, “adaptive” chimeras (IFNα/β-responsive 
only in adaptive immune cells) could not reject this tumor challenge, while the majority 
of “innate” IFNAR1-/- chimeras (IFNα/β-responsive only in innate immune cells) 
displayed normal rejection of H31m1.   
 Although there was not a statistically significant difference between the percent 
tumor growth in “innate+adaptive” as compared to “innate” IFNAR1-/- chimeras (2/17 
versus 7/25, p=0.27), it is not clear whether complete recovery of anti-tumor immunity 
was achieved in “innate” IFNAR1-/- chimeras.  There are two possibilities that might 
account for a potential difference, though at present we cannot distinguish between the 
two;  either (i) there exists a minor role for T and/or B lymphocyte IFNα/β sensitivity, or 
(ii) the minor fraction of IFNα/β-unresponsive innate immune cells present in “innate” 
IFNAR1-/- chimeras (due to the 4:1 RAG2-/-:IFNAR1-/- HSC mixing ratio) have an 
inhibitory effect.  In either case, the previously described findings support the conclusion 
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that the major, and perhaps only, functionally relevant role of type I IFN on host cells 
during tumor rejection is mediated by the innate immune compartment. 
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Figure 7.  Rejection of immunogenic tumor cells requires IFNα/β’s actions on cells of 
the innate immune compartment.  1x106 H31m1 tumor cells were injected into groups of 
control and IFNAR1-/- mixed bone marrow chimeric mice and tumor growth was 
monitored.  The mean tumor diameter ± s.e.m. over time is shown in (A) and percent 
tumor growth is summarized in (B) for the indicated group sizes.  Data represent the 
cumulative results of at least 3 independent experiments.    
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Demonstration of the Normal Functional Reconstitution of IFNAR1-/- Mixed Bone 
Marrow Chimeras 
 
 In order to address the possibility that tumor growth in IFNAR1-/- mixed chimeras 
was due to residual immune dysfunction or incomplete hematopoietic reconstitution, we 
utilized the F515 RAG2-/- regressor tumor, which requires lymphocytes and IFNγ, but not 
host IFNα/β sensitivity, for its rejection.  As shown in Figure 8, F515 was rejected when 
transplanted into WT mice, WT mice treated with control mAb, and IFNAR1-/- mice, but 
grew progressively in RAG2-/- mice and WT mice treated with anti-IFNγ mAb.  Similar 
to IFNAR1-/- control mice, this tumor challenge was rejected in IFNAR1-/- mixed 
chimeras of each type, confirming the functional reconstitution of the immune 
compartment in these mice.  In addition, we also assessed spleen cellularity and 
confirmed the normal representation of various immune cell subsets within the spleens of 
mixed chimeras as another measure of hematopoietic reconstitution (Figure 9).  Finally, 
to rule out the presence of a hyperactive immunological state in these reconstituted mice, 
we challenged groups of IFNAR1-/- mixed chimeras and control mice with the 1877 WT 
progressor tumor, which grew similarly in all of the mice (Figure 10).   
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Figure 8.  Functional immune reconstitution in IFNAR1-/- mixed bone marrow chimeras.  
The indicated groups of control, mAb-treated, and mixed bone marrow chimeric mice 
were injected with 1x106 F515 RAG2-/- regressor tumor cells.  As shown, rejection of this 
tumor is independent of host IFNα/β sensitivity but requires IFNγ signaling.  Results 
represent cumulative data from 2 independent experiments with n=7-10 mice/group.   
 
Controls Chimeras
RAG2-/-
IFNAR1-/- 
WT
WT+α-IFNγ
WT+ctrl Ig
Neither
Innate+Adaptive
Adaptive
Innate
Days post transplant
M
ea
n 
tu
m
or
 d
iam
et
er
 (m
m
)
130 
 131 
 
 
 
 
 
 
Figure 9.  Normal spleen cellularity and immune composition in IFNAR1-/- mixed bone 
marrow chimeras.  Spleens were harvested from mixed chimeras of each type at 12 
weeks post-reconstitution, and both cellularity (A) and immune subset composition (B) 
were analyzed.   
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Figure 10.  Absence of hyperactive immunological state in IFNAR1-/- mixed chimeras.  
Groups of control and mixed chimeric mice were injected with 1x106 1877 progressor 
tumor cells.  Mean tumor diameter ± s.e.m. over time are shown.   
 
 
Days post transplant
M
ea
n 
tu
m
or
 d
iam
et
er
 (m
m
)
134 
 135 
Innate Immune Type I IFN Responsiveness Promotes the Generation of Tumor-
Specific T Cells 
 
 We have previously demonstrated that the anti-tumor defect in IFNAR1-/- hosts 
correlates with the absence of detectable tumor-specific T cells in the spleen after ex vivo 
restimulation (see Chapter 2, Figure 6).  A similar type of analysis was thus performed 
with IFNAR1-/- mixed bone marrow chimeras to determine whether the presence of 
IFNα/β-responsive innate immune cells was sufficient to restore the generation of tumor-
specific T cells to wild type levels.  At day +20 relative to H31m1 tumor challenge, 
spleens from representative control and chimeric mice were harvested, splenocytes were 
restimulated once in vitro with irradiated tumor cells, and the cells were then used as 
effectors in a standard cytotoxicity assay with radio-labeled tumor (Figure 11).  As 
observed in prior experiments, splenocytes from WT mice displayed robust tumor cell 
killing, whereas those from IFNAR1-/- mice did not.  Similar results were also seen with 
control WT→WT and IFNAR1-/-→IFNAR1-/- chimeras.  Reconstitution of IFNα/β 
sensitivity within hematopoietic cells (in “innate+adaptive” chimeras) restored tumor cell 
killing to levels comparable to WT→WT chimeras – further illustrating the importance of 
IFNα/β’s actions on hematopoietic cells for the development of an anti-tumor immune 
response.  Within the hematopoietic compartment, selective reconstitution of innate 
immune IFNα/β sensitivity (in “innate” chimeras) was able to recapitulate the normal 
generation of H31m1-specific T cells.  In contrast, “adaptive” chimeras – containing 
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IFNα/β-responsive cells exclusively in the adaptive immune compartment – showed no 
recovery of tumor-specific T cell priming.   
 To assess whether tumor cell cytotoxicity was attributable to CD8+ T cell killing, 
we added blocking mAb’s specific for either CD4 or CD8 to the culture of effector and 
target cells.  As shown in Figure 12, addition of a blocking anti-CD8 antibody, but not 
anti-CD4 antibody, inhibited the cytotoxic activity of “innate” chimera splenocytes 
against H31m1 tumor cells.  This result also demonstrates that the defect in tumor cell 
killing observed in IFNAR1-/- mice is, in fact, due to the lack of T cell priming rather than 
inherent deficits in the effector function of IFNAR1-/- CD8+ T cells, since T cells in 
“innate” chimeras are exclusively IFNAR1-deficient. 
 While IFNα/β’s actions on innate immune cells can promote tumor-specific T cell 
generation, these data do not formally establish this effect as the mechanism responsible 
for tumor rejection in “innate” IFNAR1-/- chimeras.  To directly address this question, we 
used a mixture of monoclonal antibodies that deplete CD4+ and CD8+ cells to ask 
whether T cells were indeed required for tumor rejection.  As depicted in Figure 13, 
treatment of WT mice with the combination of anti-CD4/CD8 mAb’s blocked the 
rejection of H31m1 tumor cells in 5/6 mice, while treatment with control mAb had no 
effect.  Similarly, H31m1 tumor cells grew progressively in 5/5 “innate” IFNAR1-/- 
chimeras treated with anti-CD4/CD8 mAb’s, yet in only 2/6 “innate” chimeras treated 
with control mAb.  Taken together, these data underscore the important function of innate 
immune IFNα/β sensitivity for the generation of tumor-specific T cells, while confirming 
the essential role of these effector cells during tumor rejection.     
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Figure 11.  Innate immune IFNα/β sensitivity restores the generation of tumor-specific T 
cells.  Splenocytes were isolated from control and IFNAR1-/- mixed chimeric mice 
injected 20 days prior with 1x106 H31m1 tumor cells.  After a single in vitro 
restimulation, cells were used as CTL effectors in a 4 hr-cytotoxicity assay with 
radiolabeled H31m1 tumor cells.  Percent specific lysis at the indicated E:T ratio is 
plotted for n=3-5 mice per group assayed in duplicate from 2-3 independent experiments.  
In each case, cytotoxicity against the irrelevant RAG2-/- regressor tumor 1773 was 
assayed to confirm specificity of killing (data not shown).  Background levels of 
cytotoxicity obtained with naïve splenocytes following in vitro stimulation and tumor 
coculture are shown.   
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Figure 12.  CD8+ T cells are responsible for enhanced tumor-specific cytotoxicity 
elicited by IFNα/β-responsive innate immune cells.  Splenocytes from an IFNAR1-/- 
mixed chimera with selective IFNα/β sensitivity in innate immune cells were isolated at 
day 20 post-transplant with 1x106 H31m1 tumor cells.  Ex vivo cytotoxicity was assayed 
in the presence of blocking anti-CD4 (GK1.5), anti-CD8 (YTS-169.4), or control (PIP) 
mAb.  Percent specific lysis at the indicated E:T ratios are shown.  Similar results were 
obtained using splenocytes from WT mice following H31m1 tumor challenge (data not 
shown).   
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Figure 13.  T cells are required for tumor rejection in innate immune IFNα/β-responsive 
mixed bone marrow chimeras.  (A) 1x106 H31m1 tumor cells were injected into RAG2-/- 
controls or groups of WT mice and innate IFNAR1-/- mixed chimeras treated with either 
control PIP mAb or anti-CD4/CD8 mAb’s.  Mean tumor diameter ± s.e.m. over time is 
shown from 2 independent experiments.  Percent tumor growth for the respective groups 
is indicated in (B).         
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NK Cells are Not Required for IFNα/β-Dependent Tumor Rejection 
 
 Having established the importance of IFNα/β’s actions on cells of the innate 
immune compartment, we sought to identify the functionally relevant responding cells 
within this compartment mediating its anti-tumor effects.  As NK cells are one population 
of innate immune cells that (i) have a host protective role in some models of primary and 
transplantable tumorigenesis (116, 170), and (ii) display enhanced cytotoxic activity in 
response to type I IFN (171), we investigated the role of NK cells in the IFNα/β-
dependent rejection of immunogenic fibrosarcomas.  The finding that T cells play an 
obligate function in the rejection of RAG2-/- regressor tumors suggests that NK-mediated 
cytotoxicity is not the sole effector mechanism responsible for tumor elimination; 
however, early tumor cell recognition and killing, and/or the production of pro-
inflammatory cytokines, may be imperative for the induction of an effective anti-tumor 
immune response.         
 For these experiments we utilized MCA-induced RAG2-/- regressor sarcomas on a 
C57Bl/6 background, which have recently been generated in the laboratory, in order to 
allow for NK cell depletion in B6 strain mice via treatment with the anti-NK1.1 mAb 
PK136 (172).  We confirmed by FACS analysis the effective depletion of both NK and 
NKT cells in the spleen following anti-NK1.1 mAb treatment (Figure 14 and data not 
shown).  A standard assay for NK cell function involving ex vivo killing of 51Cr-labeled 
YAC-1 target cells following polyI:C injection, also showed complete abrogation of NK 
killing upon anti-NK1.1 mAb treatment (Figure 15A).  In addition, the in vivo control of 
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a low dose challenge with MHC class I-deficient RMA-S tumor cells was abolished by 
anti-NK1.1 but not anti-CD4/CD8 mAb treatment (Figure 15B), as previously reported 
(173).  
 Despite the complete elimination of NK cell function using this treatment 
protocol, we observed no effect on the rejection of three representative B6 RAG2-/- 
regressor tumors (1969, 7835, and 6494), as shown in Figure 16.  Similar to 129 SvEv 
strain RAG2-/- regressors, the immune-mediated rejection of these B6 sarcomas required 
IFNα/β responsiveness at the level of the host (see Chapter 2).  Taken together, these 
data therefore indicate that the actions of endogenous type I IFN on NK cells are not 
absolutely required to mediate the protective effects of this cytokine family.     
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Figure 14.  Effective NK cell depletion by anti-NK1.1 PK136 mAb treatment.  WT B6 
mice were treated with PBS or PK136 mAb by i.p. injection as indicated in Materials and 
Methods.  Splenocytes were analyzed at day +2 of the treatment regimen by FACS 
analysis using the NK cell markers DX5 and NKp46.  Splenocytes were gated on CD3- 
cells, and the percentages of DX5+NKp46+ cells are indicated.  Similar depletion was also 
observed at day +6 (data not shown).   
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Figure 15.  Abrogation of ex vivo NK killing activity and in vivo NK cell function with 
anti-NK1.1 mAb PK136 treatment.  (A) Splenocytes from WT B6 mice treated with 
either PBS or anti-NK1.1 mAb PK136 were isolated at day +4 of the treatment regimen, 
following i.p. injection of 300 µg polyI:C 24 hours prior.  Cells were used as effectors in 
a standard 4 hr cytotoxicity assay with NK-sensitive YAC-1 targets.  Percent specific 
lysis at the indicated E:T ratios is shown for n=4 mice/group assayed in duplicate from 
two independent experiments.  (B) PBS or PK136 mAb-treated mice were injected s.c 
with a low-dose challenge of 1x105 RMA-S cells and tumor growth was monitored.  
Mean tumor diameters ± s.e.m. for 3 mice/group are shown for one of two independent 
experiments with similar results.   
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Figure 16.  NK cells are not required for rejection of immunogenic sarcomas.  Groups of 
RAG2-/- controls or WT mice treated with either PBS or anti-NK1.1 mAb PK136 were 
challenged with 1x106 1969, 7835, or 6494 B6 RAG2-/- regressor tumor cells.  Data 
represent pooled results from two independent experiments with n=6-8 (WT) or n=4 
(RAG2-/-) mice.    
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NK Cell-Independent Effects of Anti-asGM1 Antibody Treatment Inhibits Anti-
Tumor Immunity 
 
 During the course of the prior studies, we observed that treatment of mice with 
polyclonal antiserum against the surface glycolipid asialo-GM1 (anti-asGM1 Ab) was 
able to inhibit the rejection of two 129 regressor tumors, H31m1 and d38m2, in a 
proportion of mice (Figure 17).  This antibody is frequently used in non-NK1.1 
expressing mouse strains to deplete NK cells; however, depletion is not specific since 
asialo-GM1 is also expressed on activated macrophages and on subsets of naïve and 
activated T cells.  In fact, it has been reported that asialo-GM1 is induced on the majority 
of virus-specific CD4+ and CD8+ T cells following acute viral infection, and that these 
cells are largely depleted by in vivo administration of anti-asGM1 Ab (174, 175).  In our 
studies, we found that anti-asGM1 Ab treatment depleted NK cells but not NKT cells 
(Figure 18) as previously reported (176), and that NK cell function is effectively 
eliminated when assessed using both in vitro and in vivo assays (Figure 19).  In addition, 
percentages of CD4+ and particularly CD8+ T cells were reduced in the spleens of naïve 
129 and B6 strain mice following anti-asGM1 Ab treatment (Figure 18 and data not 
shown).  Though we did not observe depletion of F4/80+CD11b+ macrophages within the 
spleen, macrophage expression of asialo-GM1 at high levels is typical seen only upon 
activation (177).         
 Given the possibility that NK cell-independent effects of anti-asGM1 Ab might be 
responsible for its inhibition of anti-tumor immunity, we tested this hypothesis using the 
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three B6 regressor tumors previously shown to be rejected in mice lacking NK cells (see 
Figure 16).  When transplanted into WT mice treated with anti-asGM1 Ab, two of the 
three tumors (1969 and 6494, but not 7835) now grew progressively.  As these same 
tumors were rejected in WT mice treated with anti-NK1.1 mAb, the effects of anti-
asGM1 Ab treatment must be mediated by depletion or blockade of a non-NK cell 
population.  Although the depletion of effector T cells may be solely responsible, it is 
intriguing to speculate that the elimination of activated macrophages might be involved.  
Future studies using clodronate liposomes or CD11b-DTR mice to achieve macrophage 
depletion will be required to clarify their function during tumor rejection.   
 In addition to potential effects on macrophages, recent studies have suggested that 
a population of innate-like central memory CD8+ T cells is readily depleted by anti-
asGM1 Ab treatment of naïve mice (178).  This subset of asGM1+CD8+ T cells (which 
also express CD44, CD122, CD62L, and CCR7) were potent producers of early IFNγ 
upon anti-CD3 stimulation both in vitro and in vivo compared to the asGM1-CD8+ 
central memory T cell population.  In our experiments, we indeed noted significant 
depletion of a CD3+CD122+ T cell population with anti-asGM1 Ab treatment (data not 
shown).  Recent studies in our laboratory have shown that most memory phenotype 
CD8+CD44+ T cells also express high levels of the chemokine receptor CXCR3 and can 
be selectively depleted in vivo using the anti-CXCR3 mAb CXCR3-173 (179) (R. 
Uppaluri, J.J. Brotman, and R.D. Schreiber, unpublished data).  Depletion of this subset, 
however, had no effect on the rejection of several tumors which grew progressively with 
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anti-asGM1 Ab treatment (R. Uppaluri, J.J. Brotman, and R.D. Schreiber, unpublished 
data), suggesting that these cells are not the relevant targets of anti-asGM1 Ab.    
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Figure 17.  Anti-asGM1 Ab treatment inhibits RAG2-/- regressor tumor rejection via NK 
cell-independent effects.  1x106 cells of the indicated 129 or B6 strain regressor tumors 
were injected into groups of RAG2-/- mice, WT mice treated with PBS, or WT mice 
treated with anti-asGM1 as indicated in Materials and Methods.   
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Figure 18.  Depletion of NK cells and T cell subsets in mice treated with anti-asGM1.  
Splenocytes were isolated at day +4 from naïve B6x129 F1 mice treated with either PBS 
or anti-asGM1 and immune cell subsets were examined by FACS.  Similar NK cell and T 
cell, but not NKT cell, depletion was also observed in B6 strain mice (data not shown).     
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Figure 19.  Elimination of NK cell function in 129 and B6 mice treated with anti-asGM1 
Ab.  (A) 129/SvEv mice were treated with either PBS or anti-asGM1 Ab and splenocytes 
were isolated at day +4, following injection of 300 µg polyI:C 24 hrs prior.  NK killing 
assays were performed using YAC-1 target cells, and percent specific lysis is plotted for 
n=3-4 mice/group from two independent experiments.  (B) B6 mice treated with anti-
asGM1 were also injected with a low-dose RMA-S challenge (1x105 cells) and growth 
was monitored.   
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Cross-Presentation by CD8α+ Dendritic Cells is Required for Tumor-Specific CTL 
Priming and Tumor Rejection 
 
 As our previous findings have (i) established an important role for innate immune 
IFNα/β sensitivity during tumor-specific T cell priming and tumor rejection, and (ii) 
ruled out a prominent function for NK cells during this process, we turned our attention 
toward other innate immune cell populations – including professional APCs such as DCs 
and macrophages which are particularly adept at initiating adaptive T cell responses.  As 
a first step toward examining the specific function of IFNα/β on these cell populations 
during tumor rejection, we wanted to ask more broadly whether the presence of these cell 
types was absolutely essential for rejection of transplantable tumors.  Unfortunately, there 
are few ways to achieve selective and long-term depletion of DCs and macrophages in 
vivo.   
 Gene-targeted mice lacking the AP-1 family member p21SNFT (also known as 
Batf3) were recently developed by Kai Hildner, Ken Murphy, and colleagues (151).  
Analyses of genome-wide expression profiles across an array of tissues and immune cell 
subsets had identified this gene as almost exclusively expressed in conventional DCs 
(cDCs), though low expression in monocytes was also observed.  Interestingly, 
p21SNFT-/- mice were found to selectively lack the CD8α+ cDC subset, while normal 
representation of other DC subsets and hematopoietic lineages was maintained.  Detailed 
examination of tissue resident DCs within the skin and lung, however, also revealed the 
selective absence of a population of recently described migratory Langerin+ DCs 
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(DEC205+CD103+Langerin+) found in the dermis as well as lung and liver (180-182).  
This population is distinct from previously described dermal DCs (which are Langerin- 
and CD11bhigh) and although they do not express CD8α, they share phenotypic markers 
(CD103+, DEC205+, and CD11blo/-) and functional similarities with the CD8α+ cDC 
subset, including responsiveness to TLR3 ligands and the ability to cross-present antigen, 
though their functional significance in this regard is still unclear.  The absence of 
Langerin+ dermal DCs in p21SNFT-/- mice suggests that this population may be 
developmentally related to CD8α+ DCs, yet further studies will be required to investigate 
this possibility. 
 When challenged with West Nile virus (WNV), p21SNFT-/- exhibited normal 
antibody and CD4+ T cell responses, which are required for protective immunity, and 
hence they showed no increased susceptibility to infection (151).  Examination of CD8+ 
T cell responses, however, revealed a significant reduction in the generation of WNV-
specific CD8+ T cells.  T cell adoptive transfer experiments demonstrated that this deficit 
was associated with the absence of CD8α+ DCs rather than a cell intrinsic defect in CD8+ 
T cell function.  Additional studies also confirmed normal cell-intrinsic responses in 
CD4+ and CD8+ T cells as well as NK cells, supporting the conclusion that deficient DC 
function is responsible for the phenotype of p21SNFT-/- mice.    
 To assess the role of cross-presentation by CD8α+ DCs in the rejection of 
immunogenic tumors, we challenged p21SNFT-/- mice with three representative 
syngeneic RAG2-/- regressor tumors.  Whereas all three tumor lines (H31m1, 1773, and 
d38m2) were rejected in WT mice, these tumors grew rapidly in p21SNFT-/- hosts with 
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kinetics comparable to those observed in RAG2-/- controls (Figure 20).  In addition, ex 
vivo analysis of tumor-specific CD8+ T cell cytotoxicity revealed a complete lack of 
tumor reactivity, and we confirmed that both CD8+ and CD4+ cells were required for 
rejection of H31m1 (Figure 22A-B).  Interestingly, analysis of TIL populations within the 
tumors of WT and p21SNFT-/- mice at day 11 following H31m1 injection showed a 
substantial decrease in CD8+ T cell infiltration, but no change in CD4+ T cell abundance 
(data not shown).  While p21SNFT-/- mice exhibit a striking defect in tumor rejection, 
dose titrations of H31m1 tumor cells showed that there is not an absolute deficiency in 
mounting adaptive responses, since a fraction of mice injected with 1x105 or 1x104 tumor 
cells could reject this challenge, in contrast to RAG2-/- mice (Figure 21).  Moreover, 
those p21SNFT-/- mice that had rejected low-dose H31m1 challenge manifested some 
H31m1-specific CTL killing activity ex vivo, though perhaps only a partial response 
(Figure 22C).  This result suggests that either cross-presentation of tumor-derived 
antigens by other APC populations can occur with lesser efficiency, or that there may be 
a small contribution of direct priming (directly by the tumor cells), which has been 
observed in other model systems (183).   
 Although adoptive transfer of DC populations is difficult due to their limited life 
span and the need to recapitulate proper trafficking in vivo, we tested whether transfer of 
WT DCs into p21SNFT-/- mice prior to tumor challenge could provide some recovery of 
anti-tumor function.  For this purpose, WT and p21SNFT-/- donor mice were injected 
with a regimen of fms-like tyrosine kinase 3 (flt3) ligand-Fc to induce in vivo DC 
expansion.  CD11c+ cells from the spleen were then positively selected by MACS, 
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incubated with whole tumor lysate in the presence of LPS, and injected into p21SNFT-/- 
recipients via both s.c. and i.v. routes immediately prior to tumor challenge.  As shown in 
Figure 23, transfer of p21SNFT-/- DCs had no effect on H31m1 tumor growth in 
p21SNFT-/- mice, yet transfer of WT DCs induced a significant slowing of growth in a 
fraction of p21SNFT-/- recipients.  This observation suggests that transferred WT DCs, 
but not p21SNFT-/- DCs  (which lack the CD8α+ subset as shown in Figure 23B) can 
restore some anti-tumor immunity, though it would be interesting to assess levels of 
H31m1-specific T cell priming by ex vivo cytotoxicity assay.  Collectively, these data 
demonstrate a prominent role for cross-presentation via the CD8α+ DC subset during the 
generation of protective anti-tumor responses.   
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Figure 20.  Lack of tumor rejection in CD8α+ DC-deficient p21SNFT-/- mice.  Groups of 
WT, p21SNFT-/-, and RAG2-/- mice on a 129/SvEv background were injected s.c. with 
1x106 H31m1, 1773, or d38m2 fibrosarcoma cells and tumor growth was measured over 
time.  Data are presented as mean tumor diameter ± s.e.m. of n=10 (H31m1) or n=3-5 
(1773 and d38m2) mice/group.   
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Figure 21.  Titration of H31m1 tumor cells in RAG2-/- and p21SNFT-/- mice.  Groups of 
RAG2-/- and p21SNFT-/- mice were challenged with 106, 105, or 104 H31m1 tumor cells 
and growth was monitored.  Each line represents an individual mouse.   
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Figure 22.  Lack of tumor-specific CTL response in p21SNFT-/- mice.  (A) WT mice 
treated with either anti-CD4, anti-CD8, anti-CD4/CD8, or control mAb’s as indicated 
were challenged with 1x106 H31m1 tumor cells.  Data represent mean tumor diameter ± 
s.e.m. of n=4 mice/group.  (B) WT and p21SNFT-/- mice were injected with 1x106 
H31m1 tumor cells and splenocytes were isolated at day 9.  Cells were cocultured with 
IFNγ-pretreated, irradiated H31m1 tumor cells and after 5 days, cells were used as CTL 
effectors in a 4 hr cytotoxicity assay with 51Cr-labeled H31m1 or 1773 tumor cells as 
targets.  (C) Splenocytes from p21SNFT-/- mice that had rejected a low-dose (1x105) 
H31m1 challenge were treated as in (B).     
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Figure 23.  Partial reconstitution of anti-tumor immunity by adoptive transfer of WT DC 
into p21SNFT-/- mice.  (A) Protocol for adoptive transfer of WT or p21SNFT-/- DCs.  
Briefly, donor mice were treated i.p. with flt3 ligand-Fc for three consecutive days.  After 
another 7 days, CD11c+ splenocytes were positively selected by MACS (purity>90%), 
cultured with H31m1 whole tumor lysates in the presence of LPS for 4 hrs ex vivo, and 
transferred into p21SNFT-/- recipients both i.v. and s.c. (9x106 cells each).  (B) CD11c+ 
MACS-purified splenocytes from WT and p21SNFT-/- mice were analyzed by FACS 
using the indicated markers to assess enrichment of CD8α+CD11chi cDCs and 
CD11cintB220+ pDCs.  (C) Control WT and p21SNFT-/- mice receiving no cells were 
injected with 1x106 H31m1 tumor cells.  (D) p21SNFT-/- receiving either p21SNFT-/- or 
WT CD11c+ cells as indicated (n=4/group) were challenged with 1x106 H31m1 cells.  
Each line represents an individual mouse.          
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CD8α+ DCs are Important Sites of IFNα/β’s Actions 
 
 While the preceding experiments reveal an obligate function for CD8α+ DCs 
during tumor rejection, they do not address whether these cells are the relevant type I IFN 
responder cells.  A large amount of both in vitro and in vivo data show that IFNα/β can 
have potent effects in inducing functional maturation of DCs (including upregulation of 
MHC class I and II, CD40, CD80, CD86), which also correlates with their enhanced 
ability to cross-present antigen to naïve CD8+ T cells (184).  In addition, IFNα/β’s 
actions specifically on DCs were found to promote the generation of antibody responses 
and class switching, though these experiments involved injection of exogenous IFNα 
(121).  The effects of IFNα/β specifically on CD8α+ DCs, however, has not been 
investigated, and whether these mechanisms are operative during anti-tumor responses is 
unclear.   
 We therefore hypothesized that DCs, and specifically the CD8α+ cDC, may be a 
critical innate immune target of type I IFN during tumor rejection.  We first confirmed 
the presence of normal numbers of DC subsets, including CD8α+ cDCs, in the spleen and 
lymph nodes of IFNAR1-/- mice (Figure 24), as well as the ability of IFNAR1-/- DCs to 
expand normally in vivo in response to fms-like tyrosine kinase 3 (flt3) ligand-Fc 
treatment (data not shown).  In collaboration with Mona Mashayekhi and Ken Murphy, 
we then examined the function of type I IFN during cross-presentation in vitro by 
culturing splenic DCs isolated from WT or IFNAR1-/- mice with irradiated ovalbumin-
loaded MHC class I-deficient cells and OT-I T cells.  Total CD11c+ cells purified from 
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WT mice were more effective than IFNAR1-/--derived cells in inducing the proliferation 
of OT-I T cells, though this defect could be overcome at very high doses of antigen 
(Figure 25A).  Additionally, cross-presentation by WT CD11c+ cells was enhanced by 
treatment with exogenous IFNα and inhibited by antibody-mediated IFNα/β blockade 
(Figure 25B).  When WT and IFNAR1-/- DCs were further purified into CD8α+ and CD4+ 
subsets, the CD8α+ DC was confirmed to be the critical cross-presenting cell in this 
assay, and a more significant deficit was observed in the capacity of IFNAR1-/- CD8α+ 
DCs to activate OT-I T cells (Figure 25C).  These findings reveal a critical function for 
type I IFN acting on CD8α+ DCs during cross-presentation of antigen to CD8+ T cells.   
 To address the role of IFNα/β’s actions on DCs in vivo during tumor rejection, 
we pursued both adoptive transfer and mixed bone marrow chimera approaches.  In 
collaboration with Hirokazu Matsushita in the laboratory, we adoptively transferred 
CD11c+ cells isolated from the spleens of naïve WT or IFNAR1-/- mice into IFNAR1-/- 
recipients challenged with GAR4.GR1 tumor cells.  The IFNAR1-deficient GAR4.GR1 
tumor line was used to ensure that potential priming of an anti-IFNAR1 immune response 
by transfer of WT cells into IFNAR1-/- mice could not contribute to tumor cell killing.  
Although transfer of WT CD11c+ cells but not IFNAR1-/--derived cells could induce a 
delay in tumor growth and a corresponding increase in tumor-specific CTL priming (data 
not shown), this effect was variable, perhaps due to the technical difficulty of such a 
transfer and the unknown half-life and trafficking properties of the transferred cells.  In 
addition, since transferred CD11c+ cells contained a mixture of CD8α+, CD4+, and 
CD8α-CD4- cDC subsets as well as pDCs, future studies utilizing adoptive transfer of 
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purified CD8α+ cDCs will be required to specifically examine their role during the anti-
tumor response.   
 Mixed bone marrow chimeras with HSCs from CD8α+ DC-deficient p21SNFT-/- 
mice were also generated in order to investigate the function of type I IFN on this DC 
subset.  Mice with IFNα/β-unresponsive CD8α+ DCs were produced by reconstituting 
lethally-irradiated IFNAR1-/- recipients with a 4:1 mixture of p21SNFT-/- and RAG2-/-
IFNAR1-/- FLCs (p21SNFT-/-+RAG2-/-IFNAR1-/-→IFNAR1-/-).  Control chimeras with 
IFNα/β-responsive CD8α+ DCs were similarly generated by reconstituting IFNAR1-/- 
mice with unequal mixtures of p21SNFT-/- and RAG2-/- FLCs (p21SNFT-/-+RAG2-/-
→IFNAR1-/-).  Finally, chimeras lacking CD8α+ DCs were made by reconstituting 
IFNAR1-/- mice with p21SNFT-/- FLCs alone (p21SNFT-/-→IFNAR1-/-).  The phenotypes 
of these chimeras were confirmed by FACS analysis of splenocytes, which showed the 
expected hematopoietic reconstitution of all non-DC lineages (data not shown).  Within 
the DC compartment, the percentage of CD8α+ DCs in p21SNFT-/-+RAG2-/-IFNAR1-/-
→IFNAR1-/- and p21SNFT-/-+RAG2-/-→IFNAR1-/- mixed chimeras was approximately 
half of that in unmanipulated control WT and IFNAR1-/- mice (data not shown).  
Interestingly, analyses of p21SNFT+/- heterozygotes also showed a reduction in CD8α+ 
DC percentages (151), suggesting a haploinsufficiency of this gene as well as a possible 
cell-extrinsic effect related to occupation of a required developmental niche.   
 Despite a reduction in CD8α+ DC percentages, analyses of IFNAR1 expression in 
splenocytes from p21SNFT-/-+RAG2-/-IFNAR1-/-→IFNAR1-/- mixed chimeras revealed 
that CD8α+ DCs were IFNAR1-deficient whereas other DC subsets were predominantly 
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IFNAR1-sufficient (data not shown).  Conversely, all DC subsets in p21SNFT-/-+RAG2-/-
→IFNAR1-/- chimeras were IFNAR1-sufficient.  Preliminary tumor transplantation 
experiments – in which control and chimeric mice were challenged with immunogenic 
RAG2-/- regressor tumor cells – yielded results that were inconsistent, though suggestive 
of a role for IFNα/β sensitivity in CD8α+ DCs.  Additional experiments will be required 
to clarify these data and to further define the in vivo function of type I IFN acting on 
CD8α+ DCs during tumor rejection.   
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Figure 24.  Normal percentages of DC subsets in IFNAR1-/- mice.  Cells were isolated 
from the spleens and lymph nodes of WT, IFNAR1-/-, and p21SNFT-/- mice by 
collagenase digestion and DC subsets were analyzed by flow cytometry.  (A) Relative 
number (shown as a percentage of live cells) of CD11chi conventional DCs (cDC) and 
CD11cintB220+ plasmacytoid DCs (pDC) are shown.  Data represent the average ± s.e.m. 
of spleens from 4 WT, 4 IFNAR1-/- mice, and 2 p21SNFT-/- mice, or values from pooled 
inguinal LNs.  (B) Splenocytes and LN cells were gated on CD11chi cDCs and analyzed 
for CD8α, CD4, CD11b, and CD24 expression.  FACS plots from a representative 
sample of WT, IFNAR1-/-, and p21SNFT-/- splenocytes, or pooled LN cells are shown.  
The percent of cells in the indicated gates are noted.   
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Figure 25.  IFNα/β sensitivity in CD8α+ DCs enhances cross-presentation of antigen.  
(A) CD11c+ cells isolated from the spleens of WT or IFNAR1-/- mice were cocultured 
with the indicated number of irradiated, ovalbumin-loaded MHC class I-/- splenocytes and 
CFSE-labeled OT-I T cells.  After a 3-day incubation, proliferation of OT-I T cells was 
determined by CSFE dilution.  Histograms represent CFSE levels in the CD8+ T cell 
population, with the percentage of cells in the indicated gate noted.  (B) WT and 
IFNAR1-/- CD11c+ cells or WT CD11c+ cells incubated with exogenous IFNα (1,000 
U/ml) or IFNAR1-specific mAb MAR1-5A3 (5 µg/ml) were treated as in (A) at a dose of 
25,000 MHC class I-/- splenocytes.  (C) Purified CD8α+ and CD4+ DC subsets isolated 
from WT or IFNAR1-/- mice were treated as in (A) with the indicated number of 
ovalbumin-loaded MHC class I-/- splenocytes.  Data represent one of at least two 
independent experiments with similar results.   
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DISCUSSION 
 
 In this study, we have examined the host cell requirements for IFNα/β sensitivity 
during the rejection of immunogenic tumors.  We first confirmed prior data using two 
additional RAG2-/- regressor tumors, demonstrating that IFNα/β’s actions on host 
hematopoietic cells were necessary and sufficient for rejection of H31m1 and d38m2 
tumor cells.  As type I IFN can exert potent immunomodulatory effects on both innate 
and adaptive immune cells, mixed bone marrow chimeras with selective IFNα/β 
responsiveness were generated to assess the relative importance of IFNα/β’s actions.  
These studies demonstrated that innate immune cells were the essential population 
requiring IFNα/β responsiveness for rejection.     
 We had previously shown that IFNAR1-/- mice exhibit a defect in the priming of 
tumor specific CTL (see Chapter 2).  Examination of IFNAR1-/- mixed bone marrow 
chimeras revealed that IFNα/β-responsive innate immune cells were indeed sufficient to 
restore CTL priming to WT levels.  In addition, mAb depletion studies confirmed that T 
cells were required for tumor rejection in these chimeras.  To assess the role of NK cells 
in IFNα/β-dependent rejection, we utilized B6 strain RAG2-/- regressor tumors and 
achieved NK depletion via treatment with anti-NK1.1 mAb.  Despite complete 
abrogation of NK cell function in mAb-treated mice, we observed no effect on the 
rejection of three B6 regressor tumors.  Finally, tumor transplantation studies in 
p21SNFT-/- mice – which have a selective deficiency in the development of CD8α+ DCs 
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– showed that cross-presentation by this DC subset was required for the rejection of 
immunogenic tumors.   
 In a recent study, type I IFN was shown to have an important role in promoting 
NK cell-dependent control of RMA-S tumor growth (43).  Antibody blockade 
experiments also showed that the temporal requirement for IFNα/β’s actions 
corresponded to the requirements for NK function, as IFNα/β blockade or NK depletion 
at day 3 had no effect on RMA-S rejection.  Although type I IFN can strongly augment 
NK cell cytotoxicity, we do not believe these cells represent an important innate immune 
target of IFNα/β in our model.  Whereas anti-NK1.1 mAb treatment abrogated control of 
a low-dose RMA-S challenge in our studies, this treatment regimen had no adverse effect 
on the efficacy or kinetics of B6 regressor rejection.  Nevertheless, since NK cells have 
been shown to be critical for protection against primary MCA tumorigenesis, experiments 
with mice having NK cell-specific conditional ablation of IFNAR1 will be required to 
clarify a possible role for type I IFN on NK cells during primary tumorigenesis.   
 The finding that CD8α+ DCs were required for the rejection of immunogenic 
tumors supports the notion that cross-presentation is the critical mechanism leading to 
CTL priming.  Although some studies have similarly suggested a requirement for 
presentation of tumor antigens by bone marrow-derived cells (185), others have argued 
that direct priming can be a more efficient or merely redundant mechanism (183, 186).  
To investigate the role of IFNα/β’s actions specifically on CD8α+ DCs, we employed an 
in vitro cross-presentation assay, demonstrating that type I IFN sensitivity within this DC 
subset promotes antigen cross-presentation and activation of naïve CD8+ T cells.  Work is 
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ongoing to test this potential mechanism during tumor rejection in vivo using adoptive 
transfer and conditional knockout approaches.   
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More Extensive Requirement for IFNγ  
 
Sensitivity during Tumor Rejection 
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INTRODUCTION 
 
 There is strong experimental support for the existence of a cancer 
immunosurveillance system, and the IFNs have emerged as fundamentally important 
components.  Some of the first studies inciting renewed interest in the immune-mediated 
surveillance of cancer focused on the role of IFNγ, demonstrating that tumor cell 
responsiveness to this cytokine was a significant factor influencing in vivo growth (17, 
18).  Subsequently, IFNγ unresponsive mice were shown to have an enhanced 
susceptibility to tumor development in various models of carcinogen-induced, 
spontaneous, and transplantable tumor formation (3, 11).  Work to define the critical 
functions of IFNγ during this process has established the tumor cell as an important 
target.  When IFNγ responsiveness was restored to various genetically deficient tumor 
cell lines, these progressively growing tumor cells were now rejected in 
immunocompetent hosts (5, 16, 18).  Moreover, enforced expression of individual 
components of the antigen processing and presentation pathway in IFNγ-insensitive cells 
had a similar effect (5).  Thus, enhancement of tumor cell immunogenicity represents one 
relevant downstream pathway induced by IFNγ’s actions on the tumor.     
 Recent studies performed in our laboratory, also highlight a prominent role for 
host IFNγ sensitivity, since RAG2-/- regressors tumors exhibit progressive growth when 
injected into IFNGR1-/- mice (G.P. Dunn and R.D. Schreiber, unpublished data).  Other 
groups have also reported that IFNγ’s actions on the host were critical, though these 
studies predominantly used immunization and rechallenge tumor models or adoptive T 
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cell transfer (22-24).  In one such study, it was suggested that nonhematopoietic host cells 
represented the critical IFNγ targets, and a mechanism involving IFNγ-mediated 
angiostasis was proposed (23).  Since this model was entirely dependent on prior 
immunization and involved only delayed tumor growth rather than rejection, it will be 
important to test this hypothesis in models of naturally-occurring immune responses to 
rejectable tumors in naïve mice. 
 In this study we provide additional support for the important role of tumor cell 
IFNγ responsiveness, through experiments involving selective reconstitution of a 
genetically-deficient cell line as well as RNAi-mediated knockdown of IFNGR1 in a 
normally responsive regressor tumor.  In addition, we examined the relevant targets of 
IFNγ’s actions on the host, using reciprocal bone marrow chimeras to assess the role of 
hematopoietic versus nonhematopoietic cells.  In contrast to our previous findings with 
IFNα/β, we demonstrate an essential function for IFNγ acting on both hematopoietic and 
nonhematopoietic host cells.     
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MATERIALS AND METHODS 
 
Mice.  Inbred 129/SvEv and 129/SvPas mice were purchased from Taconic Farms and 
Charles River Laboratories, respectively.  129 RAG2-/-, IFNAR1-/-, and IFNGR1-/- mice 
were bred in our specific pathogen-free animal facility.      
 
Tumor cells.  129 RAG2-/- regressor fibrosarcomas were previously generated by s.c. 
MCA injection of RAG2-/- mice as described (5).  129 WT progressor tumors 1877 and 
F244 were induced by MCA treatment of WT mice.  The GAR4 tumor cell line is an 
MCA-induced sarcoma derived from a IFNGR1-/-xIFNAR1-/- mouse, and has been 
reconstituted with either the missing IFNγ receptor component (GAR4.GR1 cells) or the 
missing IFNα/β receptor component (GAR4.AR1 cells) as previously described (16).   
 
Tumor transplantation experiments.  Tumor cells were thawed from frozen stocks and 
cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 
2 mM L-glutamate, 1 mM sodium pyruvate, 50 U/ml penicillin, 50 µg/ml streptomycin, 
and 50 µM β-mercaptoethanol (R-10 medium).  After expansion for several passages, 
cells were harvested by incubation in 0.05% trypsin, washed once with R-10 medium, 
and washed three times with sterile, endotoxin-free PBS.  Prior to the last wash, cells 
were counted using a hemacytometer and cell viability was assessed by trypan blue 
exclusion (injected cells were >90% viable).  Cells were injected subcutaneously in a 
volume of 0.15 ml PBS into the shaved flanks of mice.  Tumor size was measured on the 
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indicated days and is presented as the average of two perpendicular diameters.  When 
calculating percent tumor growth, mice with tumors larger than 6x6 mm in diameter at 
the end of the observation period were counted as positive.  
 
Flow cytometry.  Single cell suspensions were isolated, incubated with purified anti-
CD16/CD32 mAb (2.4G2) (BD Biosciences) to prevent non-specific antibody binding to 
Fc receptors, then stained with the indicated antibodies prior to data collection on a BD 
FACSCalibur (BD Biosciences) and data analysis using FlowJo software (Tree Star).  
The following were purchased from BioLegend:  anti-CD3-FITC (145-2C11), anti-DX5-
PE (DX5), anti-B220-FITC (RA3-6B2), anti-CD11b-PE (M1/70), and SA-APC.  Anti-
CD11c-PE (HL3), anti-IFNGR1-biotin (GR20), anti-H-2Db-PE (KH95), and anti-H-2Kb 
(AF6-88.5) were from BD Biosciences, and anti-IFNAR1-biotin (MAR1-5A3) was 
described previously (64).  Immediately prior to analysis, propidium iodide (PI) was 
added to assess cell viability.   
 
Generation of bone marrow chimeras.  E14.5 fetal liver cells were used to reconstitute 
lethally-irradiated recipients.  Embryos were extracted 14 days following implantation, 
livers were removed, and FLCs were isolated by homogenization through a metal mesh 
strainer with a 6 cc syringe plunger.  Following RBC lysis by incubation in Hybrimax 
RBC lysing buffer (Sigma-Aldrich), cells were filtered through a 40 µm cell strainer, 
washed 2 times with sterile endofree PBS, and counted.  Cells were resuspended in PBS 
for injection of 5x106 FLCs per mouse in a volume of 0.2 ml using a 0.5 cc 29 gauge 
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insulin syringe.  Recipient mice, lethally irradiated with a single dose of 9.5 Gy several 
hours prior, were anesthetized by i.p. avertin and FLCs were infused i.v. via retro-orbital 
injection.  Animals were generally maintained on TMS water for 4 weeks following 
irradiation and reconstitution, and tumor transplantation experiments were performed at 
least 10-12 weeks post-reconstitution. 
 
Ex vivo analysis of tumors and immune infiltrate.  Tumors were excised from 
euthanized control and bone marrow chimeric mice, physically disaggregated by mincing 
with razor blades, then enzymatically disaggregated by digestion with 1 mg/ml 
collagenase IA (Sigma-Aldrich) in 10 ml HBSS medium for 1-1.5 hours in a 37°C water 
bath with occasional mixing.  Cell suspensions were washed once with R-10 medium, 
RBCs were lysed with Hybrimax RBC lysing buffer (Sigma-Aldrich), and cells were 
filtered through a 40 µm strainer to remove aggregates and debris.  Cells were incubated 
with purified anti-CD16/CD32 mAb (2.4G2) (BD Biosciences) to prevent non-specific 
antibody binding to Fc receptors, then stained with FITC-conjugated anti-panCD45 
(clone 30-F11) (BioLegend), PE-conjugated anti-CD31 (BioLegend), and biotinylated 
anti-IFNGR1 (BD Biosciences) followed by SA-APC (BioLegend).  Immediately prior to 
flow cytometry, propidium iodide (PI) was added and cells were filtered again to prevent 
clogging.   
 
 
 189 
RESULTS 
 
Differential Requirements for IFNγ  and IFNα/β  Sensitivity during Immune-
Mediated Rejection of the GAR4 Tumor 
 
 In this set of experiments, we have investigated the requirements for IFN 
sensitivity in both tumor cells and host cells using the MCA-induced sarcoma GAR4, 
which was derived from an IFNGR1-/-xIFNAR1-/- doubly deficient mouse.  Although 
GAR developed in an immunodeficient environment (thus being unedited), this tumor 
grows progressively when transplanted into immunocompetent WT mice.  As previous 
data had demonstrated the importance of IFNγ’s actions on tumor cells for tumor 
rejection (17, 18), Allen Bruce in the laboratory decided to selectively restore IFNγ or 
IFNα/β responsiveness to GAR4 through retroviral transduction of the missing IFNGR1 
or IFNAR1 receptor component.  We screened clones of each type and isolated 
representative clones which displayed normal levels of the appropriate IFN receptor as 
well as normal biologic responsiveness to cytokine treatment (MHC class I upregulation 
and LPS+IFN-induced NO production) (Figures 1-2, (16) and data not shown).   
 To test the effect of selective reconstitution of IFN sensitivity on the in vivo 
growth of GAR4, we injected groups of WT and RAG2-/- mice with GAR4, GAR4.AR1, 
or GAR4.GR1 tumor cells (Figure 3).  All three of these tumor cell lines grew 
progressively with similar kinetics in RAG2-/- hosts.  Yet, whereas GAR4 and 
GAR4.AR1 also grew in WT mice, GAR4.GR1 tumor cells were rejected – indicating 
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that IFNγ sensitivity, but not IFNα/β sensitivity, was essential for GAR4 rejection by a 
functional immune system.  We also injected GAR4.GR1 tumor cells, as well as GAR4 
and GAR4.AR1 as controls, into IFNGR1-/- and IFNAR1-/- hosts to assess the function of 
host cell IFN sensitivity for rejection of reconstituted GAR4 (Figure 3).  Although 
rejected in WT mice, GAR4.GR1 now grew progressively (similar to GAR4 and 
GAR4.AR1) in the absence of host cell responsiveness to IFNα/β or IFNγ.  Taken 
together, these studies highlight the essential function of IFNγ on the tumor cell but both 
IFNγ and IFNα/β on host cells during the rejection of immunogenic tumors.   
 In the course of the above experiments, we noted that the growth of GAR4.GR1 
was often more aggressive in IFNAR1-/- hosts as compared to IFNGR1-/- mice.  To 
examine the relative dependency on host IFNα/β versus IFNγ sensitivity, we performed 
dose titration experiments in which groups of IFN receptor deficient or control mice were 
injected with decreasing doses of GAR4.GR1 tumor cells ranging from 3x106 to 0.1x106 
cells/mouse (Figure 4).  At the highest tumor dose, GAR4.GR1 cells grew with similar 
kinetics in both IFNAR1-/- and IFNGR1-/- mice (and also grew in WT mice, though with 
slower kinetics).  At intermediate doses of tumor, however, slightly increased growth 
kinetics were observed in IFNAR1-/- compared to IFNGR1-/- mice, including growth in 
only 3/4 IFNGR1-/- mice at the 0.5x106 cell dose but 4/4 IFNAR1-/- mice at the same 
dose.  This difference was even more pronounced upon injection of 0.1x106 cells/mouse, 
in which case the tumor grew in 0/3 IFNGR1-/- mice but 4/4 IFNAR1-/- mice.   
 To investigate the possibility that an immune response against the transduced 
IFNGR1 receptor component (foreign to IFNGR1-/- mice) might explain this differential 
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phenotype, we tested the growth of GAR4 cells transduced with a dominant-negative 
IFNGR1 receptor component lacking the cytoplasmic signaling domain (IFNGR1.ΔIC) in 
WT and IFNGR1-/- mice.  As shown in Figure 5A, GAR4.GR1ΔIC cells contained highly 
overexpressed levels of IFNGR1 (at least a log above WT levels), yet still grew similarly 
in both WT and IFNGR1-/- mice (Figure 5B).  This result not only confirms the 
importance of IFNγ’s actions on GAR4 cells for their rejection in WT mice (since 
GAR4.GR1ΔIC but not GAR4.GR1 grows progressively), but also indicates the lack of 
an alloresponse against the IFNGR1 protein in IFNGR1-/- mice.  These data therefore 
demonstrate that for rejection of the GAR4.GR1 tumor, host cell sensitivity to IFNα/β is 
more critical than host responsiveness to IFNγ.  Similar to findings that the rejection of 
certain regressor tumors require IFNα/β but not IFNγ (or vice versa), this observation 
adds to the notion that endogenous type I and type II IFN are performing distinct 
functions on the host during the anti-tumor immune response.     
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Figure 1.  Selective reconstitution of IFNγ or IFNα/β sensitivity in the GAR4 tumor.  
Parental GAR4 cells, IFNγ receptor-reconstituted GAR4.GR1, and IFNα/β receptor-
reconstituted GAR4.AR1 cells were analyzed by FACS for expression of IFNGR1, 
IFNAR1, and MHC class I molecule H-2Db as indicated.  Isotype control Ab staining is 
shown in the thin black lines.  For IFNγ and IFNα treatment, cells were cultured for 48 
hrs with 1000 U/ml of the indicated cytokine prior to H-2Db staining.  A representative 
clone of GAR4.GR1 and GAR4.AR1 cells is shown.     
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Figure 2.  Appropriate cytokine responsiveness of reconstituted GAR4 clones.  GAR4, 
GAR4.GR1, and GAR4.AR1 cells were treated with LPS plus either IFNγ or IFNα at the 
indicated doses for 48 hours and levels of NO production were assessed.  One 
representative experiment of several with similar results is shown.       
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Figure 3.  Tumor cell sensitivity to IFNγ but not IFNα/β is critical for GAR4 rejection, 
whereas host cell responsiveness to both IFNγ and IFNα/β is required.  1x106 GAR4, 
GAR4.GR1, or GAR4.AR1 tumor cells were injected s.c. into groups of WT, RAG2-/-, 
IFNGR1-/- and IFNAR1-/- mice and tumor growth was measured over time.  Data from at 
least two independent experiments with n=5-11 mice/group is shown.          
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Figure 4.  Differential importance of host cell sensitivity to IFNγ and IFNα/β for 
rejection of reconstituted GAR4.GR1 tumor cells.  A dose titration of GAR4.GR1 tumor 
cells was performed in which groups of WT, RAG2-/-, IFNGR1-/-, and IFNAR1-/- mice 
were injected with 3x106, 1x106, 0.5x106, or 0.1x106 GAR4.GR1 cells.  Data are 
presented as mean tumor diameter ± s.e.m. of n=3-4 mice/group.       
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Figure 5.  An alloresponse against IFNGR1 is not responsible for less robust growth of 
reconstituted GAR4.GR1 tumor cells in IFNGR1-/- mice.  (A) IFNGR1 levels by FACS 
are shown for GAR4.GR1ΔIC tumor cells, which overexpress the nonfunctional 
IFNGR1ΔIC receptor chain, or splenocytes from WT and IFNGR1-/- mice as controls.  
(B) 1x106 GAR4.GR1ΔIC tumor cells were injected into groups of WT and IFNGR1-/- 
mice (n=5 mice/group) and tumor growth was monitored over time.        
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RNAi-Mediated Knockdown of IFNGR1 in a RAG2-/- Regressor Sarcoma Abrogates 
Tumor Rejection 
 
 Prior work in the laboratory evaluated the importance of tumor cell IFNγ 
sensitivity for the rejection of RAG2-/- regressor sarcomas by overexpression of a 
dominant-negative IFNGR1.ΔIC construct, rendering these tumors IFNγ-unresponsive 
(G.P. Dunn, C.M. Koebel, and R.D. Schreiber, unpublished data).  These studies showed 
progressive growth of 4/5 IFNγ-dependent 129 regressor tumors (H31m1, d42m1, 
d38m2, and F510) after paralysis of IFNγ signaling.  Yet, the possibility remained that 
profound overexpression of IFNGR1.ΔIC (which can presumably still bind ligand) on the 
tumor cells could be binding and sequestering IFNγ within the tumor microenvironment, 
effectively inhibiting its actions on infiltrating host cells as well.  In order to address this 
potential caveat, we took a second approach to abrogate IFNγ signaling within tumor 
cells – knockdown of IFNGR1 expression by RNAi.   
 We transduced H31m1 cells with a retroviral vector driving expression of 
IFNGR1-specific shRNA molecules, and following several rounds of transduction and 
FACS sorting, we isolated bulk cell lines with significantly reduced IFNGR1 expression.  
Sequential transduction and sorting were necessary as the retroviral construct contained 
no selectable marker, given concerns that any foreign protein might serve as a rejection 
antigen in vivo.  Nevertheless, empty vector transduced cells treated similarly and sorted 
for the lowest IFNGR1 expressors yielded no reduction in receptor levels, signifying that 
IFNGR1 knockdown was mediated by the introduced shRNA and not due to naturally 
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arising variants present in the original population.  After single cell cloning of the 
respective bulk lines, we screened clones for IFNGR1 expression levels and biologic 
responsiveness to IFNγ treatment by MHC class I upregulation.  Shown in Figure 6 are 
representative empty vector and IFNGR1 shRNA transduced clones as well as the 
parental H31m1 tumor line.  A number of clones were isolated expressing 10-15% of 
parental levels of surface IFNGR1 by FACS.  These cells, however, showed no change in 
surface expression of several control genes, including IFNAR1, H-2Kb, H-2Db, and 
CD1d (Figure 6 and data not shown).  When treated with high doses of IFNγ in vitro, 
IFNGR1 shRNA transduced cells displayed greatly reduced, but not completely absent, 
biologic responses to IFNγ – as a minority of cells could upregulate MHC class I, though 
still not to levels seen in parental H31m1 cells.  Further analysis has determined that 
IFNGR1 knockdown was stable for extended periods of time after both in vitro and in 
vivo passage (data not shown). 
 To assess the effect of IFNGR1 knockdown on in vivo growth of H31m1 cells, 
we injected several clones of each type into groups of WT and RAG2-/- mice.  As shown 
for representative clones in Figure 7, both H31m1 parental and empty vector transduced 
cells were rejected in WT mice but grew progressively in RAG2-/- mice.  In contrast, 
IFNGR1 shRNA transduced cells grew progressively in both RAG2-/- and WT hosts.  
These data therefore corroborate prior findings and confirm the importance of tumor cell 
IFNγ responsiveness for RAG2-/- regressor rejection using an additional experimental 
approach.  These studies also provide proof of principle suggesting the utility of this 
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strategy for RNAi knockdown of other molecules in order to assess their contribution to 
tumor cell immunogenicity in vivo.   
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Figure 6.  RNAi-induced knockdown of IFNGR1 expression and inhibition of IFNγ 
responsiveness in H31m1 tumor cells.  Parental, empty vector-transduced, and IFNGR1 
shRNA-transduced H31m1 tumor cells were analyzed by FACS for expression of 
IFNGR1, IFNAR1, and H-2Kb.  IFN-induced upregulation of MHC class I was assessed 
following 3 day treatment with IFNγ (10 and 1000 U/ml; in red) or IFNα (3000 U/ml; in 
blue).   
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Figure 7.  IFNGR1 knockdown in H31m1 tumor cells prevents their rejection.  WT and 
RAG2-/- mice were injected with 1x106 parental, empty vector-transduced, or IFNGR1 
shRNA-transduced H31m1 tumors cells.  Growth was measured over time and is 
presented as mean tumor diameter ± s.e.m. of n=5 (WT) or n=2 (RAG2-/-) mice for each 
tumor.         
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IFNγ  Responsiveness in Host Cells is also Required for Tumor Rejection  
 
 In addition to the well-documented function for IFNγ signaling directly on the 
tumor cell, recent data in the laboratory has also revealed a role for IFNγ sensitivity of 
host cells for the rejection of immunogenic RAG2-/- regressor sarcomas (G.P. Dunn, and 
R.D. Schreiber, unpublished data).  We confirmed these results by injecting groups of 
WT, RAG2-/-, and IFNGR1-/- mice with several 129 regressor tumors (H31m1, d38m2, 
and d42m1) as shown in Figure 8.  These tumors were rejected in WT mice, but grew 
progressively in RAG2-/- controls and in the majority of IFNGR1-/- mice injected.  We 
have also shown that IFNGR1-/- animals, similar to IFNAR1-/- mice, displayed a defect in 
the generation of tumor-specific T cells (see Chapter 2, Figure 6).  These 129 regressor 
tumors – requiring IFNγ’s actions on host cells – were utilized in subsequent studies to 
investigate the functionally important host cell targets of IFNγ during the anti-tumor 
immune response.   
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Figure 8.  Requirement for host sensitivity to IFNγ for rejection of immunogenic RAG2-/- 
regressor tumors.  Groups of WT, IFNGR1-/-, and RAG2-/- mice were injected with 1x106 
H31m1, d38m2, or d42m1 tumor cells and growth was measured over time.          
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Host Sensitivity to IFNγ  in Both Hematopoietic and Nonhematopoietic Cells is 
Critical for Tumor Rejection 
 
 Given the importance of IFNγ responsiveness at the level of the host for tumor 
rejection, we used bone marrow chimeras to localize the functionally relevant effects of 
IFNγ to either hematopoietic or nonhematopoietic cells.  We employed a similar 
approach and protocol as used previously (see Chapter 3), in order to generate chimeric 
mice with selective IFNγ sensitivity only in hematopoietic cells (WT→IFNGR1-/-), 
nonhematopoietic cells (IFNGR1-/-→RAG2-/-), or as controls, in both compartments 
(WT→WT) or neither compartment (IFNGR1-/-→IFNGR1-/-) (Figure 9A).  The expected 
phenotypes of these mice were confirmed via IFNGR1 staining of splenocytes (Figure 
9B).  In addition, normal hematopoietic reconstitution was verified by examining the cell 
density and immune composition of the spleen (Figure 10).   
 Groups of control mice and bone marrow chimeras were then challenged with the 
IFNγ-dependent RAG2-/- regressor sarcomas d38m2 and H31m1, and tumor growth was 
monitored over time.  As depicted in Figure 11, d38m2 tumor cells showed progressive 
growth in IFNGR1-/- and RAG2-/- control mice but were rejected in the presence of a wild 
type immune compartment.  Similarly, d38m2 cells were rejected in WT→WT bone 
marrow chimeras, yet grew in 73% (24/33) of IFNGR1-/-→IFNGR1-/- mice.  When mice 
could only respond to IFNγ in hematopoietic cells (WT→IFNGR1-/- chimeras), we 
observed progressive growth in 42% (14/33) of mice; whereas selective IFNγ 
responsiveness in only nonhematopoietic cells (IFNGR1-/-→RAG2-/- chimeras) yielded 
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growth in 50% (16/32) of mice.  These findings reveal a requirement for both 
hematopoietic and nonhematopoietic IFNγ sensitivity for rejection of d38m2 tumor cells.  
Yet, given the partial phenotypes in WT→IFNGR1-/- and IFNGR1-/-→RAG2-/- chimeras 
compared to globally unresponsive IFNGR1-/-→IFNGR1-/- mice, sensitivity in either 
compartment alone appears to afford some tumor protection.   
 When cohorts of mice were instead challenged with H31m1 tumor cells, we again 
noted a prominent requirement for nonhematopoietic IFNγ responsiveness, with growth 
in 44% (7/16) of WT→IFNGR1-/- chimeras compared to 8% (1/12) of WT→WT and 
69% (11/16) of IFNGR1-/-→IFNGR1-/- controls (Figure 12).  Similar to findings with 
d38m2, the defect in the absence of nonhematopoietic IFNγ sensitivity appeared partial 
compared to globally unresponsive chimeras.  Although H31m1 cells did not grow in 
IFNGR1-/-→RAG2-/- chimeras, IFNγ’s actions on hematopoietic cells still seemed to be 
important as tumor rejection in these mice was considerably delayed compared to 
WT→WT controls.  Taken together, data with both the d38m2 and H31m1 RAG2-/- 
regressor sarcomas support a role for IFNγ acting on both hematopoietic and 
nonhematopoietic cells of the host.  We have therefore demonstrated with two different 
immunogenic tumors that the requirements for host cell sensitivity to IFNγ and IFNα/β 
are, in fact, distinct.  While hematopoietic cells – and specifically, the innate immune 
compartment – are the essential targets of IFNα/β (see Chapter 3), sensitivity to IFNγ 
within both hematopoietic and nonhematopoietic cells is critical.      
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Figure 9.  Generation and validation of bone marrow chimeras with hematopoietic or 
nonhematopoietic IFNγ sensitivity.  (A) Strategy for producing chimeras with differential 
host cell IFNγ responsiveness.  (B) Splenocytes from a representative cohort of chimeric 
and control mice were analyzed for IFNGR1 expression by FACS.  Shown are the 
percent IFNGR1+ cells within the indicated gate for n=7-12 chimeras or n=4-5 controls.   
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Figure 10.  Reconstitution of the hematopoietic compartment in IFNGR1-/- bone marrow 
chimeric mice.  Splenocytes were harvested from representative cohorts of control and 
IFNGR1-/- chimeric mice and analyzed for cellularity and immune composition.  (A) Cell 
density of the spleen (calculated as total cell number/wt of tissue) is shown for 3 control 
and chimeric mice of each type.  (B) Cellular percentages of the indicated immune cell 
subsets were determined by flow cytometry for control and chimeric mice of each type.  
Mean values (expressed as a percentage of total splenocytes) ± s.e.m. for 3 mice/group 
are shown, and cell populations were defined as follows (after gating for PI- live cells): 
CD4+ T cells (CD3+CD4+), CD8+ T cells (CD3+CD8+), B cells (B220+), NK cells 
(DX5+CD3-), dendritic cells (CD11chi), and myeloid cells (CD11b+). 
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Figure 11.  Both hematopoietic and nonhematopoietic IFNγ responsiveness is critical for 
rejection of d38m2 tumor cells.  (A) Groups of control and chimeric mice were injected 
s.c. with 1x106 d38m2 RAG2-/- regressor cells and tumor size was measured over time.  
Percent of mice exhibiting progressive tumor growth is plotted in (B).  Data represent 
cumulative results from five independent experiments with the indicated group sizes.         
 
RAG2-/-
WT
IFNGR1-/-
WT→WT IFNGR1-/-→IFNGR1-/-
WT→IFNGR1-/-IFNGR1-/-→RAG2-/-
Days post transplant
M
ea
n 
tu
m
or
 d
iam
et
er
 (m
m
)
Tu
m
or
 g
ro
wt
h 
(%
)
18/18
3/29
21/33
24/33
14/33
1/30
16/32
A
B
219 
 220 
 
 
 
 
 
 
Figure 12.  More important role for nonhematopoietic than hematopoietic IFNγ 
sensitivity for H31m1 rejection.  (A) Control and bone marrow chimeric mice were 
injected with 1x106 H31m1 tumor cells and growth was monitored over time.  Data from 
three independent experiments are shown with group sizes as indicated in (B).     
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Demonstration of the Normal Functional Reconstitution of IFNGR1-/- Bone Marrow 
Chimeric Mice 
 
 To confirm that the immune compartment in IFNGR1-/- bone marrow chimeras 
has been functionally reconstituted, we challenged control and chimeric mice with the 
F535 RAG2-/- regressor, a tumor rejected in WT mice in a lymphocyte-dependent but 
largely IFNγ-independent fashion (C.M. Koebel and R.D. Schreiber, unpublished data).  
As shown in Figure 13, F535 tumor cells were rejected in WT controls and in the 
majority of IFNGR1-/- mice transplanted, yet grew progressively in RAG2-/- hosts.  When 
injected into IFNGR1-/- bone marrow chimeras of each type, the F535 tumor was also 
uniformly rejected, with the exception of a minor proportion (1/6) of IFNGR1-/-
→IFNGR1-/- chimeras, comparable to the phenotype in IFNGR1-/- controls (2/11).  We 
have additionally examined the growth of two representative WT progressor tumors, 
1877 and F244, to rule out the presence of a hyperactive immunological state in the 
IFNGR1-/- chimeras (Figure 14).  As expected, both tumors grew progressively with 
similar kinetics in control and chimeric mice.   
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Figure 13.  Demonstration of functional immune reconstitution in IFNGR1-/- bone 
marrow chimeras.  (A) Groups of WT, IFNGR1-/-, and RAG2-/- control mice as well as 
bone marrow chimeric mice of each type were injected with 1x106 F535 tumor cells.  As 
shown, rejection of this tumor is independent of host IFNγ responsiveness.  Data from 
two independent experiments with group sizes as indicated in (B) are shown.      
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Figure 14.  No evidence for immune hyper-reactivity in IFNGR1-/- bone marrow 
chimeras.  Control and bone marrow chimeric mice were injected with either 1877 (A) or 
F244 (B) WT progressor tumor cells at a dose of 1x106 cells/mouse.  Mean tumor 
diameter ± s.e.m. over time is shown.      
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Tumor-Associated Endothelium in IFNGR1-/- Bone Marrow Chimeras is Derived 
from Nonhematopoietic Host Cells Whereas TILs are Donor Bone Marrow Derived 
 
 The origin of endothelial cells comprising the blood vessels which infiltrate and 
sustain a growing tumor has become increasingly controversial.  In the adult, 
neovascularization was traditionally thought to arise through the process of angiogenesis 
– that is, via outgrowth from existing vessels through endothelial cell proliferation and 
migration.  Some recent studies, however, have questioned this view, providing evidence 
for an alternate process known as vasculogenesis – involving the recruitment and 
differentiation of circulating bone marrow-derived endothelial precursors.  Although the 
identity of endothelial precursor cells remains unclear due to the lack of definitive 
markers, a number of studies report the incorporation of bone marrow-derived cells into 
newly formed endothelium (187-192).  Using different model systems including tumor 
growth, myocardial and hindlimb ischemia, and cutaneous wounding, genetically-marked 
cells arising from the bone marrow could be detected within the endothelium.  In most 
cases the bone marrow contribution was rather small, yet it has been suggested that 
progenitor cells might be more prominent during the early stages of neovascularization 
but are then diluted out by later expansion of existing endothelium (190).   
 Additional recent data, however, refute these claims, finding that bone marrow-
derived precursors do not contribute to newly formed endothelium in the adult and are 
not, in fact, required for tumor growth (193-198).  In one such study, Purhonen et al 
examined vessel formation in models of both transplantable and spontaneous tumor 
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growth, yet failed to detect cells of bone marrow origin within the endothelium (198).  
Nevertheless, all of the aforementioned studies find abundant bone marrow-derived cells 
directly adjacent to and underlying the endothelial cell layer.  Furthermore, there is 
increasing evidence that such cells – determined to be mostly leukocytes, but also 
pericytes and fibroblasts – play an important accessory role in promoting the formation of 
new vasculature (197, 199).  While the precise contribution of bone marrow-derived cells 
remains contentious, it is likely that their role during neovascularization is tissue- and 
model-dependent.   
 Given our findings that nonhematopoietic as well as hematopoietic IFNγ 
sensitivity is important for tumor rejection, we wanted to ask whether tumor-associated 
endothelium in IFNGR1-/- chimeras was recipient-derived or donor bone marrow-derived.  
We injected groups of control and chimeric mice with the WT progressor tumor 1877, 
then harvested tumors at day 16 for analysis.  Following mechanical and enzymatic 
disaggregation, cells isolated from the tumor tissue were stained with antibodies specific 
for the endothelial cell marker CD31 (PECAM-1), the hematopoietic lineage marker 
CD45, and the IFNγ receptor subunit IFNGR1, allowing us to assess the origins of the 
endothelium as well as tumor-infiltrating leukocytes (TILs) within the tumor (Figure 15).   
 When we gated on tumor cells (CD45-CD31-), which comprised the major cellular 
population within the mixture, we detected similar IFNGR1-positive staining in all of the 
samples – thus providing an internal control for IFNGR1 staining.  Consistent with our 
previous analyses of splenocytes from IFNGR1-/- chimeras (see Figure 9), when we 
instead gated on TILs (CD45+CD31-) we found these cells to be strictly donor bone 
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marrow derived.  For example, tumors isolated from IFNGR1-/-→RAG2-/- chimeras 
contained IFNGR1-negative TILs, while the TILs from tumor-bearing WT→IFNGR1-/- 
mice were IFNGR1-positive.  In contrast, endothelial cells within the tumor 
(CD31+CD45-) were uniformly derived form the nonhematopoietic compartment, thus 
being IFNGR1-positive in IFNGR1-/-→RAG2-/- mice and IFNGR1-negative in 
WT→IFNGR1-/- mice.  Although it could be argued that any bone marrow contribution 
might be diluted out by day 16 of tumor growth, studies documenting this phenomenon 
can still detect some contribution in late tumors (190).  Since we find no evidence of 
bone marrow derived cells, it is likely that in this model of tumor growth, infiltrating 
vessels are derived from existing endothelium.   
 In order to look more closely at different subpopulations of infiltrating leukocytes 
within the tumor, we also costained the TILs with CD45 and markers for myeloid cells 
(CD11b), dendritic cells (CD11c), or T lymphocytes (CD3).  These analyses showed that 
all TIL subpopulations were donor bone marrow-derived (data not shown), ruling out the 
possibility that tissue resident macrophages or DCs persist following bone marrow 
transplantation and comprise a significant proportion of the tumor infiltrate.  This 
possibility would perhaps also be unlikely given the large number of leukocytes within 
the tumor that are presumably recruited from the blood or differentiate from blood-borne 
precursor cells.   
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Figure 15.  Tumor-associated endothelium in IFNGR1-/- bone marrow chimeras is 
derived from nonhematopoietic host cells.  Tumors from control and chimeric mice were 
harvested 16 days after injection of 1x106 1877 tumor cells.  Following disaggregation, 
cell suspensions were stained with antibodies for CD45, CD31, and IFNGR1.  Tumors 
were analyzed by gating on endothelial cells (CD31+CD45-), tumor-infiltrating 
leukocytes (CD45+CD31-), or tumor cells (CD45-CD31-) as shown in (A).  IFNGR1 
expression levels were then examined on individual cell populations from control and 
bone marrow chimeric mice (B).  IFNGR1 positivity on the cells of the tumor served as 
an internal control for staining.       
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DISCUSSION 
 
 In this study, we have explored the functionally relevant sites of IFNγ’s actions 
during anti-tumor immune responses.  Initial experiments provided additional support for 
the conclusion that the tumor cell represents a critical target of IFNγ.  Through selective 
reconstitution of GAR4 tumor cells (derived from an IFNGR1-/-xIFNAR1-/- mouse) with 
either the missing IFNγ receptor component (IFNGR1) or IFNα/β receptor component 
(IFNAR1), we found that rejection of this tumor required tumor cell IFNγ but not IFNα/β 
sensitivity.  Yet, when we instead examined the host cell IFN requirements, both IFNγ 
and IFNα/β responsiveness were essential for its rejection.  In another set of experiments, 
we took the converse approach using H31m1 cells, which are normally IFNγ-responsive 
and are rejected when injected into WT mice.  RNAi-mediated knockdown of IFNGR1 
expression in these cells showed that sensitivity to IFNγ was indeed required for its 
rejection, corroborating results obtained using a dominant-negative IFNGR1ΔIC 
construct.     
 Since prior work in the laboratory has also demonstrated a requirement for IFNγ’s 
actions on host cells for rejection of RAG2-/- regressor tumors, we used bone marrow 
chimeras with selective IFNγ sensitivity to ask whether hematopoietic cells or 
nonhematopoietic cells represented the essential responders.  Analyses of two 
independent regressor tumors revealed that host responsiveness to IFNγ in both 
hematopoietic and nonhematopoietic cells was important for tumor rejection.  When 
injected with d38m2 tumor cells, chimeras lacking either hematopoietic or 
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nonhematopoietic IFNγ sensitivity showed a similar defect in anti-tumor immunity.  Yet, 
this phenotype was not quite as severe as that observed in chimeras with complete IFNγ 
insensitivity, suggesting that IFNγ’s actions on cells within either compartment can 
provide some tumor protection.  Experiments with the H31m1 tumor also showed a 
similar defect, though again partial, in chimeras lacking nonhematopoietic IFNγ 
responsiveness.  In chimeras selectively lacking hematopoietic responsiveness, we 
observed only significantly delayed rejection.   
 Taken together, our results demonstrate an essential function for IFNγ’s actions 
on both hematopoietic and nonhematopoietic cells during tumor rejection.  Analyses from 
the previous chapter using the same two regressor tumors established that IFNα/β 
responsiveness in hematopoietic cells was required, yet showed no role for 
nonhematopoietic IFNα/β sensitivity.  Thus, although these tumors require sensitivity to 
both IFNγ and IFNα/β within the host for their rejection, the respective IFNs are acting 
on distinct tissue compartments.   
 In contrast to our results, a previous study suggested that IFNγ sensitivity in 
nonhematopoietic cells was necessary and sufficient for anti-tumor immunity (23).  This 
work, however, relied on an immunization/rechallenge model in which mice were first 
immunized with irradiated tumor cells two weeks prior to challenge with live tumor.  In 
addition, this tumor model depended primarily on CD4+ T cells, and only a delay in 
growth rather than complete rejection was observed.  Since our regressor tumor model 
employs naïve mice and both CD4+ and CD8+ T cells are required for rejection, 
differences in our respective results may be related to the models employed. Nevertheless 
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it will be important to address this question using additional experimental approaches, 
including the use of conditional knockout mice to dissect with more specificity the 
individual cell types responsible for tumor protection.  It will also be essential to perform 
primary tumor induction studies in addition to tumor transplantation approaches.   
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INTRODUCTION 
 
 A large body of work – beginning as early as the 1960’s – has demonstrated the 
ability of IFNα/β to inhibit tumor growth and improve survival when administered to 
tumor-bearing animals (11, 37, 200).  IFNα administration has also shown some clinical 
efficacy in the treatment of several types of human cancer, and has been approved by the 
US Food and Drug Administration (FDA) for this use since 1986 (27, 38, 201).  
Nevertheless, surprisingly little is known regarding the relevant mechanisms of action, as 
well as the reasons why only some tumor types and a subset of patients seem to benefit 
from treatment.   
 In this study, we have turned our attention toward the protective anti-tumor 
functions of exogenous, as opposed to endogenous, type I IFN.  While it is possible that 
exogenous IFNα/β merely augments the same pathway involved in tumor protection by 
endogenous type I IFN, it is equally plausible that distinct host effector mechanisms are 
invoked in the setting of high dose administration.  Clearly, a better understanding of the 
mode of action would facilitate the development of more effective regimens or improved 
combination therapies.   
 Despite the ability of IFNα/β to inhibit tumor cell growth, promote apoptosis, and 
enhance immune recognition through upregulation of MHC class I molecules, it has 
become increasingly apparent that the efficacy of exogenous IFNα/β treatment is 
mediated largely by its effects on the host rather than the tumor (200).  For example, it 
was shown that IFN-insensitive tumor cell clones were still responsive to exogenous 
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IFNα/β treatment (30, 32, 33), whereas the absence of host sensitivity to type I IFN 
abrogated the effect (35).  Given the array of immunomodulatory activities ascribed to 
the type I IFNs – including the enhancement of NK and macrophage cytotoxicity, 
inhibition of angiogenesis, activation of DCs, and augmentation of T and B cell function 
– identification of the key mechanisms evoked by exogenous IFNα/β has been 
challenging.   
 A large number of studies have investigated potential mechanisms involved, 
primarily using model systems in which tumor cells were engineered to overexpress 
individual IFNα/β subtypes.  Conclusions from this work were varied, however, as some 
reports suggested a prominent role for protective T cell responses, while others 
implicated anti-angiogenic effects or innate immune killing by NK cells and 
macrophages (200, 202, 203).  Yet, since all of the cells of the host could potentially 
respond to IFNα/β in these models, distinguishing between effects on various cell 
populations was not possible.   
 In order to investigate the critical host cell mediators, we have utilized a model in 
which IFNα/β-unresponsive tumor cells (normally non-immunogenic and resistant to 
immunologic control) were engineered to constitutively express IFNβ.  Given prior data 
indicating the importance of local type I IFN delivery and the obligate role for host 
IFNα/β sensitivity, the use of IFNAR1-/--derived tumor cells ensured that all effects were 
mediated by the host, while tumor cell secretion permitted localized IFNβ delivery.  The 
use of bone marrow chimeras with selective IFNα/β responsiveness then allowed us to 
assess the effects on various host cell compartments.   
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MATERIALS AND METHODS 
 
Tumor cells.  IFNAR1-/--derived progressor tumors d103m503 and d97m915 and WT-
derived progressor F244 were induced by MCA treatment as described (5, 16).  GFP- and 
IFNβ-expressing tumor cell lines were generated by retroviral transduction.  The IFNγ-
unresponsive H31m1.IFNGR1ΔIC tumor was generated previously by overexpression of 
a dominant-negative IFNGR1 construct.   
 
Flow cytometry.  Tumor cells were stained directly, while splenocytes were first 
incubated with purified anti-CD16/CD32 mAb (2.4G2) (BD Biosciences) to prevent non-
specific antibody binding to Fc receptors.  Data was collected using a BD FACSCalibur 
(BD Biosciences) and analyzed with FlowJo software (Tree Star).  Anti-H-2Kb-PE (AF6-
88.5) and anti-CD11c-PE (HL3) were purchased from BD Biosciences; anti-DX5-PE 
(DX5), anti-CD11b-PE (M1/70), and SA-APC were from BioLegend; and anti-IFNAR1-
biotin (MAR1-5A3) has been described (64).  For MHC class I upregulation assays, cells 
were treated with the indicated dose of recombinant murine IFNγ (Genentech).    
 
Mice.  Inbred 129/SvPas mice were purchased from Charles River Laboratories, while 
129 IFNAR1-/- and RAG2-/- mice were bred in our specific pathogen-free animal facility.  
RAG2-/-IFNAR1-/- mice were generated previously in our laboratory by intercrossing 
RAG2-/- and IFNAR1-/- mice on a 129 background.   
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Tumor transplantation experiments.  Tumor cells were thawed from frozen stocks and 
cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 
2 mM L-glutamate, 1 mM sodium pyruvate, 50 U/ml penicillin, 50 µg/ml streptomycin, 
and 50 µM β-mercaptoethanol (R-10 medium).  After expansion for several passages, 
cells were harvested by incubation in 0.05% trypsin, washed once with R-10 medium, 
and washed three times with sterile, endotoxin-free PBS.  Prior to the last wash, cells 
were counted using a hemacytometer and cell viability was assessed by trypan blue 
exclusion (injected cells were >90% viable).  Cells were injected subcutaneously in a 
volume of 0.15 ml PBS into the shaved flanks of mice.  Tumor size was measured on the 
indicated days and is presented as the average of two perpendicular diameters.  When 
calculating percent tumor growth, mice with tumors larger than 6x6 mm in diameter at 
the end of the observation period were counted as positive.   
 
Antibody treatment.  Anti-asialoGM1 antibody (Wako Chemicals) was resuspended in 
4 ml sterile endofree PBS and 100 µl (diluted to 0.5 ml in PBS) was administered by i.p. 
injection on days -2, 0, +2, and +7, then every 7 days thereafter.  Control mice received 
i.p. injections of an equal volume of PBS.  Effective cell depletion was confirmed by 
flow cytometry and functional assays.  For neutralization of IFNγ, mice were injected i.p. 
with 750 µg of anti-IFNγ mAb H22 or isotype control mAb PIP on day -1 and 250 µg 
every 7 days.  IFNα/β blockade was induced by treatment at the indicated day with 2.5 
mg anti-IFNAR1 mAb MAR1-5A3, followed weekly with a 0.5 mg i.p. injection.     
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Generation of bone marrow chimeras.  E14.5 fetal liver cells were used to reconstitute 
lethally-irradiated recipients.  Embryos were extracted 14 days following implantation, 
livers were removed, and FLCs were isolated by homogenization through a metal mesh 
strainer with a 6 cc syringe plunger.  Following RBC lysis by incubation in Hybrimax 
RBC lysing buffer (Sigma-Aldrich), cells were filtered through a 40 µm cell strainer, 
washed 2 times with sterile endofree PBS, and counted.  Cells were resuspended in PBS 
for injection of 5x106 FLCs per mouse in a volume of 0.2 ml using a 0.5 cc 29 gauge 
insulin syringe.  Recipient mice, lethally irradiated with a single dose of 9.5 Gy several 
hours prior, were anesthetized by i.p. avertin and FLCs were infused i.v. via retro-orbital 
injection.  Animals were generally maintained on TMS water for 4 weeks following 
irradiation and reconstitution, and tumor transplantation experiments were performed at 
least 10-12 weeks post-reconstitution. 
 
 
 
 241 
RESULTS 
 
Type I IFN Sensitivity in Host Cells is Essential for the Control of IFNβ-Secreting 
Progressor Sarcomas   
 
 To establish a model of type I IFN cancer immunotherapy, we engineered three 
different progressor fibrosarcomas to constitutively express murine IFNβ, or GFP as a 
control.  We utilized two MCA-induced tumors originally derived from IFNAR1-/- mice 
(d103m503 and d97m915), as well as one derived from a WT mouse (F244), because this 
would allow us to distinguish between potential effects of IFNβ on host cells versus 
autocrine effects on the tumor.  After retroviral-mediated transduction, we confirmed 
expression of the introduced gene by FACS analysis for GFP levels or by testing cell 
culture supernatants for the presence of bioactive IFN via CPE assay or MHC class I 
upregulation (Figure 1).  We also examined levels of MHC class I on the bulk transduced 
cell lines themselves (Figure 2).  As expected, GFP- and IFNβ-expressing d103m503 and 
d97m915 lines showed comparable basal H-2Kb levels, whereas levels on F244.IFNβ 
were considerable elevated compared to F244.GFP.  All of the cell lines, however, were 
able to equally upregulate MHC class I in response to IFNγ treatment.  While growing 
these cells in culture, we further noted that growth of F244.IFNβ was measurably slower 
compared to its GFP-expressing counterpart, yet growth rates of the IFNAR1-deficient 
lines were comparable (data not shown).   
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 When we tested the growth of these cells in vivo, all three of the GFP-expressing 
cell lines grew progressively in WT mice with kinetics similar to growth of the parental 
tumor (Figure 3).  In contrast, the IFNβ-secreting tumor cells initially appeared to regress 
when injected into WT mice, then formed a persistent mass which remained stable in 
size.  Control of these IFNβ-secreting tumors, however, was dependent on host 
sensitivity to IFNα/β since both GFP- and IFNβ-expressing cells grew progressively in 
IFNAR1-/- mice.  The cells of the host – but not the tumor – must therefore be the 
relevant targets of IFNβ in this model, given that (i) IFNα/β-unresponsive 
d103m503.IFNβ and d97m915.IFNβ tumor cells could be controlled in WT, but not 
IFNAR1-/- mice, and (ii) IFNα/β-responsive F244.IFNβ cells still grew progressively in 
IFNAR1-/- mice.  We have therefore used this model to dissect the important host cell 
populations responding to IFNβ within the tumor microenvironment and contributing to 
tumor control.     
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Figure 1.  Generation of GFP- or IFNβ-expressing tumor cells by retroviral transduction 
and confirmation of bioactive IFNβ secretion.  (A) GFP levels by FACS of the IFNAR1-/- 
progressor tumors d103m503 and d97m915 or the WT progressor F244 were assessed 
following retroviral transduction with either RV.GFP or RV.IFNβ constructs.  (B) IFN 
secretion was confirmed by testing cell culture supernatants in a standard CPE assay for 
protection of L929 cells from viral lysis.  (C) Supernatants from the indicated cell lines 
were also tested for their ability to mediate MHC class I upregulation in H31m1 cells.  
Shown are H-2Kb levels on H31m1 following incubation with the indicated supernatant 
for 3 days.               
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Figure 2.  Basal and IFNγ-induced levels of MHC class I on IFNβ-secreting tumor cells.  
Expression levels of H-Kb on GFP- and IFNβ-expressing tumor cell lines were 
determined by FACS staining.  Basal levels are shown in black whereas IFNγ-induced 
levels (1000 U/ml for 2 days) are in red.  Irrelevant isotype ctrl Ab staining is solid gray.    
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Figure 3.  Host sensitivity to IFNα/β is required for control of IFNβ-producing tumors.  
Parental, GFP-expressing, or IFNβ-expressing d103m503, d97m915, and F244 tumor cell 
lines were injected at a dose of 1x106 cells/mouse into groups of WT and IFNAR1-/- mice 
as indicated.  Tumor size was measured over time and is depicted as the mean tumor 
diameter ± s.e.m. of n=6-10 mice/group from two independent experiments.        
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Effective Control of IFNβ-Secreting Tumors in the Absence of Adaptive Immunity 
 
 Having established the importance of host cell IFNα/β responsiveness for tumor 
control, we assessed whether adaptive immunity was required by injecting GFP- and 
IFNβ-expressing tumor cells into RAG2-/- or RAG2-/-IFNAR1-/- mice (Figure 4).  While 
both GFP- and IFNβ-expressing tumors again grew progressively in IFNα/β-
unresponsive RAG2-/-IFNAR1-/- mice, only the GFP-expressing cells displayed 
uncontrolled growth in RAG2-/- hosts.  Control of IFNβ-secreting tumor cells was 
therefore maintained in the absence of T and B lymphocytes, suggesting the involvement 
of innate immunity or nonhematopoietic cells.  Indeed, the growth of both IFNα/β-
unresponsive and IFNα/β-responsive tumor cells in RAG2-/-IFNAR1-/- mice demonstrates 
that IFNβ’s actions on host cells were still required.  Given the exclusive function of host 
cell IFNα/β sensitivity for tumor control, we used only IFNAR1-/--derived tumors in 
subsequent experiments to ensure that all effects were mediated by host cells.   
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Figure 4.  Tumor control mediated by IFNβ’s actions on the host in the absence of 
adaptive immunity.  1x106 GFP- or IFNβ-expressing d103m503, d97m915, and F244 
tumor cell lines were injected into groups of RAG2-/- and RAG2-/-IFNAR1-/- mice and 
growth was monitored.     
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NK Cells and IFNγ  Signaling are Not Required for Tumor Control Mediated by 
IFNβ  Overexpression 
 
 Since control of IFNβ-expressing tumor cells was observed to be independent of 
adaptive immunity, we asked whether NK cells, which are potently activated by type I 
IFN, were required for tumor control.  We injected d103m503.IFNβ tumor cells into WT 
mice treated with either PBS or anti-asGM1 polyclonal antibody, as well as IFNAR1-/- 
control mice.  In prior studies, we have demonstrated that our anti-asGM1 treatment 
protocol depleted NK cell numbers and completely abrogated NK function in both ex 
vivo and in vivo assays, though depletion was not specific to NK cells (see Chapter 3).  
Nevertheless, anti-asGM1 treatment had no effect on tumor control, as we observed only 
a slight increase in tumor size and tumors still remained stable over time (Figure 5A).  As 
IFNγ signaling also has important stimulatory functions on innate immune cells such as 
macrophages, we investigated the role of IFNγ during tumor control using IFNγ-specific 
neutralizing antibody.  Again, no effect was detected upon injection of d103m503.IFNβ 
or d97m915.IFNβ tumor cells into RAG2-/- mice treated with anti-IFNγ mAb as 
compared to isotype control mAb treatment (Figure 5B).   
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Figure 5.  NK cells and IFNγ signaling are dispensable for control of IFNβ-producing 
tumor cells.  (A) d103m503.IFNβ tumor cells were injected at a dose of 1x106 
cells/mouse into groups of IFNAR1-/- control mice or WT mice treated with either PBS or 
anti-asGM1 Ab.  Data from two independent experiments with n=4-6 mice/group are 
shown.  (B) 1x106 d103m503.IFNβ or d97m915.IFNβ tumor cells were injected into 
RAG2-/-IFNAR1-/- controls or RAG2-/- mice treated with anti-IFNγ mAb H22 or isotype 
control mAb PIP.  Tumor was monitored over time and is presented as mean tumor 
diameter ± s.e.m. of n=6-9 mice/group from two independent experiments.   
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Induction of a Reversible State of Equilibrium Mediated by IFNβ  Within the 
Tumor Microenvironment 
 
 Although IFNβ-expressing tumor cells initially appeared to regress, both WT and 
RAG2-/- mice eventually developed a persistent lesion at the site of tumor injection.  
Masses were stable for prolonged periods of time, though some lesions eventually 
assumed an inflammatory appearance with contracture and scar tissue formation in 
surrounding areas.  Histologically, lesions were characterized by the presence of residual 
fibrosarcoma cells as well as abundant inflammatory infiltrate and areas of necrosis (data 
not shown).  Over time, some mice also began to show signs of IFN toxicity, which was 
eventually lethal.  Necropsy revealed alterations in hematopoiesis (i.e. anemia, 
thrombocytopenia, and hypocellularity of the bone marrow), hemorrhage in several 
organs, and microvesicular fatty degeneration of the liver – all potential findings of 
chronic IFNβ exposure.  In addition, sera of mice bearing persistent lesions contained 
detectable IFN by CPE assay, and such activity could be inhibited by mAb’s specific for 
IFNAR1 or IFNβ, but not IFNα or IFNγ (Figure 6).  These observations suggest that 
residual tumor cells remain and thus cause pathology due to continual IFNβ production.   
 To investigate whether IFNβ-secreting tumors cells persisted within the stable 
masses, we treated RAG2-/- mice bearing d103m503.IFNβ tumor lesions with either anti-
IFNAR1 MAR1-5A3 mAb or isotype control GIR-208 mAb beginning at day 65 (relative 
to tumor challenge).  As expected, control mAb treatment had no effect on the persistent 
lesions and mice eventually succumbed to IFN-mediated toxicity (Figure 7A).  In mice 
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treated with anti-IFNAR1 mAb, however, progressively growing tumors emerged from 
the lesions in 10/10 mice.  The fact that anti-IFNAR1 mAb treated mice were rescued 
from lethality due to chronic IFN exposure also confirms this as the presumed cause of 
death in untreated animals.  Similar results were obtained when RAG2-/- mice were 
treated with anti-IFNAR1 beginning at day 100, as tumors arose in 6/8 mice (Figure 7B).  
In this case, treatment was unable to rescue lethality in two mice which died shortly after 
the initiation of antibody blockade.   
 Treatment of WT mice bearing stable masses with anti-IFNAR1 mAb also 
yielded progressively growing tumors, though less frequently.  As shown in Figure 8, 
masses in WT mice treated with control mAb at day 65 remained stable in size, whereas 
tumors progressed in anti-IFNAR1 mAb treated mice, ultimately leading to outgrowth in 
5/8 mice.  In several of the remaining mice, initial increases in tumor size were followed 
by eventual elimination of the mass, resolution of its inflammatory external appearance, 
and prolonged survival of the mouse (Figure 8 and data not shown).  This observation is 
potentially explained by findings (described in a subsequent section) suggesting that 
under conditions of lower IFNβ levels an adaptive immune response can lead to tumor 
elimination.  Such an effect would thus not be observed in RAG2-/- mice lacking 
lymphocytes.   
 In order to qualitatively examine the tumors that emerged following anti-IFNAR1 
mAb treatment, we harvested tumors from RAG2-/- or WT mice following day 65 mAb 
treatment and generated cell lines.  The tumorigenic potential of the harvested tumor cells 
was then assessed by transplantation into IFNAR1-/- and RAG2-/- mice.  In all cases the 
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harvested tumor cells showed progressive growth in IFNAR1-/- mice but not in RAG2-/- 
hosts, suggesting that the cells continued to secrete IFNβ (Figure 9).  Taken together, 
these data demonstrate that in both WT and RAG2-/- mice, poorly immunogenic 
progressor sarcomas can be maintained in a protracted state of equilibrium due to local 
production of type I IFN and its actions on host cells.         
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Figure 6.  Detectable IFNβ in the sera of mice bearing stable masses.  Sera from mice 
bearing stable d103m503.IFNβ tumor masses (beyond day 60 post-transplant) was tested 
for the presence of measurable IFN using a standard CPE assay (A).  One positive serum 
sample was then assayed in the presence of anti-IFNAR1 (MAR1-5A3), anti-IFNβ (MIB-
5E9), anti-panIFNα (TIF-C35), or anti-IFNγ (H22) mAb’s as shown in (B).  
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Figure 7.  IFNα/β receptor blockade at day 65 or day 100 reverses IFNβ-induced tumor 
equilibrium in RAG2-/- mice.  (A) RAG2-/- mice bearing stable masses following 
injection of d103m503.IFNβ tumor cells were treated beginning at day 65 with either 
anti-IFNAR1 mAb MAR1-5A3 (n=10) or isotype control mAb GIR-208 (n=8) and tumor 
size was monitored over time.  (B) RAG2-/- mice with stable masses were treated with 
anti-IFNAR1 mAb beginning instead at day 100 (n=8).  Each line represents an 
individual mouse.  A significant fraction of mice treated with control mAb eventually 
died due to chronic IFN exposure.            
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Figure 8.  Disruption of IFNβ-mediated equilibrium state in WT mice by IFNα/β 
receptor blockade at day 65.  WT mice with stable masses following d103m503.IFNβ 
injection were treated beginning at day 65 with either anti-IFNAR1 mAb MAR1-5A3 
(n=8) or isotype control mAb GIR-208 (n=6) and tumor growth was monitored.   
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Figure 9.  Tumors harvested from RAG2-/- and WT mice following disrupted equilibrium 
are tumorigenic in IFNAR1-/- mice and still secrete IFNβ.  Tumor cell lines established 
following anti-IFNAR1 mAb treatment were retransplanted into groups of IFNAR1-/- and 
RAG2-/- mice (n=3/group) and tumor growth was measured over time.  The growth of 4 
tumors originally harvested from RAG2-/- mice and 3 tumors harvested from WT mice is 
shown.     
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Critical Role for Both Hematopoietic and Nonhematopoietic Host Cell IFNα/β  
Sensitivity During Control of IFNβ-Secreting Tumors  
 
 We next wanted to delineate the role of hematopoietic versus nonhematopoietic 
type I IFN sensitivity for control of IFNβ-expressing tumors.  Bone marrow chimeras 
were therefore generated as previously described (see Chapter 3), and we challenged 
control and chimeric mice with IFNβ-secreting d103m503 and d97m915 tumor cells 
(Figure 10).  Similar to IFNAR1-/- and WT controls, these tumors displayed progressive 
growth in IFNAR1-/-→IFNAR1-/- chimeras but formed small stable masses in WT→WT 
chimeras.  When injected into WT→IFNAR1-/- chimeras (IFNα/β-responsive only in 
hematopoietic cells), we again observed progressive tumor growth, indicating that IFNβ’s 
actions on the host hematopoietic compartment is not sufficient for tumor control.  
Conversely, chimeras with IFNα/β sensitivity only in nonhematopoietic cells (IFNAR1-/-
→RAG2-/- chimeras) also failed to control tumor growth, yet exhibited a slightly different 
phenotype.  In these mice, tumors grew initially then began to level off upon reaching 
average diameters around 10mm, and generally remained stable in size until mice 
eventually manifested symptoms of IFN toxicity.  We also noted differences in the gross 
appearance of tumors, since they did not protrude to the same degree (as seen in the 
absence of nonhematopoietic IFNα/β sensitivity) while becoming increasing necrotic 
toward their centers (Figure 11).  These findings reveal that while IFNβ’s actions on 
nonhematopoietic cells provide some inhibition to tumor growth, its activity on both 
hematopoietic and nonhematopoietic cells are required for full control. 
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 Given prior studies showing no role for adaptive immune cells during tumor 
control, we performed similar experiments to dissect the requirements for host cell 
IFNα/β sensitivity in the absence of adaptive immunity.  For this purpose, we generated 
two sets of bone marrow chimeras, both of which lacked T and B lymphocytes (Figure 
12A).  In the first group, lethally irradiated RAG2-/-IFNAR1-/- mice were reconstituted 
with RAG2-/- FLCs, yielding mice responsive to IFNα/β in the innate immune 
compartment but not in nonhematopoietic tissues.  In the converse type of chimera, 
lethally irradiated RAG2-/- mice were reconstituted with RAG2-/-IFNAR1-/- FLCs, 
producing mice with type I IFN responsiveness in the nonhematopoietic compartment but 
not in innate immune cells.  Analysis of splenocytes for IFNAR1 expression confirmed 
the expected phenotypes of these chimeras and also showed normal spleen cellularity 
(Figure 12B-C), suggesting adequate hematopoietic reconstitution.  When transplanted 
with IFNβ-expressing tumor cells, we observed very similar phenotypes as seen with 
IFNAR1-/- chimeras (Figure 13).  These data therefore demonstrate that cells of both the 
innate immune and nonhematopoietic host compartments constitute the critical targets for 
control of IFNβ-expressing tumor cells in vivo.   
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Figure 10.  Requirement for both hematopoietic and nonhematopoietic host IFNα/β 
sensitivity for control of IFNβ-producing tumors.  Groups of control IFNAR1-/- and WT 
mice as well as bone marrow chimeric mice with selective IFNα/β sensitivity were 
injected with 1x106 d103m503.IFNβ (A) or d97m915.IFNβ (B) tumor cells and growth 
was monitored over time.  Data represent n=4-5 mice/group from two independent 
experiments. 
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Figure 11.  Differences in the gross appearance of d103m503.IFNβ tumors in the 
presence or absence of nonhematopoietic IFNα/β sensitivity.  External appearance of 
tumors is shown for representative WT, IFNAR1-/-, WT→IFNAR1-/-, and IFNAR1-/-
→RAG2-/- mice at the indicated day following injection of 1x106 d103m503.IFNβ tumor 
cells.  In the absence of nonhematopoietic IFNα/β responsiveness (WT→IFNAR1-/- 
mice), tumors grew progressively and protruded as a well-demarcated mass as observed 
in IFNAR1-/- controls.  In the presence of hematopoietic IFNα/β sensitivity (IFNAR1-/-
→RAG2-/- mice), tumors grew in a deeper location with less depth and became 
increasingly necrotic at the center, while also eventually stabilizing in size.  Growth 
phenotypes of WT→WT and IFNAR1-/-→IFNAR1-/- control chimeras recapitulated that 
seen in WT and IFNAR1-/- mice, respectively (data not shown).   
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Figure 12.  Generation of bone marrow chimeras with selective IFNα/β responsiveness 
in nonhematopoietic or innate immune cells.  (A) Strategy for producing chimeras with 
either innate immune or nonhematopoietic IFNα/β sensitivity.  (B) Spleen cellularity 
from a representative cohort of bone marrow chimeras was assessed.  (C) IFNAR1 
expression levels on several immune cell subsets from the spleens of chimeric mice.  
Shown is the percent IFNAR1+ cells within the indicated gate for n=3-4 mice/group.            
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Figure 13.  Important role for IFNβ’s actions on both innate immune and 
nonhematopoietic cells.  Cohorts of RAG2-/-IFNAR1-/- and RAG2-/- control mice or 
RAG2-/-→RAG2-/-IFNAR1-/- and RAG2-/-IFNAR1-/-→RAG2-/- bone marrow chimeras 
were injected with 1x106 d103m503.IFNβ (A) or d97m915.IFNβ (B) tumor cells and 
growth was monitored.  Plotted are the mean tumor diameters ± s.e.m. for n=7-10 
mice/group from two independent experiments.   
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Local IFNβ  Production is Required for Tumor Control 
 
 To test whether IFNβ-producing tumor cells might provide protection against 
growth of the parental tumor at a remote site, we challenged WT and RAG2-/- mice with 
IFNβ-producing d103m503.IFNβ cells on one flank and parental d103m503 cells on the 
opposite flank.  As shown in Figure 14, we found no evidence for the induction of 
concomitant immunity, as growth of the parental d103m503 tumor was identical in both 
uninjected and d103m503.IFNβ-bearing hosts.  In addition, a similar result was observed 
when mice bearing stable masses (at day 65 following d103m503.IFNβ injection) were 
injected with parental tumor cells on the opposite flank (data not shown).  Since IFNβ-
producing tumor cells do, in fact, provide protection when mixed and coinjected with 
parental tumor cells (discussed in the next section), these findings suggest that local but 
not systemic delivery of IFNβ is efficacious in this model – a notion also supported by a 
very recent study utilizing local delivery of IFNα (204).  In light of experiments outlined 
in the next section, which demonstrate lymphocyte-dependent protection at lower levels 
of IFNβ production, it would be interesting to repeat these experiments using an 
inoculum of low-expressing tumor cells.  Nevertheless, the current results provide 
support for the idea that high-expressing tumors do not elicit an effective adaptive 
immune response.   
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Figure 14.  Lack of concomitant immunity in mice bearing IFNβ-producing tumor cells.  
Groups of either untreated or d103m503.IFNβ-injected WT (A) or RAG2-/- (B) mice 
were injected on the opposite flank with 1x106 parental d103m503 tumor cells.  Shown is 
the growth of IFNβ-producing (above) and parental d103m503 (below) tumor cells over 
time (both were injected on the same day).  Results represent the mean tumor diameter ± 
s.e.m. for n=2-3 mice/group.  Similar data was also obtained when WT or RAG2-/- mice 
at day 65 following d103m503.IFNβ injection were challenged with parental d103m503 
tumor cells (data not shown).   
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Dose-Dependent Effects of IFNβ  Ranging from Long-term Tumor Persistence to 
Lymphocyte-Dependent Tumor Elimination Without Toxicity 
 
We have previously observed that production of high levels of IFNβ within the tumor 
microenvironment can mediate a reversible state of prolonged tumor persistence, yet also 
eventually results in significant toxicity due to chronic IFN exposure.  In subsequent 
experiments, we have therefore assessed whether production of lower levels of IFNβ 
within the tumor can also provide protection without toxicity.  To obtain tumor cell 
mixtures with varying levels of IFNβ production, we have mixed parental d103m503 and 
IFNβ-expressing d103m503.IFNβ cells at different ratios prior to injection into WT or 
RAG2-/- hosts.  As plotted in Figure 15, we again observed progressive growth of 
d103m503 cells while d103m503.IFNβ cells formed stable masses in both WT and 
RAG2-/- mice.  Similarly, 50:50 tumor cell mixtures also developed into persistent lesions 
in both WT and RAG2-/- recipients, though growth was seen in 1/5 RAG2-/- mice.  This 
trend continued at the 75:25 cell ratio, since we found that most WT mice exhibited 
stable masses (complete elimination was seen in 2/6 mice), whereas all RAG2-/- mice 
developed stable masses and progressive growth was eventually observed in 2/5 mice.  
With low-dose IFNβ (at the 90:10 ratio), this difference was most dramatic, as 4/6 WT 
mice completely eliminated the tumor mass (1/6 showed progressive growth, and 1/6 
developed a very small lesion) while progressive growth was observed in 4/5 RAG2-/- 
mice after an initial period of tumor control. 
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 The differential tumor control in WT and RAG2-/- mice at low doses of IFNβ 
reveals an important function for lymphocytes in this setting.  Interestingly, RAG2-/- mice 
were still capable of restricting tumor growth initially, though outgrowth eventually 
occurred around day 30 or beyond.  This is in contrast to robust growth of the 90:10 
mixture in IFNAR1-/- hosts (see Figure 17 in this chapter), suggesting that innate immune 
mechanisms can mediate initial control yet adaptive immune function is ultimately 
required for long-term tumor control as well as tumor elimination.  At higher doses, 
however, tumor cells persist and lymphocytes are not, in fact, required for control of 
stable masses.  In addition to successful tumor elimination in WT mice challenged with 
low-dose IFNβ-expressing tumor cells, we also found that mice did not manifest signs of 
IFN toxicity.  Whereas no toxicity was evident in WT mice treated with the 90:10 tumor 
cell mixture, over half of WT mice injected with d103m503.IFNβ in this experiment 
eventually died due to chronic IFN exposure (Figure 15 and data not shown). 
 These findings may provide an explanation for the previously observed difference 
in tumor outgrowth between RAG2-/- and WT mice (each bearing stable masses after 
d103m503.IFNβ injection) upon anti-IFNAR1 mAb treatment at day 65 (see Figures 7-
8).  Whereas outgrowth occurred in all RAG2-/- mice, it was seen less frequently in WT 
mice.  Moreover, a few tumors in WT mice initially grew and were then completely 
eliminated.  Perhaps partial blockade of IFNβ’s actions thus allowed for the generation or 
increased efficacy of an adaptive immune response, eventually leading to tumor 
elimination.  This hypothesis would imply that high levels of IFNβ within the tumor are, 
in fact, inhibitory toward the adaptive immune response – a notion supported by the 
 281 
observation that high-expressing tumors persist as stable lesions, whereas low-expressing 
tumors are completely eliminated.   
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Figure 15.  Elimination of tumors expressing lower levels of IFNβ is lymphocyte 
dependent.  (A) Groups of WT and RAG2-/- mice were injected with mixtures of parental 
d103m503 and d103m503.IFNβ tumor cells (1x106 total cells/mouse) and tumor growth 
was monitored over time.  Ratios indicate composition of d103m503:d103m503.IFNβ 
cells.  Each line represents an individual mouse.  (B) Summary of percent tumor growth 
for each group (n=4-6 mice/group) is plotted.  Data from two independent experiments 
with similar results are shown.   
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Growth Inhibition of IFNγ-Unresponsive Tumor Cells via Local IFNβ  Production is 
Lymphocyte Dependent 
 
 Although we have shown that coinjection of IFNβ-producing tumor cells with the 
parental progressor tumor is protective, we wanted to test whether local IFNβ production 
could also inhibit the growth of antigenically unrelated and IFNγ-unresponsive 
progressor tumor cells.  We therefore coinjected a 50:50 mixture of d103m503.IFNβ cells 
and H31m1.IFNGR1ΔIC cells (which overexpress a dominant-negative form of the IFNγ 
receptor component IFNGR1 and hence are IFNγ-insensitive).  When injected 
individually, H31m1.IFNGR1ΔIC cells formed rapidly growing tumors in both RAG2-/- 
and WT hosts, whereas d97m915.IFNβ tumor growth reaches a plateau around 5x5 mm 
and remains stable (Figure 16).  In contrast, growth of the 50:50 tumor cell mixture was 
rapid in RAG2-/- mice but significantly inhibited in WT mice, though in a fraction of 
mice tumors eventually grew out.  The actions of lymphocytes are therefore important in 
mediating delayed growth of this tumor mixture.  Since the H31m1.IFNGR1ΔIC tumor is 
still responsive to IFNα/β, it is possible that tumor cell apoptosis mediated by local IFNβ 
is contributing to the development of an adaptive immune response – though rapid 
growth in RAG2-/- mice rules out direct anti-proliferative or pro-apoptotic effects as the 
primary cause of the delay.  Alternately, local production of IFNβ may be inducing MHC 
class I upregulation on IFNγ-unresponsive H31m1 cells, thus rescuing the potential 
defect in adaptive immune recognition.  It would be interesting to assess whether lower 
levels of local IFNβ production are more effective in mediating complete rejection of 
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H31m1.IFNGR1ΔIC cells as we observed with the parental d103m503 tumor. 
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Figure 16.  Inhibition of IFNγ-unresponsive tumor cell growth by local production of 
IFNβ is mediated by lymphocytes.  Groups of RAG2-/- or WT mice were injected with 
1x106 IFNγ-insensitive H31m1.IFNGR1ΔIC cells, IFNβ-producing d97m915.IFNβ cells, 
or a 50:50 mixture (2x106 total cells) of both cell lines and tumor growth was monitored 
over time.  Data are presented as mean tumor diameter ± s.e.m. of n=2-3 (RAG2-/-) or 
n=5-6 (WT) mice per group.           
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Tumor Rejection via Low-Dose IFNβ  Reveals Tissue-Selective Requirements for 
Host Cell IFNα/β  Sensitivity 
 
 Since the elimination of tumors with low-dose IFNβ production was found to 
require the actions of adaptive immunity, we postulated that the critical host cell targets 
of IFNβ may in this case be distinct from those with high-dose IFNβ.  To test this 
hypothesis, we again utilized bone marrow chimeras with selective type I IFN 
responsiveness in hematopoietic or nonhematopoietic cells.  Groups of control and 
chimeric mice were challenged with a 90:10 ratio of parental to IFNβ-expressing 
d103m503 tumor cells and growth was monitored over time (Figure 17).  As in control 
mice, this tumor challenge was rejected in WT→WT chimeras but showed unrestrained 
growth in IFNAR1-/-→IFNAR1-/- chimeras.  Unexpectedly, IFNβ’s actions on 
hematopoietic cells were now sufficient for tumor elimination, as WT→IFNAR1-/- 
chimeras exhibited an identical phenotype as WT→WT controls.  In contrast, tumors in 
IFNAR1-/-→RAG2-/- chimeras progressed initially then eventually leveled off, as seen 
with high-dose IFNβ.  Nonhematopoietic cells could thus provide some protection 
against unrestrained tumor expansion, yet it is IFNβ’s actions on hematopoietic cells (and 
the actions of lymphocytes as determined previously) that ultimately mediate tumor 
elimination.   
 With the injection of d103m503 tumor cells expressing higher levels of IFNβ, the 
outcome of tumor challenge in WT→IFNAR1-/- chimeras was dramatically different (see 
Figure 10A).  Progressive growth in this setting indicates that high doses of IFNβ are, in 
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fact, inhibitory toward the anti-tumor actions of host hematopoietic cells.  Taken 
together, these data reveal that (i) levels of type I IFN within the tumor environment 
represent an important parameter determining the efficacy of IFNα/β immunotherapy, 
and (ii) successful anti-tumor responses are mediated by exogenous IFNα/β’s actions on 
host hematopoietic cells and require the actions of lymphocytes for complete tumor 
elimination. 
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Figure 17.  Host hematopoietic type I IFN sensitivity is both necessary and sufficient for 
elimination of low dose IFNβ-producing tumors.  Groups of WT, IFNAR1-/-, and RAG2-/- 
control mice or bone marrow chimeric mice with selective IFNα/β responsiveness were 
challenged with 1x106 d103m503.IFNβ tumor cells and growth was measured over time.  
Results represent mean tumor diameter ± s.e.m. of at least 4 mice/group.       
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DISCUSSION 
 
 Given the therapeutic efficacy of exogenously administered IFNα for the 
treatment of several types of human cancer, we wanted to explore whether the actions of 
IFNα/β in promoting anti-tumor immunity in a therapeutic setting was similar to that of 
endogenously produced type I IFN during a naturally occurring anti-tumor response.  
Prior work from several groups using mouse models of immunotherapy suggests that 
exogenous IFNα/β functions predominantly in a host stimulatory capacity, rather than 
through anti-proliferative or pro-apoptotic effects directly on the tumor.  We therefore 
utilized MCA-induced progressor tumors derived from IFNAR1-/- mice, to ensure that all 
effects of IFNα/β treatment are due to actions on host cells.  Although the parental tumor 
lines are poorly immunogenic and resistant to immune control, growth of the IFNβ-
producing tumors could be controlled when injected into WT and RAG2-/-, but not 
IFNAR1-/- hosts.   
 While tumors did not grow progressively, stable masses were observed to persist 
for long periods of time until a fraction of mice eventually died from IFN-mediated 
toxicity.  To assess whether IFNβ-producing tumor cells persisted within these stable 
masses, we treated mice either at day 65 or day 100 with anti-IFNAR1 mAb.  Such 
treatment could effectively interrupt IFNβ-mediated tumor equilibrium, leading to tumor 
outgrowth in both RAG2-/- and WT mice.  In addition, harvest and retransplant of the 
resulting tumors showed that they still produced IFNβ and could be controlled in RAG2-/- 
mice, yet were highly tumorigenic in IFNAR1-/- hosts.  Finally, experiments using bone 
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marrow chimeras demonstrated that IFNα/β sensitivity in both the nonhematopoietic and 
innate immune compartments was required for tumor control, though adaptive immunity 
was dispensable.   
 Since mice exhibiting stable masses eventually manifested significant toxicity due 
to chronic IFNβ exposure, we examined whether tumor cells expressing lower levels of 
IFNβ could be controlled without inducing toxicity.  In this case, we observed that 
tumors were effectively eliminated with no remaining lesions (and no toxicity) in the 
majority of WT mice.  Yet, adaptive immunity was found to be required, as low-dose 
IFNβ-producing tumor cells eventually grew progressively in RAG2-/- mice following a 
brief initial period of tumor control.  The enhanced efficacy with low-dose IFNβ and the 
requirement for adaptive immunity, suggested that IFNβ at high levels within the tumor 
environment was, in fact, inhibitory toward the generation of a protective adaptive 
response and tumors therefore persisted.  When we explored the cellular targets required 
for elimination of low-dose IFNβ-producing tumors, we found that in contrast to earlier 
observations, hematopoietic IFNα/β sensitivity was necessary and sufficient for tumor 
elimination.  These data therefore reveal an interesting difference in the cellular 
mediators and ultimate outcome depending on levels of exogenous IFNβ within the 
tumor microenvironment.  At high levels, IFNβ can inhibit tumor growth through actions 
on both innate immune and nonhematopoietic cells, but is inhibitory toward the 
generation of fully protective adaptive immune responses, and tumors persisted in a state 
of prolonged and reversible equilibrium.  Alternatively, IFNβ at lower doses could 
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mediate complete tumor elimination through its actions on hematopoietic cells, but this 
outcome now required adaptive immunity.   
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SUMMARY 
 
 Building on previous work identifying the type I (IFNα/β) and type II (IFNγ) 
interferons as key effector molecules in immunologic protection against tumor 
development, the overarching goal of this thesis was to further understand the critical 
host stimulatory functions mediated by these cytokines.  Whereas prior studies have 
shown that tumor cell sensitivity to IFNγ, but not IFNα/β, is important, responsiveness 
within the host to both IFNα/β and IFNγ was found to be essential (11, 16).  We reasoned 
that further characterization of the IFN-dependent anti-tumor response – and more 
specifically, the elucidation of the functionally relevant host cell targets of IFNα/β and 
IFNγ – would lead us closer to understanding the crucial immunomodulatory functions of 
the IFNs during this process.   
 In the first study, we took a descriptive approach to further examine the anti-
tumor immune response to immunogenic tumors and its dependence on the IFNs.  Using 
a new cohort of RAG2-/--derived regressor tumors from C57Bl/6 strain mice, we 
generalized original observations made with 129 tumors by showing that rejection of B6 
regressors also required IFNγ signaling as well as host responsiveness to IFNα/β.  To 
determine when during the immune response the respective IFNs were acting, we 
performed antibody blockade experiments and demonstrated that whereas the early 
actions of IFNα/β were sufficient for tumor rejection, the temporal requirement for 
IFNγ’s actions was more prolonged.  We further showed that in the absence of host 
sensitivity to either IFNα/β or IFNγ, generation of tumor-specific T cells with effector 
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activity is severely impaired, suggesting a central role in promoting the initiation of 
adaptive responses to tumors.  Using mixtures of immunogenic and non-immunogenic 
tumor cells, we then confirmed that specific adaptive immune killing was responsible for 
rejection, since regressor tumor cells were selectively eliminated within tumor cell 
mixtures.  Finally, because the type I IFN family consists of a large number of individual 
subtypes which might possess non-redundant functions in vivo, we examined whether 
IFNβ was essential during the rejection of transplantable tumors.  IFNβ-deficient mice, 
however, showed no defect in their ability to reject immunogenic 129 regressor tumors, 
suggesting potential redundancy or a more prominent role for the IFNα subtypes. 
 Several pieces of data gleaned from these initial studies provide preliminary 
evidence that the IFNs might be performing distinct functions on the host during tumor 
rejection.  In addition to their differing temporal requirements, analysis of STAT1Y701F 
mutant mice showed that growth of transplantable tumor cells was more aggressive in 
mice lacking responsiveness to both IFNα/β and IFNγ than in mice lacking sensitivity to 
one or the other.  In addition, the identification of individual tumors that require only the 
actions of IFNα/β but not IFNγ (or vice versa) for their rejection, also implies their 
unique function.  Although mechanisms contributing to allogeneic tumor rejection may 
be quite different from those involved in the rejection of immunogenic syngeneic tumors, 
we also observed that allogeneic rejection of aggressive progressor tumors required host 
sensitivity to IFNγ but not IFNα/β.   
 In the second study of this thesis, we have investigated the requirements for host 
cell sensitivity to IFNα/β during tumor rejection.  Initial work confirmed and extended 
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prior studies demonstrating the importance of IFNα/β’s actions on hematopoietic cells of 
the host.  We now show that for rejection of two additional immunogenic RAG2-/- 
regressor tumors, H31m1 and d38m2, IFNα/β responsiveness in host hematopoietic cells 
is both necessary and sufficient for rejection.  The hematopoietic compartment, however, 
includes all immune cells, and type I IFN can exert potent immunomodulatory functions 
on an array of cells.  Therefore, we generated mixed bone marrow chimeras to 
specifically reconstitute IFNα/β sensitivity within either innate or adaptive immune cells.  
Using these chimeras, we found that cells of the innate immune compartment were the 
obligate targets of endogenous IFNα/β for rejection of H31m1 and d38m2 tumor cells.  
As a control, we verified the hematopoietic reconstitution in these chimeras, 
demonstrating normal rejection of F515 tumors cells, which require IFNγ signaling and 
adaptive immunity, but not IFNα/β responsiveness, for their rejection.  Finally, we 
demonstrated that selective type I IFN responsiveness in innate immune cells was able to 
restore the defect in tumor-specific CTL priming, also confirming that T cells were, in 
fact, required for tumor rejection in innate IFNα/β-responsive chimeras.   
 Since type I IFN is a strong activator of NK cell function that has been shown to 
be important for NK cell-mediated anti-tumor responses (43), we asked whether NK cells 
were critical effectors during the rejection of immunogenic transplantable sarcomas.  For 
these experiments, we utilized regressor tumors derived from C57Bl/6 strain RAG2-/- 
mice, allowing for depletion of NK cells by injection of anti-NK1.1 mAb PK136.  When 
we examined three different B6 regressor tumors that required host sensitivity to IFNα/β 
for their rejection, we found that NK cell depletion had no effect their rejection.  In 
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contrast, when we examined the role of CD8α+ dendritic cells during tumor rejection, we 
observed a strong requirement for this immune subset (151).  Using an in vitro cross-
presentation assay, we furthermore showed that the direct actions of type I IFN on 
CD8α+ DCs enhanced cross-priming of naïve CD8+ T cells.  Studies to ascertain whether 
CD8α+ DCs are also essential direct targets of type I IFN during tumor rejection in vivo 
are currently ongoing.   
 In the third study, we examined the key cellular targets of IFNγ during the 
rejection of immunogenic tumors.  Initial experiments provided additional evidence for 
the importance of tumor cell IFNγ sensitivity.  Analysis of the GAR4 tumor (derived 
from IFNGR1-/-xIFNAR1-/- mice) demonstrated that selective reconstitution of IFNγ 
responsiveness, but not IFNα/β sensitivity, could mediate rejection.  When host cell IFN 
requirements were examined, however, responsiveness to both IFNγ and IFNα/β were 
required.  In the course of these experiments, we noticed that rejection of the 
reconstituted GAR4.GR1 tumor showed a stronger requirement for host IFNα/β than 
IFNγ sensitivity, providing an additional hint that they might have non-overlapping 
functions on the host.  Finally, to confirm the essential role of IFNγ’s actions on the 
tumor, we also used RNAi to show that IFNGR1 knockdown in a regressor tumor 
normally responsive to IFNγ could now abrogate tumor rejection.   
 Since IFNγ sensitivity at the level of the host is also required for the rejection of 
RAG2-/- regressor tumors, we used bone marrow chimeras to examine the nature of this 
requirement.  In contrast to type I IFN, we found that host responsiveness to IFNγ in both 
hematopoietic and nonhematopoietic cells was essential for tumor rejection.  When 
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injected with d38m2 tumor cells, chimeras lacking either hematopoietic or 
nonhematopoietic IFNγ sensitivity showed a similar defect in anti-tumor immunity.  This 
phenotype, however, was not quite as severe as that observed in chimeras with complete 
IFNγ insensitivity, suggesting that IFNγ’s actions on cells within either compartment can 
provide some tumor protection.  When we instead examined the requirements for H31m1 
rejection, we found a similar defect – though again partial – in chimeras lacking 
nonhematopoietic IFNγ responsiveness.  In this case, a more significant function was 
found for nonhematopoietic compared to hematopoietic IFNγ sensitivity, though 
chimeras selectively lacking hematopoietic responsiveness showed significantly delayed 
rejection.  Taken together, these data demonstrate critical functions for IFNγ acting on 
both hematopoietic and nonhematopoietic host cells, but also suggest that these anti-
tumor mechanisms may be independent of one another.  Indeed, host responsiveness to 
IFNγ in one compartment or the other still afforded some tumor protection.   
 Importantly, we have shown that the constellation of requirements for IFNγ’s 
actions on the host is, in fact, distinct from that of IFNα/β.  Whereas immune-mediated 
rejection of H31m1 and d38m2 tumor cells required the actions of IFNα/β solely on 
hematopoietic cells, an essential role for IFNγ’s actions on both hematopoietic and 
nonhematopoietic cells was found for these same tumors.  This observation therefore 
establishes that IFNα/β and IFNγ must perform unique functions at the level of the host, 
in addition to their disparate importance at the level of the tumor.  
 In the final study of this thesis, we focused on the role of exogenous as opposed to 
endogenous IFN in mediating tumor protection.  It has long been recognized that the 
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administration of exogenous type I IFN – either through injection of recombinant protein, 
in vivo delivery by viral vectors, or its overexpression in tumor cells – can inhibit tumor 
growth or induce fully protective anti-tumor responses through its actions on cell of the 
host (200).  Relatively little is known, however, concerning the relevant cellular targets 
eliciting these effects.  To address this issue, we have used a model of IFNα/β 
immunotherapy consisting of IFNβ-producing fibrosarcoma cells derived from IFNAR1-/- 
mice, thus ensuring that observed effects are due solely to actions on the host rather than 
the tumor.  Although the parental tumor lines are poorly immunogenic and resistant to 
immune control, growth of the IFNβ-producing tumors could be controlled when injected 
into WT and RAG2-/-, but not IFNAR1-/- hosts.   
 While tumors did not grow progressively, stable masses were observed to persist 
for long periods of time until a fraction of mice eventually died from IFN-mediated 
toxicity.  To assess whether IFNβ-producing tumor cells persisted within these stable 
masses, we treated mice either at day 65 or day 100 with anti-IFNAR1 mAb.  Such 
treatment could effectively interrupt IFNβ-mediated tumor equilibrium, leading to tumor 
outgrowth in both RAG2-/- and WT mice.  In addition, harvest and retransplant of the 
resulting tumors showed that they still produced IFNβ and could be controlled in RAG2-/- 
mice, yet were highly tumorigenic in IFNAR1-/- hosts.  Finally, experiments using bone 
marrow chimeras demonstrated that IFNα/β sensitivity in both the nonhematopoietic and 
innate immune compartments was required for tumor control, though adaptive immunity 
was dispensable.   
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 Since mice exhibiting stable masses eventually manifested significant toxicity due 
to chronic IFNβ exposure, we examined whether tumor cells expressing lower levels of 
IFNβ could be controlled without inducing toxicity.  In this case, we observed that 
tumors were effectively eliminated with no remaining lesions (and no toxicity) in the 
majority of WT mice.  Yet, adaptive immunity was found to be required, as low-dose 
IFNβ-producing tumor cells eventually grew progressively in RAG2-/- mice following a 
brief initial period of tumor control.  The enhanced efficacy with low-dose IFNβ and the 
requirement for adaptive immunity, suggested that IFNβ at high levels within the tumor 
environment was, in fact, inhibitory toward the generation of a protective adaptive 
response and tumors therefore persisted.  When we explored the cellular targets required 
for elimination of low-dose IFNβ-producing tumors, we found that in contrast to earlier 
observations, hematopoietic IFNα/β sensitivity was necessary and sufficient for tumor 
elimination.  These data therefore reveal an interesting difference in the cellular 
mediators and ultimate outcome depending on levels of exogenous IFNβ within the 
tumor microenvironment.  At high levels, IFNβ can inhibit tumor growth through actions 
on both innate immune and nonhematopoietic cells, but is inhibitory toward the 
generation of fully protective adaptive immune responses, and tumors persisted in a state 
of prolonged and reversible equilibrium.  Alternatively, IFNβ at lower doses could 
mediate complete tumor elimination through its actions on hematopoietic cells, but this 
outcome now required adaptive immunity.   
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FUTURE DIRECTIONS 
 
Identifying the critical targets of endogenous type I and type II IFN 
 Using mixed bone marrow chimeric mice, our prior studies have established that 
the relevant cellular targets of IFNα/β during tumor rejection reside in the innate immune 
compartment.  Whereas NK cells were ruled out as obligate innate immune effectors 
during IFNα/β-dependent rejection, CD8α+ DCs were found to be absolutely required for 
successful anti-tumor immune responses.  Furthermore, the direct actions of IFNα/β on 
CD8α+ DCs enhanced cross-presentation of cell-associated antigen to naïve CD8+ T cells 
in vitro.  Taken together, the evidence demonstrating that (i) IFNα/β promotes tumor-
specific CTL priming, (ii) IFNα/β acts on innate immune cells to mediate its anti-tumor 
effects, (iii) CD8α+ DCs are absolutely required for CTL priming and tumor rejection in 
vivo, and (iv) IFNα/β acts directly on CD8α+ DCs to promote CTL priming in vitro, 
collectively supports a host protective function involving direct actions of type I IFN on 
CD8α+ cDCs.  However, studies to more directly assess the role of IFNα/β on CD8α+ 
DCs in vivo will be instructive.   
 Although technically challenging, ex vivo and adoptive transfer approaches may 
be used to address this question.  Since IFNα/β is a potent activator of DCs, ex vivo 
analysis of the activation status of DC subsets from WT and IFNAR1-/- mice at different 
time points following tumor challenge could be pursued.  In addition, the ability of 
isolated DC subsets to prime T cells could be assayed by incubation with tumor-specific 
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T cell clones in vitro, using T cell proliferation or IFNγ production as a readout.  This 
approach was employed in a recent study demonstrating the key role of skin-derived 
migratory CD103+ DCs in CD8+ T cell priming during herpes simplex virus infection 
(205).  Since p21SNFT-/- mice were also found to lack the closely related subset of tissue-
resident CD103+ cDCs in addition to lymphoid resident CD8α+ cDCs (151, 206), 
comparable ex vivo experiments in the tumor system with tumor antigen-specific T cell 
clones (or naïve CD8+ T cells from tumor antigen-specific transgenic mice) could clarify 
the respective functions of these DC subsets during cross-priming.  Similarly, a possible 
tumor antigen transport function of Langerhans cells migrating from the skin to the dLN 
could be investigated using one of several animal models of Langerhans cell deficiency 
(207).   
 As discussed in Chapter 3, adoptive transfer of total CD11c+ cells isolated from 
WT or IFNAR1-/- mice into tumor challenged IFNAR1-/- hosts yielded encouraging 
though inconsistent results.  Recapitulating the normal function of adoptively transferred 
DCs is a significant obstacle to such approaches, especially given the limited half-life and 
unknown migratory and stimulatory properties of transferred cells; yet, preliminary 
studies have shown that tumor-specific CTL priming and anti-tumor responses can be 
augmented by transfer of WT CD11c+ cells.  Thus, additional studies – perhaps involving 
transfer of FACS-purified CD8α+ cDC populations instead of total CD11c+ cells – are 
warranted.  As a complementary approach, we also generated mixed bone marrow 
chimeric mice with p21SNFT-/- HSCs as described in Chapter 3, and additional work 
using this strategy may be helpful.  Finally, conditional knockout strategies using 
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IFNAR1-flox mice, which were recently generated by Kalinke and colleagues (208), will 
be valuable for examining the effects of tissue-specific IFNAR1 ablation in conjunction 
with the appropriate cre-expressing strains (Table 1).  We are currently in the process of 
backcrossing IFNAR1-flox mice onto a pure C57Bl/6 genetic background in preparation 
for their use in both tumor transplantation and primary MCA induction studies.   
 In addition to further clarifying the in vivo functions of type I IFN during tumor 
rejection, the mechanism involved in IFNα/β’s enhancement of cross-presentation by 
CD8α+ cDCs is an area worthy of future investigation.  The effects of type I IFN on 
CD8α+ cDC function at various levels can be envisioned, including modulation of 
antigen capture or processing, peptide shuttling and MHC loading, MHC class I and/or 
costimulatory molecule expression, cellular migration or survival, or the induction of 
secondary cytokines/chemokines.  While current understanding of the cell biology of 
cross-presentation is limited, some data indicate that heightened or altered antigen 
processing, rather than better antigen capture, underlies the ability of the CD8α+ cDC to 
efficiently cross-present antigen (209).  In vitro studies, including analyses of antigen 
processing and presentation as well as unbiased approaches such as global gene 
expression profiling, can be used to compare the relevant phenotypes of WT and 
IFNAR1-/- CD8α+ DCs, or of WT CD8α+ DCs in the presence or absence of exogenous 
type I IFN. 
 Interestingly, a recent study suggested that steady-state production of low levels 
of IFNβ promotes antigen presentation by cDCs to both CD8+ and CD4+ T cells via 
upregulation of heat shock protein 70, which boosts formation of MHC-peptide 
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complexes (210).  Additional mechanisms must be involved, however, since baseline 
antigen presentation (in the presence of low-level IFNβ) induces cross-tolerance in the 
absence of DC activation triggered by inflammatory signals such as enhanced IFNα/β 
production (209).  In fact, the presence of other inflammatory stimuli which may 
collaborate with type I IFN to activate CD8α+ cDCs is suggested by detection of residual 
low-level priming in the absence of IFNα/β signaling, as well as the somewhat more 
robust tumor growth in p21SNFT-/- mice (lacking CD8α+ cDCs) compared to IFNAR1-/- 
mice (containing normal numbers of IFNα/β-unresponsive CD8α+ cDCs).  The 
involvement of other inflammatory stimuli and their interrelation with type I IFN 
therefore also remains to be investigated.   
 In our studies to evaluate the host cell targets of IFNα/β, we also demonstrated 
that type I IFN acts in a manner distinct from IFNγ, which also performs essential 
functions on the host during tumor rejection.  Whereas hematopoietic-derived innate 
immune cells were obligate targets of IFNα/β’s actions, IFNγ sensitivity within both 
hematopoietic and nonhematopoietic cells was critical.  Additional work will be 
necessary to further delineate the relevant host cell targets of IFNγ.  Interestingly though, 
our results suggested that several collaborating mechanisms may be involved – since 
mice with IFNγ sensitivity in either the hematopoietic or nonhematopoietic compartment 
alone appeared to have an intermediate phenotype compared to globally unresponsive 
mice.  Future studies utilizing mixed bone marrow chimeras could assess the relative 
contribution within the hematopoietic compartment of IFNγ’s actions on innate versus 
adaptive immune cells.  A more targeted look, however, will require the use of 
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conditional knockout mice to abrogate IFNγ responsiveness in specific cell types.  The 
generation of IFNGR1-flox mice will thus provide a critical reagent for examination of 
IFNGR1 ablation in defined cellular populations by intercrossing with tissue-specific cre 
mice (Table 1).  Finally, since all of the experiments performed up to this point have 
relied on tumor transplantation approaches, it will be important to test tissue-specific 
knockout mice in primary MCA tumor induction studies as well as tumor transplantation.   
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Table 1.  Cre-expressing mice useful for conditional ablation of IFN responsiveness.  
Intercrossing IFNAR1-flox and IFNGR1-flox mice with the indicated tissue-specific cre 
mice to generate hosts with cell type specific deletion of the respective IFN receptor will 
provide critical reagents for future studies.  Both tumor transplantation and primary MCA 
induction studies using such mice will further clarify the important host cell targets of 
IFNα/β and IFNγ in cancer immunoediting.   
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                                    Priorities for:     *IFNAR1-flox     *IFNGR1-flox 
 
 
Tissue-Specific Cre Mice Cellular Compartment(s) 
Vav-cre Hematopoietic cells, endothelial cells 
Lck-cre * * T, B lymphocytes 
CD4-cre T lymphocytes, CD4+ DCs 
CD8-cre * T lymphocytes, CD8+ DCs 
NKp46-cre NK cells 
CD11c-cre * DCs, NK cells 
LysM-cre * Macrophages, granulocytes 
Langerin-cre Langerhans cells 
VE-cadherin-creERT2 * Endothelial cells (inducible) 
Fibroblast-specific protein-1 (FSP1)-cre * Fibroblasts 
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Unique functions for IFNα/β  subtypes? 
 Our studies using IFNβ-/- mice have suggested that IFNβ is not essential during 
the rejection of transplantable 129 strain regressor tumors.  Since we have recently 
completed the backcrossing of this mouse to the C57Bl/6 strain, additional experiments 
using B6 RAG2-/- regressor tumors will be important to further test this conclusion.  
Moreover, use of both 129 and/or B6 strain IFNβ-/- mice in primary MCA tumorigenesis 
experiments would clarify the role of IFNβ during primary tumor formation.  These 
approaches could also be supplemented by the generation and use of blocking mAb’s 
specific for IFNβ, as this reagent would additionally allow for temporally-controlled 
blockade of IFNβ’s actions. 
 Examination of the role of IFNα subtypes is more challenging given the large 
number of IFNα’s and the difficulties in eliminating all subtypes or individual species.  
The number of IFNα genes would make genetic targeting of this locus difficult, while 
slight differences in structure could preclude the generation of an antibody reacting 
against all subtypes.  Given the presumed importance of IFNα4 as an initially induced 
species critical for augmenting production of the remaining IFNα subtypes, specific 
targeting of this molecule (either through IFNα4-specific mAb’s or gene-targeted mice) 
may be worthwhile.  Alternatively, generation of a panel of mAb’s each capable of 
neutralizing individual IFNα subtypes would allow for elimination of all IFNα’s using a 
mAb cocktail.  Such reagents will be critical for specific elimination of IFNα subtypes, 
but not IFNβ, in order to rigorously test whether the IFNα subtypes, or a subset thereof, 
are the critical mediators or merely functionally redundant with IFNβ.        
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What cells and molecular pathways mediate IFN production? 
 The observation that IFNα/β and IFNγ must act on distinct cellular targets during 
tumor rejection could reflect unique functions of these cytokines, or alternately could be a 
product of their differential sites of production.  At present, however, we have very 
limited information as to where, when, and by whom the interferons are being produced 
during naturally-occurring anti-tumor responses.  Although all cells are capable of 
making IFNα/β, the production of IFNγ has traditionally been ascribed to a 
comparatively smaller subset of cell types (which includes NK, NKT, αβ T cells, and γδ 
T cells).  Some, however, have suggested that IFNγ can also be produced by APCs (96-
98).  Prior studies in the literature support a role for γδ T cells as important early 
producers of IFNγ during responses to transplantable tumor challenge and during primary 
MCA-induced carcinogenesis (99).  Yet, other studies have indicated that innate immune 
rather than T cell IFNγ production is important for anti-tumor immunity (100).  While 
this question has not been addressed for IFNα/β production in a tumor system, a recent 
study using IFNα6-GFP knockin mice indicated that alveolar macrophages were the 
major type I IFN producers during viral infection of the lung (211).   
 As an initial approach to study this question, we could examine levels of 
expression of IFNα/β and IFNγ by qRT-PCR in total RNA isolated from the tumor, 
draining lymph node, and spleens of mice at different days following tumor challenge.  If 
this crude analysis is successful in localizing cytokine production, more specific 
approaches could then be used to specifically identify the relevant producing cells.  
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Sorting cells by FACS or MACS bead purification prior to RNA isolation would allow 
for examination of individual populations, and this strategy has been used previously to 
identify the primary producers of IFNβ in the context of DNase II-deficiency (212).  
Intracellular staining has also been reported for the detection of IFNα production (213).  
Additional approaches might involve the use of immunohistochemistry or in situ 
hybridization on tissue sections.  As previously alluded to, gene-targeted reporter mice 
have also been employed for the detection of IFN production, hence these approaches 
could also be used. 
 Initial information regarding levels of IFN induction and relevant cellular 
producers during anti-tumor immunity will facilitate downstream studies into the 
molecular pathways leading to its induction.  Since TCR stimulation or the actions of 
cytokines can lead to IFNγ production, the relevant stimuli mediating its induction are 
perhaps easier to surmise.  For type I IFN, however, the major stimuli characterized to 
date are of microbial origin.  It is therefore unclear what the physiologically important 
inducers in the setting of a growing tumor might be, although TLR-mediated recognition 
of endogenous danger signals such as heat shock proteins, HMGB-1, uric acid, and 
calreticulin have been suggested (214, 215).  A number of different molecular pathways 
leading to type I IFN production have been described, including those transduced through 
the TLRs, RIG I-like helicases (RLHs), NOD-like receptors (NLRs), and lectin receptors, 
as well as a recently described cytoplasmic DNA receptor .  Gene-targeted knockout mice 
or loss-of-function mutants are available for many of these receptors and/or their 
signaling components, in addition to some molecules (e.g. IRF-3, IRF-7, and IKKε) 
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common to multiple pathways.  Use of such mice may provide initial information about 
the relevant stimuli associated with immunogenic tumors.            
  
Therapeutic targets of exogenous type I IFN 
 Some of the same reagents and experimental approaches described earlier could 
also be used to identify the functionally relevant host cell targets of exogenous IFNα/β.  
Previous experiments with bone marrow chimeras and a model of IFNβ immunotherapy 
have suggested an important role for hematopoietic IFNα/β responsiveness during tumor 
elimination under conditions of low-level IFNβ production within the tumor.  Conditional 
IFNAR1 knockout mice would therefore be useful to investigate individual cell 
populations within the hematopoietic compartment. one could use this approach to 
investigate the role of IFNβ’s direct actions on T cells, B cells, DCs, macrophages, and 
NK cells.  Alternately, mixed bone marrow chimeras could be generated to examine the 
relative importance of innate versus adaptive IFNα/β sensitivity.   
 Additional studies might also be instructive in determining the mechanism of 
tumor control and elimination.  Whereas high-level IFNβ secretion led to tumor 
persistence and eventual toxicity due to chronic IFN exposure, low-level IFNβ mediated 
tumor elimination with no observable toxicity.  Our studies in RAG2-/- mice showed that 
this effect is lymphocyte dependent, but we have not yet specifically examined the 
generation of tumor-reactive T cells in WT mice.  It would be interesting to compare 
levels of T cell priming in mice challenged with tumor cells expressing high-dose versus 
low-dose IFNβ.  This could be done by rechallenging mice with parental tumor cells on 
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the opposite flank or by ex vivo T cell killing assay using parental tumor cells as targets.  
Whereas a lack of tumor-specific CTL priming with high-dose IFNβ may suggest defects 
in innate immune function or T cell clonal expansion, the detection of equal levels of 
tumor-reactive T cells would instead indicate a defect in T cell effector function, perhaps 
due to high local concentrations of IFNβ within the tumor environment potentially 
inducing apoptosis or rendering effector cells anergic.  These approaches could therefore 
provide further insight into the inhibition of adaptive immunity by high level IFNβ 
production within the tumor microenvironment.   
 An alternate hypothesis is that B cell function rather than T cell function is the 
critical mediator within the adaptive immune compartment contributing to tumor 
elimination.  Such a possibility perhaps though tumor-specific antibody eliciting ADCC 
by NK cells and macrophages.  This hypothesis is easily tested, however, by tumor 
transplantation into B cell-deficient mice.  In additional to these functional assays, further 
characterization of the immune infiltrate by histology or FACS analysis might be useful, 
in addition to an examination of angiogenesis by tissue staining with endothelial cell 
markers.   
 
 315 
 
 
 
 
REFERENCES 
 
 
 
 
 
 316 
1. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100:57-
70. 
2. Vogelstein, B., and K. W. Kinzler. 2004. Cancer genes and the pathways they 
control. Nat Med 10:789-799. 
3. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer 
immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-
998. 
4. Burnet, F. M. 1970. The concept of immunological surveillance. Prog Exp Tumor 
Res 13:1-27. 
5. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and 
R. D. Schreiber. 2001. IFNgamma and lymphocytes prevent primary tumour 
development and shape tumour immunogenicity. Nature 410:1107-1111. 
6. Ikeda, H., L. J. Old, and R. D. Schreiber. 2002. The roles of IFN gamma in 
protection against tumor development and cancer immunoediting. Cytokine 
Growth Factor Rev 13:95-109. 
7. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer 
immunoediting. Annu Rev Immunol 22:329-360. 
8. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer 
immunosurveillance and immunoediting. Immunity 21:137-148. 
9. Smyth, M. J., D. I. Godfrey, and J. A. Trapani. 2001. A fresh look at tumor 
immunosurveillance and immunotherapy. Nat Immunol 2:293-299. 
10. Smyth, M. J., G. P. Dunn, and R. D. Schreiber. 2006. Cancer immunosurveillance 
and immunoediting: the roles of immunity in suppressing tumor development and 
shaping tumor immunogenicity. Adv Immunol 90:1-50. 
11. Dunn, G. P., C. M. Koebel, and R. D. Schreiber. 2006. Interferons, immunity and 
cancer immunoediting. Nat Rev Immunol 6:836-848. 
12. Svane, I. M., A. M. Engel, M. B. Nielsen, H. G. Ljunggren, J. Rygaard, and O. 
Werdelin. 1996. Chemically induced sarcomas from nude mice are more 
immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol 
26:1844-1850. 
13. Engel, A. M., I. M. Svane, J. Rygaard, and O. Werdelin. 1997. MCA sarcomas 
induced in scid mice are more immunogenic than MCA sarcomas induced in 
congenic, immunocompetent mice. Scand J Immunol 45:463-470. 
 317 
14. Smyth, M. J., K. Y. Thia, S. E. Street, E. Cretney, J. A. Trapani, M. Taniguchi, T. 
Kawano, S. B. Pelikan, N. Y. Crowe, and D. I. Godfrey. 2000. Differential tumor 
surveillance by natural killer (NK) and NKT cells. J Exp Med 191:661-668. 
15. Street, S. E., J. A. Trapani, D. MacGregor, and M. J. Smyth. 2002. Suppression of 
lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 
196:129-134. 
16. Dunn, G. P., A. T. Bruce, K. C. Sheehan, V. Shankaran, R. Uppaluri, J. D. Bui, 
M. S. Diamond, C. M. Koebel, C. Arthur, J. M. White, and R. D. Schreiber. 2005. 
A critical function for type I interferons in cancer immunoediting. Nat Immunol 
6:722-729. 
17. Dighe, A. S., E. Richards, L. J. Old, and R. D. Schreiber. 1994. Enhanced in vivo 
growth and resistance to rejection of tumor cells expressing dominant negative 
IFN gamma receptors. Immunity 1:447-456. 
18. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet, L. J. Old, and 
R. D. Schreiber. 1998. Demonstration of an interferon gamma-dependent tumor 
surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 
95:7556-7561. 
19. Street, S. E., E. Cretney, and M. J. Smyth. 2001. Perforin and interferon-gamma 
activities independently control tumor initiation, growth, and metastasis. Blood 
97:192-197. 
20. Seliger, B. 2008. Molecular mechanisms of MHC class I abnormalities and APM 
components in human tumors. Cancer Immunol Immunother 57:1719-1726. 
21. Dunn, G. P., K. C. Sheehan, L. J. Old, and R. D. Schreiber. 2005. IFN 
unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. 
Cancer Res 65:3447-3453. 
22. Mumberg, D., P. A. Monach, S. Wanderling, M. Philip, A. Y. Toledano, R. D. 
Schreiber, and H. Schreiber. 1999. CD4(+) T cells eliminate MHC class II-
negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad 
Sci U S A 96:8633-8638. 
23. Qin, Z., and T. Blankenstein. 2000. CD4+ T cell--mediated tumor rejection 
involves inhibition of angiogenesis that is dependent on IFN gamma receptor 
expression by nonhematopoietic cells. Immunity 12:677-686. 
24. Qin, Z., J. Schwartzkopff, F. Pradera, T. Kammertoens, B. Seliger, H. Pircher, 
and T. Blankenstein. 2003. A critical requirement of interferon gamma-mediated 
angiostasis for tumor rejection by CD8+ T cells. Cancer Res 63:4095-4100. 
 318 
25. Fallarino, F., and T. F. Gajewski. 1999. Cutting edge: differentiation of antitumor 
CTL in vivo requires host expression of Stat1. J Immunol 163:4109-4113. 
26. Nishikawa, H., T. Kato, I. Tawara, H. Ikeda, K. Kuribayashi, P. M. Allen, R. D. 
Schreiber, L. J. Old, and H. Shiku. 2005. IFN-gamma controls the 
generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune 
response. J Immunol 175:4433-4440. 
27. Gutterman, J. U. 1994. Cytokine therapeutics: lessons from interferon alpha. Proc 
Natl Acad Sci U S A 91:1198-1205. 
28. Gresser, I., C. Bourali, J. P. Levy, D. Fontaine-Brouty-Boye, and M. T. Thomas. 
1969. Increased survival in mice inoculated with tumor cells and treated with 
interferon preparations. Proc Natl Acad Sci U S A 63:51-57. 
29. Gresser, I., and C. Bourali. 1969. Exogenous interferon and inducers of interferon 
in the treatment Balb-c mice inoculated with RC19 tumour cells. Nature 223:844-
845. 
30. Gresser, I., C. Maury, and D. Brouty-Boye. 1972. Mechanism of the antitumour 
effect of interferon in mice. Nature 239:167-168. 
31. Gresser, I., D. Brouty-Boye, M. T. Thomas, and A. Macieira-Coelho. 1970. 
Interferon and cell division. II. Influence of various experimental conditions on 
the inhibition of L1210 cell multiplication in vitro by interferon preparations. J 
Natl Cancer Inst 45:1145-1153. 
32. Belardelli, F., I. Gresser, C. Maury, and M. T. Maunoury. 1982. Antitumor effects 
of interferon in mice injected with interferon-sensitive and interferon-resistant 
Friend leukemia cells. I. Int J Cancer 30:813-820. 
33. Belardelli, F., I. Gresser, C. Maury, and M. T. Maunoury. 1982. Antitumor effects 
of interferon in mice injected with interferon-sensitive and interferon-resistant 
Friend leukemia cells. II. Role of host mechanisms. Int J Cancer 30:821-825. 
34. Gresser, I., C. Maury, C. Carnaud, E. De Maeyer, M. T. Maunoury, and F. 
Belardelli. 1990. Anti-tumor effects of interferon in mice injected with interferon-
sensitive and interferon-resistant Friend erythroleukemia cells. VIII. Role of the 
immune system in the inhibition of visceral metastases. Int J Cancer 46:468-474. 
35. Lesinski, G. B., M. Anghelina, J. Zimmerer, T. Bakalakos, B. Badgwell, R. 
Parihar, Y. Hu, B. Becknell, G. Abood, A. R. Chaudhury, C. Magro, J. Durbin, 
and W. E. Carson, 3rd. 2003. The antitumor effects of IFN-alpha are abrogated in 
a STAT1-deficient mouse. J Clin Invest 112:170-180. 
 319 
36. Belardelli, F., and I. Gresser. 1996. The neglected role of type I interferon in the 
T-cell response: implications for its clinical use. Immunol Today 17:369-372. 
37. Belardelli, F., M. Ferrantini, E. Proietti, and J. M. Kirkwood. 2002. Interferon-
alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 
13:119-134. 
38. Quesada, J. R., J. Reuben, J. T. Manning, E. M. Hersh, and J. U. Gutterman. 
1984. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J 
Med 310:15-18. 
39. Pfeffer, L. M., C. A. Dinarello, R. B. Herberman, B. R. Williams, E. C. Borden, 
R. Bordens, M. R. Walter, T. L. Nagabhushan, P. P. Trotta, and S. Pestka. 1998. 
Biological properties of recombinant alpha-interferons: 40th anniversary of the 
discovery of interferons. Cancer Res 58:2489-2499. 
40. Reid, L. M., N. Minato, I. Gresser, J. Holland, A. Kadish, and B. R. Bloom. 1981. 
Influence of anti-mouse interferon serum on the growth and metastasis of tumor 
cells persistently infected with virus and of human prostatic tumors in athymic 
nude mice. Proc Natl Acad Sci U S A 78:1171-1175. 
41. Gresser, I., F. Belardelli, C. Maury, M. T. Maunoury, and M. G. Tovey. 1983. 
Injection of mice with antibody to interferon enhances the growth of 
transplantable murine tumors. J Exp Med 158:2095-2107. 
42. Picaud, S., B. Bardot, E. De Maeyer, and I. Seif. 2002. Enhanced tumor 
development in mice lacking a functional type I interferon receptor. J Interferon 
Cytokine Res 22:457-462. 
43. Swann, J. B., Y. Hayakawa, N. Zerafa, K. C. Sheehan, B. Scott, R. D. Schreiber, 
P. Hertzog, and M. J. Smyth. 2007. Type I IFN contributes to NK cell 
homeostasis, activation, and antitumor function. J Immunol 178:7540-7549. 
44. Isaacs, A., and J. Lindenmann. 1957. Virus interference. I. The interferon. Proc R 
Soc Lond B Biol Sci 147:258-267. 
45. Wheelock, E. F. 1965. Interferon-like virus-inhibitor induced in human 
leukocytes by phytohemagglutinin. Science 149:310-311. 
46. Farrar, M. A., and R. D. Schreiber. 1993. The molecular cell biology of 
interferon-gamma and its receptor. Annu Rev Immunol 11:571-611. 
47. Le Bon, A., and D. F. Tough. 2002. Links between innate and adaptive immunity 
via type I interferon. Curr Opin Immunol 14:432-436. 
 320 
48. Kotenko, S. V., G. Gallagher, V. V. Baurin, A. Lewis-Antes, M. Shen, N. K. 
Shah, J. A. Langer, F. Sheikh, H. Dickensheets, and R. P. Donnelly. 2003. IFN-
lambdas mediate antiviral protection through a distinct class II cytokine receptor 
complex. Nat Immunol 4:69-77. 
49. Sheppard, P., W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer, T. E. 
Whitmore, R. Kuestner, U. Garrigues, C. Birks, J. Roraback, C. Ostrander, D. 
Dong, J. Shin, S. Presnell, B. Fox, B. Haldeman, E. Cooper, D. Taft, T. Gilbert, F. 
J. Grant, M. Tackett, W. Krivan, G. McKnight, C. Clegg, D. Foster, and K. M. 
Klucher. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat 
Immunol 4:63-68. 
50. Uze, G., and D. Monneron. 2007. IL-28 and IL-29: newcomers to the interferon 
family. Biochimie 89:729-734. 
51. Ank, N., H. West, and S. R. Paludan. 2006. IFN-lambda: novel antiviral 
cytokines. J Interferon Cytokine Res 26:373-379. 
52. Pestka, S., C. D. Krause, and M. R. Walter. 2004. Interferons, interferon-like 
cytokines, and their receptors. Immunol Rev 202:8-32. 
53. Theofilopoulos, A. N., R. Baccala, B. Beutler, and D. H. Kono. 2005. Type I 
interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 
23:307-336. 
54. Hardy, M. P., C. M. Owczarek, L. S. Jermiin, M. Ejdeback, and P. J. Hertzog. 
2004. Characterization of the type I interferon locus and identification of novel 
genes. Genomics 84:331-345. 
55. van Pesch, V., H. Lanaya, J. C. Renauld, and T. Michiels. 2004. Characterization 
of the murine alpha interferon gene family. J Virol 78:8219-8228. 
56. Oritani, K., and Y. Tomiyama. 2004. Interferon-zeta/limitin: novel type I 
interferon that displays a narrow range of biological activity. Int J Hematol 
80:325-331. 
57. Foster, G. R., and N. B. Finter. 1998. Are all type I human interferons equivalent? 
J Viral Hepat 5:143-152. 
58. Ortaldo, J. R., R. B. Herberman, C. Harvey, P. Osheroff, Y. C. Pan, B. Kelder, 
and S. Pestka. 1984. A species of human alpha interferon that lacks the ability to 
boost human natural killer activity. Proc Natl Acad Sci U S A 81:4926-4929. 
59. Rani, M. R., G. R. Foster, S. Leung, D. Leaman, G. R. Stark, and R. M. 
Ransohoff. 1996. Characterization of beta-R1, a gene that is selectively induced 
 321 
by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem 271:22878-
22884. 
60. Der, S. D., A. Zhou, B. R. Williams, and R. H. Silverman. 1998. Identification of 
genes differentially regulated by interferon alpha, beta, or gamma using 
oligonucleotide arrays. Proc Natl Acad Sci U S A 95:15623-15628. 
61. Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, and R. D. Schreiber. 
1998. How cells respond to interferons. Annu Rev Biochem 67:227-264. 
62. Muller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, 
and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral 
defense. Science 264:1918-1921. 
63. Bogdan, C. 2000. The function of type I interferons in antimicrobial immunity. 
Curr Opin Immunol 12:419-424. 
64. Sheehan, K. C., K. S. Lai, G. P. Dunn, A. T. Bruce, M. S. Diamond, J. D. Heutel, 
C. Dungo-Arthur, J. A. Carrero, J. M. White, P. J. Hertzog, and R. D. Schreiber. 
2006. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor 
subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic 
transfection. J Interferon Cytokine Res 26:804-819. 
65. Jouanguy, E., S. Y. Zhang, A. Chapgier, V. Sancho-Shimizu, A. Puel, C. Picard, 
S. Boisson-Dupuis, L. Abel, and J. L. Casanova. 2007. Human primary 
immunodeficiencies of type I interferons. Biochimie 89:878-883. 
66. Stetson, D. B., and R. Medzhitov. 2006. Type I interferons in host defense. 
Immunity 25:373-381. 
67. Bogdan, C., J. Mattner, and U. Schleicher. 2004. The role of type I interferons in 
non-viral infections. Immunol Rev 202:33-48. 
68. Carrero, J. A., B. Calderon, and E. R. Unanue. 2004. Type I interferon sensitizes 
lymphocytes to apoptosis and reduces resistance to Listeria infection. J Exp Med 
200:535-540. 
69. Auerbuch, V., D. G. Brockstedt, N. Meyer-Morse, M. O'Riordan, and D. A. 
Portnoy. 2004. Mice lacking the type I interferon receptor are resistant to Listeria 
monocytogenes. J Exp Med 200:527-533. 
70. O'Connell, R. M., S. K. Saha, S. A. Vaidya, K. W. Bruhn, G. A. Miranda, B. 
Zarnegar, A. K. Perry, B. O. Nguyen, T. F. Lane, T. Taniguchi, J. F. Miller, and 
G. Cheng. 2004. Type I interferon production enhances susceptibility to Listeria 
monocytogenes infection. J Exp Med 200:437-445. 
 322 
71. Carrero, J. A., B. Calderon, and E. R. Unanue. 2006. Lymphocytes are 
detrimental during the early innate immune response against Listeria 
monocytogenes. J Exp Med 203:933-940. 
72. Schoenborn, J. R., and C. B. Wilson. 2007. Regulation of interferon-gamma 
during innate and adaptive immune responses. Adv Immunol 96:41-101. 
73. Schroder, K., P. J. Hertzog, T. Ravasi, and D. A. Hume. 2004. Interferon-gamma: 
an overview of signals, mechanisms and functions. J Leukoc Biol 75:163-189. 
74. Sen, G. C. 2001. Viruses and interferons. Annu Rev Microbiol 55:255-281. 
75. Katze, M. G., Y. He, and M. Gale, Jr. 2002. Viruses and interferon: a fight for 
supremacy. Nat Rev Immunol 2:675-687. 
76. Platanias, L. C. 2005. Mechanisms of type-I- and type-II-interferon-mediated 
signalling. Nat Rev Immunol 5:375-386. 
77. Bach, E. A., M. Aguet, and R. D. Schreiber. 1997. The IFN gamma receptor: a 
paradigm for cytokine receptor signaling. Annu Rev Immunol 15:563-591. 
78. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to 
interferon-gamma. Annu Rev Immunol 15:749-795. 
79. Gil, M. P., E. Bohn, A. K. O'Guin, C. V. Ramana, B. Levine, G. R. Stark, H. W. 
Virgin, and R. D. Schreiber. 2001. Biologic consequences of Stat1-independent 
IFN signaling. Proc Natl Acad Sci U S A 98:6680-6685. 
80. Ramana, C. V., M. P. Gil, Y. Han, R. M. Ransohoff, R. D. Schreiber, and G. R. 
Stark. 2001. Stat1-independent regulation of gene expression in response to IFN-
gamma. Proc Natl Acad Sci U S A 98:6674-6679. 
81. Perry, A. K., G. Chen, D. Zheng, H. Tang, and G. Cheng. 2005. The host type I 
interferon response to viral and bacterial infections. Cell Res 15:407-422. 
82. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat Rev Immunol 
4:499-511. 
83. Fitzgerald, K. A., S. M. McWhirter, K. L. Faia, D. C. Rowe, E. Latz, D. T. 
Golenbock, A. J. Coyle, S. M. Liao, and T. Maniatis. 2003. IKKepsilon and 
TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 
4:491-496. 
84. Stetson, D. B., and R. Medzhitov. 2006. Recognition of cytosolic DNA activates 
an IRF3-dependent innate immune response. Immunity 24:93-103. 
 323 
85. Taniguchi, T., and A. Takaoka. 2002. The interferon-alpha/beta system in 
antiviral responses: a multimodal machinery of gene regulation by the IRF family 
of transcription factors. Curr Opin Immunol 14:111-116. 
86. Marie, I., J. E. Durbin, and D. E. Levy. 1998. Differential viral induction of 
distinct interferon-alpha genes by positive feedback through interferon regulatory 
factor-7. Embo J 17:6660-6669. 
87. Sato, M., H. Suemori, N. Hata, M. Asagiri, K. Ogasawara, K. Nakao, T. Nakaya, 
M. Katsuki, S. Noguchi, N. Tanaka, and T. Taniguchi. 2000. Distinct and 
essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for 
IFN-alpha/beta gene induction. Immunity 13:539-548. 
88. Sharma, S., B. R. tenOever, N. Grandvaux, G. P. Zhou, R. Lin, and J. Hiscott. 
2003. Triggering the interferon antiviral response through an IKK-related 
pathway. Science 300:1148-1151. 
89. Siegal, F. P., N. Kadowaki, M. Shodell, P. A. Fitzgerald-Bocarsly, K. Shah, S. 
Ho, S. Antonenko, and Y. J. Liu. 1999. The nature of the principal type 1 
interferon-producing cells in human blood. Science 284:1835-1837. 
90. Cella, M., D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajima, A. Lanzavecchia, 
and M. Colonna. 1999. Plasmacytoid monocytes migrate to inflamed lymph nodes 
and produce large amounts of type I interferon. Nat Med 5:919-923. 
91. Colonna, M., G. Trinchieri, and Y. J. Liu. 2004. Plasmacytoid dendritic cells in 
immunity. Nat Immunol 5:1219-1226. 
92. Kawai, T., S. Sato, K. J. Ishii, C. Coban, H. Hemmi, M. Yamamoto, K. Terai, M. 
Matsuda, J. Inoue, S. Uematsu, O. Takeuchi, and S. Akira. 2004. Interferon-alpha 
induction through Toll-like receptors involves a direct interaction of IRF7 with 
MyD88 and TRAF6. Nat Immunol 5:1061-1068. 
93. Honda, K., Y. Ohba, H. Yanai, H. Negishi, T. Mizutani, A. Takaoka, C. Taya, and 
T. Taniguchi. 2005. Spatiotemporal regulation of MyD88-IRF-7 signalling for 
robust type-I interferon induction. Nature 434:1035-1040. 
94. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, 
Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7 is the master 
regulator of type-I interferon-dependent immune responses. Nature 434:772-777. 
95. Hemmi, H., T. Kaisho, K. Takeda, and S. Akira. 2003. The roles of Toll-like 
receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the 
effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 170:3059-
3064. 
 324 
96. Munder, M., M. Mallo, K. Eichmann, and M. Modolell. 1998. Murine 
macrophages secrete interferon gamma upon combined stimulation with 
interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage 
activation. J Exp Med 187:2103-2108. 
97. Harris, D. P., L. Haynes, P. C. Sayles, D. K. Duso, S. M. Eaton, N. M. Lepak, L. 
L. Johnson, S. L. Swain, and F. E. Lund. 2000. Reciprocal regulation of polarized 
cytokine production by effector B and T cells. Nat Immunol 1:475-482. 
98. Frucht, D. M., T. Fukao, C. Bogdan, H. Schindler, J. J. O'Shea, and S. Koyasu. 
2001. IFN-gamma production by antigen-presenting cells: mechanisms emerge. 
Trends Immunol 22:556-560. 
99. Gao, Y., W. Yang, M. Pan, E. Scully, M. Girardi, L. H. Augenlicht, J. Craft, and 
Z. Yin. 2003. Gamma delta T cells provide an early source of interferon gamma 
in tumor immunity. J Exp Med 198:433-442. 
100. Li, Z., F. Pradera, T. Kammertoens, B. Li, S. Liu, and Z. Qin. 2007. Cross-talk 
between T cells and innate immune cells is crucial for IFN-gamma-dependent 
tumor rejection. J Immunol 179:1568-1576. 
101. Taieb, J., N. Chaput, C. Menard, L. Apetoh, E. Ullrich, M. Bonmort, M. 
Pequignot, N. Casares, M. Terme, C. Flament, P. Opolon, Y. Lecluse, D. 
Metivier, E. Tomasello, E. Vivier, F. Ghiringhelli, F. Martin, D. Klatzmann, T. 
Poynard, T. Tursz, G. Raposo, H. Yagita, B. Ryffel, G. Kroemer, and L. Zitvogel. 
2006. A novel dendritic cell subset involved in tumor immunosurveillance. Nat 
Med 12:214-219. 
102. Oritani, K., P. W. Kincade, C. Zhang, Y. Tomiyama, and Y. Matsuzawa. 2001. 
Type I interferons and limitin: a comparison of structures, receptors, and 
functions. Cytokine Growth Factor Rev 12:337-348. 
103. Clemens, M. J. 2003. Interferons and apoptosis. J Interferon Cytokine Res 23:277-
292. 
104. Thyrell, L., S. Erickson, B. Zhivotovsky, K. Pokrovskaja, O. Sangfelt, J. Castro, 
S. Einhorn, and D. Grander. 2002. Mechanisms of Interferon-alpha induced 
apoptosis in malignant cells. Oncogene 21:1251-1262. 
105. Balachandran, S., P. C. Roberts, T. Kipperman, K. N. Bhalla, R. W. Compans, D. 
R. Archer, and G. N. Barber. 2000. Alpha/beta interferons potentiate virus-
induced apoptosis through activation of the FADD/Caspase-8 death signaling 
pathway. J Virol 74:1513-1523. 
 325 
106. Takaoka, A., S. Hayakawa, H. Yanai, D. Stoiber, H. Negishi, H. Kikuchi, S. 
Sasaki, K. Imai, T. Shibue, K. Honda, and T. Taniguchi. 2003. Integration of 
interferon-alpha/beta signalling to p53 responses in tumour suppression and 
antiviral defence. Nature 424:516-523. 
107. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 
88:323-331. 
108. Kerbel, R., and J. Folkman. 2002. Clinical translation of angiogenesis inhibitors. 
Nat Rev Cancer 2:727-739. 
109. Strieter, R. M., J. A. Belperio, R. J. Phillips, and M. P. Keane. 2004. CXC 
chemokines in angiogenesis of cancer. Semin Cancer Biol 14:195-200. 
110. Welsh, R. M., Jr. 1978. Cytotoxic cells induced during lymphocytic 
choriomeningitis virus infection of mice. I. Characterization of natural killer cell 
induction. J Exp Med 148:163-181. 
111. Orange, J. S., and C. A. Biron. 1996. Characterization of early IL-12, IFN-
alphabeta, and TNF effects on antiviral state and NK cell responses during murine 
cytomegalovirus infection. J Immunol 156:4746-4756. 
112. Biron, C. A., K. B. Nguyen, and G. C. Pien. 2002. Innate immune responses to 
LCMV infections: natural killer cells and cytokines. Curr Top Microbiol Immunol 
263:7-27. 
113. Sato, K., S. Hida, H. Takayanagi, T. Yokochi, N. Kayagaki, K. Takeda, H. 
Yagita, K. Okumura, N. Tanaka, T. Taniguchi, and K. Ogasawara. 2001. Antiviral 
response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. 
Eur J Immunol 31:3138-3146. 
114. Nguyen, K. B., T. P. Salazar-Mather, M. Y. Dalod, J. B. Van Deusen, X. Q. Wei, 
F. Y. Liew, M. A. Caligiuri, J. E. Durbin, and C. A. Biron. 2002. Coordinated and 
distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses 
to viral infection. J Immunol 169:4279-4287. 
115. Yokoyama, W. M., S. Kim, and A. R. French. 2004. The dynamic life of natural 
killer cells. Annu Rev Immunol 22:405-429. 
116. Smyth, M. J., Y. Hayakawa, K. Takeda, and H. Yagita. 2002. New aspects of 
natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850-861. 
117. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of 
immunity. Nature 392:245-252. 
 326 
118. Luft, T., K. C. Pang, E. Thomas, P. Hertzog, D. N. Hart, J. Trapani, and J. Cebon. 
1998. Type I IFNs enhance the terminal differentiation of dendritic cells. J 
Immunol 161:1947-1953. 
119. Gallucci S, L. M., Matzinger P. 1999. Natural adjuvants: endogenous activators of 
dendritic cells. Nature Medicine 5:1249-1255. 
120. Montoya, M., G. Schiavoni, F. Mattei, I. Gresser, F. Belardelli, P. Borrow, and D. 
F. Tough. 2002. Type I interferons produced by dendritic cells promote their 
phenotypic and functional activation. Blood 99:3263-3271. 
121. Le Bon, A., G. Schiavoni, G. D'Agostino, I. Gresser, F. Belardelli, and D. F. 
Tough. 2001. Type i interferons potently enhance humoral immunity and can 
promote isotype switching by stimulating dendritic cells in vivo. Immunity 
14:461-470. 
122. Le Bon, A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. Borrow, 
and D. F. Tough. 2003. Cross-priming of CD8+ T cells stimulated by virus-
induced type I interferon. Nat Immunol 4:1009-1015. 
123. Tough, D. F. 2004. Type I interferon as a link between innate and adaptive 
immunity through dendritic cell stimulation. Leuk Lymphoma 45:257-264. 
124. Sprent, J., D. F. Tough, and S. Sun. 1997. Factors controlling the turnover of T 
memory cells. Immunol Rev 156:79-85. 
125. Tough, D. F., P. Borrow, and J. Sprent. 1996. Induction of bystander T cell 
proliferation by viruses and type I interferon in vivo. Science 272:1947-1950. 
126. Zhang, X., S. Sun, I. Hwang, D. F. Tough, and J. Sprent. 1998. Potent and 
selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. 
Immunity 8:591-599. 
127. Marrack, P., J. Kappler, and T. Mitchell. 1999. Type I interferons keep activated 
T cells alive. J Exp Med 189:521-530. 
128. Dondi, E., G. Roue, V. J. Yuste, S. A. Susin, and S. Pellegrini. 2004. A dual role 
of IFN-alpha in the balance between proliferation and death of human CD4+ T 
lymphocytes during primary response. J Immunol 173:3740-3747. 
129. Curtsinger, J. M., C. S. Schmidt, A. Mondino, D. C. Lins, R. M. Kedl, M. K. 
Jenkins, and M. F. Mescher. 1999. Inflammatory cytokines provide a third signal 
for activation of naive CD4+ and CD8+ T cells. J Immunol 162:3256-3262. 
 327 
130. Curtsinger, J. M., D. C. Lins, and M. F. Mescher. 2003. Signal 3 determines 
tolerance versus full activation of naive CD8 T cells: dissociating proliferation 
and development of effector function. J Exp Med 197:1141-1151. 
131. Curtsinger, J. M., J. O. Valenzuela, P. Agarwal, D. Lins, and M. F. Mescher. 
2005. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal 
expansion and differentiation. J Immunol 174:4465-4469. 
132. Ogasawara, K., S. Hida, Y. Weng, A. Saiura, K. Sato, H. Takayanagi, S. 
Sakaguchi, T. Yokochi, T. Kodama, M. Naitoh, J. A. De Martino, and T. 
Taniguchi. 2002. Requirement of the IFN-alpha/beta-induced CXCR3 chemokine 
signalling for CD8+ T cell activation. Genes Cells 7:309-320. 
133. Cousens, L. P., R. Peterson, S. Hsu, A. Dorner, J. D. Altman, R. Ahmed, and C. 
A. Biron. 1999. Two roads diverged: interferon alpha/beta- and interleukin 12-
mediated pathways in promoting T cell interferon gamma responses during viral 
infection. J Exp Med 189:1315-1328. 
134. Nguyen, K. B., W. T. Watford, R. Salomon, S. R. Hofmann, G. C. Pien, A. 
Morinobu, M. Gadina, J. J. O'Shea, and C. A. Biron. 2002. Critical role for 
STAT4 activation by type 1 interferons in the interferon-gamma response to viral 
infection. Science 297:2063-2066. 
135. Rogge, L., D. D'Ambrosio, M. Biffi, G. Penna, L. J. Minetti, D. H. Presky, L. 
Adorini, and F. Sinigaglia. 1998. The role of Stat4 in species-specific regulation 
of Th cell development by type I IFNs. J Immunol 161:6567-6574. 
136. Berenson, L. S., N. Ota, and K. M. Murphy. 2004. Issues in T-helper 1 
development--resolved and unresolved. Immunol Rev 202:157-174. 
137. Jego, G., A. K. Palucka, J. P. Blanck, C. Chalouni, V. Pascual, and J. Banchereau. 
2003. Plasmacytoid dendritic cells induce plasma cell differentiation through type 
I interferon and interleukin 6. Immunity 19:225-234. 
138. Leon, M. L., and S. H. Zuckerman. 2005. Gamma interferon: a central mediator in 
atherosclerosis. Inflamm Res 54:395-411. 
139. Takaoka, A., Y. Mitani, H. Suemori, M. Sato, T. Yokochi, S. Noguchi, N. 
Tanaka, and T. Taniguchi. 2000. Cross talk between interferon-gamma and -
alpha/beta signaling components in caveolar membrane domains. Science 
288:2357-2360. 
140. Koebel, C. M., W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig, L. J. Old, M. J. 
Smyth, and R. D. Schreiber. 2007. Adaptive immunity maintains occult cancer in 
an equilibrium state. Nature 450:903-907. 
 328 
141. Sheehan, K. C., J. Calderon, and R. D. Schreiber. 1988. Generation and 
characterization of monoclonal antibodies specific for the human IFN-gamma 
receptor. J Immunol 140:4231-4237. 
142. Schreiber, R. D., L. J. Hicks, A. Celada, N. A. Buchmeier, and P. W. Gray. 1985. 
Monoclonal antibodies to murine gamma-interferon which differentially modulate 
macrophage activation and antiviral activity. J Immunol 134:1609-1618. 
143. Bach, E. A., S. J. Szabo, A. S. Dighe, A. Ashkenazi, M. Aguet, K. M. Murphy, 
and R. D. Schreiber. 1995. Ligand-induced autoregulation of IFN-gamma 
receptor beta chain expression in T helper cell subsets. Science 270:1215-1218. 
144. Dialynas, D. P., Z. S. Quan, K. A. Wall, A. Pierres, J. Quintans, M. R. Loken, M. 
Pierres, and F. W. Fitch. 1983. Characterization of the murine T cell surface 
molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity 
of L3T4 to the human Leu-3/T4 molecule. J Immunol 131:2445-2451. 
145. Cobbold, S. P., A. Jayasuriya, A. Nash, T. D. Prospero, and H. Waldmann. 1984. 
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. 
Nature 312:548-551. 
146. Shuai, K., G. R. Stark, I. M. Kerr, and J. E. Darnell, Jr. 1993. A single 
phosphotyrosine residue of Stat91 required for gene activation by interferon-
gamma. Science 261:1744-1746. 
147. Meraz, M. A., J. M. White, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, 
D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, K. Carver-Moore, R. N. 
DuBois, R. Clark, M. Aguet, and R. D. Schreiber. 1996. Targeted disruption of 
the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-
STAT signaling pathway. Cell 84:431-442. 
148. Nakajima, K., Y. Yamanaka, K. Nakae, H. Kojima, M. Ichiba, N. Kiuchi, T. 
Kitaoka, T. Fukada, M. Hibi, and T. Hirano. 1996. A central role for Stat3 in IL-
6-induced regulation of growth and differentiation in M1 leukemia cells. Embo J 
15:3651-3658. 
149. Walter, M. J., D. C. Look, R. M. Tidwell, W. T. Roswit, and M. J. Holtzman. 
1997. Targeted inhibition of interferon-gamma-dependent intercellular adhesion 
molecule-1 (ICAM-1) expression using dominant-negative Stat1. J Biol Chem 
272:28582-28589. 
150. Mao, X., Z. Ren, G. N. Parker, H. Sondermann, M. A. Pastorello, W. Wang, J. S. 
McMurray, B. Demeler, J. E. Darnell, Jr., and X. Chen. 2005. Structural bases of 
unphosphorylated STAT1 association and receptor binding. Mol Cell 17:761-771. 
 329 
151. Hildner, K., B. T. Edelson, W. E. Purtha, M. Diamond, H. Matsushita, M. 
Kohyama, B. Calderon, B. U. Schraml, E. R. Unanue, M. S. Diamond, R. D. 
Schreiber, T. L. Murphy, and K. M. Murphy. 2008. Batf3 deficiency reveals a 
critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 
322:1097-1100. 
152. Curtsinger, J. M., M. Y. Gerner, D. C. Lins, and M. F. Mescher. 2007. Signal 3 
availability limits the CD8 T cell response to a solid tumor. J Immunol 178:6752-
6760. 
153. Zhang, B., Y. Zhang, N. A. Bowerman, A. Schietinger, Y. X. Fu, D. M. Kranz, D. 
A. Rowley, and H. Schreiber. 2008. Equilibrium between host and cancer caused 
by effector T cells killing tumor stroma. Cancer Res 68:1563-1571. 
154. Zhang, B., N. A. Bowerman, J. K. Salama, H. Schmidt, M. T. Spiotto, A. 
Schietinger, P. Yu, Y. X. Fu, R. R. Weichselbaum, D. A. Rowley, D. M. Kranz, 
and H. Schreiber. 2007. Induced sensitization of tumor stroma leads to eradication 
of established cancer by T cells. J Exp Med 204:49-55. 
155. Yu, P., D. A. Rowley, Y. X. Fu, and H. Schreiber. 2006. The role of stroma in 
immune recognition and destruction of well-established solid tumors. Curr Opin 
Immunol 18:226-231. 
156. Gogas, H., J. Ioannovich, U. Dafni, C. Stavropoulou-Giokas, K. Frangia, D. 
Tsoutsos, P. Panagiotou, A. Polyzos, O. Papadopoulos, A. Stratigos, C. 
Markopoulos, D. Bafaloukos, D. Pectasides, G. Fountzilas, and J. M. Kirkwood. 
2006. Prognostic significance of autoimmunity during treatment of melanoma 
with interferon. N Engl J Med 354:709-718. 
157. Kolumam, G. A., S. Thomas, L. J. Thompson, J. Sprent, and K. Murali-Krishna. 
2005. Type I interferons act directly on CD8 T cells to allow clonal expansion and 
memory formation in response to viral infection. J Exp Med 202:637-650. 
158. Havenar-Daughton, C., G. A. Kolumam, and K. Murali-Krishna. 2006. Cutting 
Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining 
clonal expansion in response to a viral but not a bacterial infection. J Immunol 
176:3315-3319. 
159. Le Bon, A., V. Durand, E. Kamphuis, C. Thompson, S. Bulfone-Paus, C. 
Rossmann, U. Kalinke, and D. F. Tough. 2006. Direct stimulation of T cells by 
type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 
176:4682-4689. 
 330 
160. Le Bon, A., C. Thompson, E. Kamphuis, V. Durand, C. Rossmann, U. Kalinke, 
and D. F. Tough. 2006. Cutting edge: enhancement of antibody responses through 
direct stimulation of B and T cells by type I IFN. J Immunol 176:2074-2078. 
161. Coro, E. S., W. L. Chang, and N. Baumgarth. 2006. Type I IFN receptor signals 
directly stimulate local B cells early following influenza virus infection. J 
Immunol 176:4343-4351. 
162. Mombaerts, P., J. Iacomini, R. S. Johnson, K. Herrup, S. Tonegawa, and V. E. 
Papaioannou. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. 
Cell 68:869-877. 
163. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. 
R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. 
Cell 76:17-27. 
164. Lybarger, L., X. Wang, M. R. Harris, H. W. t. Virgin, and T. H. Hansen. 2003. 
Virus subversion of the MHC class I peptide-loading complex. Immunity 18:121-
130. 
165. Townsend, A., C. Ohlen, J. Bastin, H. G. Ljunggren, L. Foster, and K. Karre. 
1989. Association of class I major histocompatibility heavy and light chains 
induced by viral peptides. Nature 340:443-448. 
166. Rebel, V. I., C. L. Miller, C. J. Eaves, and P. M. Lansdorp. 1996. The 
repopulation potential of fetal liver hematopoietic stem cells in mice exceeds that 
of their liver adult bone marrow counterparts. Blood 87:3500-3507. 
167. Szilvassy, S. J., T. E. Meyerrose, P. L. Ragland, and B. Grimes. 2001. Differential 
homing and engraftment properties of hematopoietic progenitor cells from murine 
bone marrow, mobilized peripheral blood, and fetal liver. Blood 98:2108-2115. 
168. Uehara, S., A. Grinberg, J. M. Farber, and P. E. Love. 2002. A role for CCR9 in T 
lymphocyte development and migration. J Immunol 168:2811-2819. 
169. Baekkevold, E. S., M. A. Wurbel, P. Kivisakk, C. M. Wain, C. A. Power, G. 
Haraldsen, and J. J. Campbell. 2005. A role for CCR4 in development of mature 
circulating cutaneous T helper memory cell populations. J Exp Med 201:1045-
1051. 
170. Wu, J., and L. L. Lanier. 2003. Natural killer cells and cancer. Adv Cancer Res 
90:127-156. 
 331 
171. Biron, C. A., K. B. Nguyen, G. C. Pien, L. P. Cousens, and T. P. Salazar-Mather. 
1999. Natural killer cells in antiviral defense: function and regulation by innate 
cytokines. Annu Rev Immunol 17:189-220. 
172. Koo, G. C., and J. R. Peppard. 1984. Establishment of monoclonal anti-Nk-1.1 
antibody. Hybridoma 3:301-303. 
173. Diefenbach, A., E. R. Jensen, A. M. Jamieson, and D. H. Raulet. 2001. Rae1 and 
H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-
171. 
174. Slifka, M. K., R. R. Pagarigan, and J. L. Whitton. 2000. NK markers are 
expressed on a high percentage of virus-specific CD8+ and CD4+ T cells. J 
Immunol 164:2009-2015. 
175. Moore, M. L., M. H. Chi, K. Goleniewska, J. E. Durbin, and R. S. Peebles, Jr. 
2008. Differential regulation of GM1 and asialo-GM1 expression by T cells and 
natural killer (NK) cells in respiratory syncytial virus infection. Viral Immunol 
21:327-339. 
176. Smyth, M. J., N. Y. Crowe, and D. I. Godfrey. 2001. NK cells and NKT cells 
collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int 
Immunol 13:459-463. 
177. Wiltrout, R. H., A. Santoni, E. S. Peterson, D. C. Knott, W. R. Overton, R. B. 
Herberman, and H. T. Holden. 1985. Reactivity of anti-asialo GM1 serum with 
tumoricidal and non-tumoricidal mouse macrophages. J Leukoc Biol 37:597-614. 
178. Kosaka, A., D. Wakita, N. Matsubara, Y. Togashi, S. Nishimura, H. Kitamura, 
and T. Nishimura. 2007. AsialoGM1+CD8+ central memory-type T cells in 
unimmunized mice as novel immunomodulator of IFN-gamma-dependent type 1 
immunity. Int Immunol 19:249-256. 
179. Uppaluri, R., K. C. Sheehan, L. Wang, J. D. Bui, J. J. Brotman, B. Lu, C. Gerard, 
W. W. Hancock, and R. D. Schreiber. 2008. Prolongation of cardiac and islet 
allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal 
antibody. Transplantation 86:137-147. 
180. Bursch, L. S., L. Wang, B. Igyarto, A. Kissenpfennig, B. Malissen, D. H. Kaplan, 
and K. A. Hogquist. 2007. Identification of a novel population of Langerin+ 
dendritic cells. J Exp Med 204:3147-3156. 
181. Sung, S. S., S. M. Fu, C. E. Rose, Jr., F. Gaskin, S. T. Ju, and S. R. Beaty. 2006. 
A major lung CD103 (alphaE)-beta7 integrin-positive epithelial dendritic cell 
 332 
population expressing Langerin and tight junction proteins. J Immunol 176:2161-
2172. 
182. del Rio, M. L., J. I. Rodriguez-Barbosa, E. Kremmer, and R. Forster. 2007. 
CD103- and CD103+ bronchial lymph node dendritic cells are specialized in 
presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells. J 
Immunol 178:6861-6866. 
183. Wolkers, M. C., G. Stoetter, F. A. Vyth-Dreese, and T. N. Schumacher. 2001. 
Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell 
responses. J Immunol 167:3577-3584. 
184. Le Bon, A., and D. F. Tough. 2008. Type I interferon as a stimulus for cross-
priming. Cytokine Growth Factor Rev 19:33-40. 
185. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. 
Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-
restricted tumor antigens. Science 264:961-965. 
186. Ochsenbein, A. F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. 
Hemmi, H. Hengartner, and R. M. Zinkernagel. 2001. Roles of tumour 
localization, second signals and cross priming in cytotoxic T-cell induction. 
Nature 411:1058-1064. 
187. Asahara, T., T. Murohara, A. Sullivan, M. Silver, R. van der Zee, T. Li, B. 
Witzenbichler, G. Schatteman, and J. M. Isner. 1997. Isolation of putative 
progenitor endothelial cells for angiogenesis. Science 275:964-967. 
188. Asahara, T., H. Masuda, T. Takahashi, C. Kalka, C. Pastore, M. Silver, M. 
Kearne, M. Magner, and J. M. Isner. 1999. Bone marrow origin of endothelial 
progenitor cells responsible for postnatal vasculogenesis in physiological and 
pathological neovascularization. Circ Res 85:221-228. 
189. Lyden, D., K. Hattori, S. Dias, C. Costa, P. Blaikie, L. Butros, A. Chadburn, B. 
Heissig, W. Marks, L. Witte, Y. Wu, D. Hicklin, Z. Zhu, N. R. Hackett, R. G. 
Crystal, M. A. Moore, K. A. Hajjar, K. Manova, R. Benezra, and S. Rafii. 2001. 
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic 
precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201. 
190. Nolan, D. J., A. Ciarrocchi, A. S. Mellick, J. S. Jaggi, K. Bambino, S. Gupta, E. 
Heikamp, M. R. McDevitt, D. A. Scheinberg, R. Benezra, and V. Mittal. 2007. 
Bone marrow-derived endothelial progenitor cells are a major determinant of 
nascent tumor neovascularization. Genes Dev 21:1546-1558. 
 333 
191. Garcia-Barros, M., F. Paris, C. Cordon-Cardo, D. Lyden, S. Rafii, A. Haimovitz-
Friedman, Z. Fuks, and R. Kolesnick. 2003. Tumor response to radiotherapy 
regulated by endothelial cell apoptosis. Science 300:1155-1159. 
192. Gao, D., D. J. Nolan, A. S. Mellick, K. Bambino, K. McDonnell, and V. Mittal. 
2008. Endothelial progenitor cells control the angiogenic switch in mouse lung 
metastasis. Science 319:195-198. 
193. Gothert, J. R., S. E. Gustin, J. A. van Eekelen, U. Schmidt, M. A. Hall, S. M. 
Jane, A. R. Green, B. Gottgens, D. J. Izon, and C. G. Begley. 2004. Genetically 
tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to 
tumor endothelium. Blood 104:1769-1777. 
194. Rajantie, I., M. Ilmonen, A. Alminaite, U. Ozerdem, K. Alitalo, and P. Salven. 
2004. Adult bone marrow-derived cells recruited during angiogenesis comprise 
precursors for periendothelial vascular mural cells. Blood 104:2084-2086. 
195. Ziegelhoeffer, T., B. Fernandez, S. Kostin, M. Heil, R. Voswinckel, A. Helisch, 
and W. Schaper. 2004. Bone marrow-derived cells do not incorporate into the 
adult growing vasculature. Circ Res 94:230-238. 
196. Zentilin, L., S. Tafuro, S. Zacchigna, N. Arsic, L. Pattarini, M. Sinigaglia, and M. 
Giacca. 2006. Bone marrow mononuclear cells are recruited to the sites of VEGF-
induced neovascularization but are not incorporated into the newly formed 
vessels. Blood 107:3546-3554. 
197. Grunewald, M., I. Avraham, Y. Dor, E. Bachar-Lustig, A. Itin, S. Jung, S. 
Chimenti, L. Landsman, R. Abramovitch, and E. Keshet. 2006. VEGF-induced 
adult neovascularization: recruitment, retention, and role of accessory cells. Cell 
124:175-189. 
198. Purhonen, S., J. Palm, D. Rossi, N. Kaskenpaa, I. Rajantie, S. Yla-Herttuala, K. 
Alitalo, I. L. Weissman, and P. Salven. 2008. Bone marrow-derived circulating 
endothelial precursors do not contribute to vascular endothelium and are not 
needed for tumor growth. Proc Natl Acad Sci U S A 105:6620-6625. 
199. Larrivee, B., and A. Karsan. 2007. Involvement of marrow-derived endothelial 
cells in vascularization. Handb Exp Pharmacol:89-114. 
200. Ferrantini, M., I. Capone, and F. Belardelli. 2007. Interferon-alpha and cancer: 
mechanisms of action and new perspectives of clinical use. Biochimie 89:884-
893. 
201. Kirkwood, J. 2002. Cancer immunotherapy: the interferon-alpha experience. 
Semin Oncol 29:18-26. 
 334 
202. Dong, Z., G. Greene, C. Pettaway, C. P. Dinney, I. Eue, W. Lu, C. D. Bucana, M. 
D. Balbay, D. Bielenberg, and I. J. Fidler. 1999. Suppression of angiogenesis, 
tumorigenicity, and metastasis by human prostate cancer cells engineered to 
produce interferon-beta. Cancer Res 59:872-879. 
203. Ryuke, Y., M. Mizuno, A. Natsume, O. Suzuki, M. Nobayashi, T. Kageshita, K. 
Matsumoto, T. Saida, and J. Yoshida. 2003. Growth inhibition of subcutaneous 
mouse melanoma and induction of natural killer cells by liposome-mediated 
interferon-beta gene therapy. Melanoma Res 13:349-356. 
204. De Palma, M., R. Mazzieri, L. S. Politi, F. Pucci, E. Zonari, G. Sitia, S. 
Mazzoleni, D. Moi, M. A. Venneri, S. Indraccolo, A. Falini, L. G. Guidotti, R. 
Galli, and L. Naldini. 2008. Tumor-targeted interferon-alpha delivery by Tie2-
expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14:299-
311. 
205. Bedoui, S., P. G. Whitney, J. Waithman, L. Eidsmo, L. Wakim, I. Caminschi, R. 
S. Allan, M. Wojtasiak, K. Shortman, F. R. Carbone, A. G. Brooks, and W. R. 
Heath. 2009. Cross-presentation of viral and self antigens by skin-derived 
CD103+ dendritic cells. Nat Immunol 10:488-495. 
206. Edelson, B. T., W. Kc, R. Juang, M. Kohyama, L. A. Benoit, P. A. Klekotka, C. 
Moon, J. C. Albring, W. Ise, D. G. Michael, D. Bhattacharya, T. S. Stappenbeck, 
M. J. Holtzman, S. S. Sung, T. L. Murphy, K. Hildner, and K. M. Murphy. 
Peripheral CD103+ dendritic cells form a unified subset developmentally related 
to CD8alpha+ conventional dendritic cells. J Exp Med 207:823-836. 
207. Kaplan, D. H., A. Kissenpfennig, and B. E. Clausen. 2008. Insights into 
Langerhans cell function from Langerhans cell ablation models. Eur J Immunol 
38:2369-2376. 
208. Kamphuis, E., T. Junt, Z. Waibler, R. Forster, and U. Kalinke. 2006. Type I 
interferons directly regulate lymphocyte recirculation and cause transient blood 
lymphopenia. Blood 108:3253-3261. 
209. Melief, C. J. 2008. Cancer immunotherapy by dendritic cells. Immunity 29:372-
383. 
210. Zietara, N., M. Lyszkiewicz, N. Gekara, J. Puchalka, V. A. Dos Santos, C. R. 
Hunt, T. K. Pandita, S. Lienenklaus, and S. Weiss. 2009. Absence of IFN-beta 
impairs antigen presentation capacity of splenic dendritic cells via down-
regulation of heat shock protein 70. J Immunol 183:1099-1109. 
 335 
211. Kumagai, Y., O. Takeuchi, H. Kato, H. Kumar, K. Matsui, E. Morii, K. Aozasa, 
T. Kawai, and S. Akira. 2007. Alveolar macrophages are the primary interferon-
alpha producer in pulmonary infection with RNA viruses. Immunity 27:240-252. 
212. Yoshida, H., Y. Okabe, K. Kawane, H. Fukuyama, and S. Nagata. 2005. Lethal 
anemia caused by interferon-beta produced in mouse embryos carrying 
undigested DNA. Nat Immunol 6:49-56. 
213. Asselin-Paturel, C., G. Brizard, K. Chemin, A. Boonstra, A. O'Garra, A. Vicari, 
and G. Trinchieri. 2005. Type I interferon dependence of plasmacytoid dendritic 
cell activation and migration. J Exp Med 201:1157-1167. 
214. Apetoh, L., F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, A. Criollo, G. 
Mignot, M. C. Maiuri, E. Ullrich, P. Saulnier, H. Yang, S. Amigorena, B. Ryffel, 
F. J. Barrat, P. Saftig, F. Levi, R. Lidereau, C. Nogues, J. P. Mira, A. Chompret, 
V. Joulin, F. Clavel-Chapelon, J. Bourhis, F. Andre, S. Delaloge, T. Tursz, G. 
Kroemer, and L. Zitvogel. 2007. Toll-like receptor 4-dependent contribution of 
the immune system to anticancer chemotherapy and radiotherapy. Nat Med 
13:1050-1059. 
215. Zitvogel, L., L. Apetoh, F. Ghiringhelli, and G. Kroemer. 2008. Immunological 
aspects of cancer chemotherapy. Nat Rev Immunol 8:59-73. 
 
 
